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Summary 
Macrophages are proposed to play an important regulatory role in the pathogenesis of 
pulmonary arterial hypertension (PAH), as excessive infiltration is detected around 
vascular lesions in patients and animal models of the disease. The exact ‘causal’ role for 
macrophages, and whether their presence or absence is required for the vascular 
remodelling seen in PAH remains unclear. Using a novel inducible macrophage depletion 
model (MacLow mouse) I aimed to determine the role of macrophages in the pulmonary 
arterial remodeling associated with PAH.  
Macrophage depletion was induced in MacLow mice by administration of doxycycline, 
where macrophage- specific induction of the cytotoxic diphtheria toxin A chain (DTA) is 
driven by the CD68 promoter. Male but not female MacLow mice developed a 
spontaneous PAH phenotype compared to controls following six week doxycycline 
treatment, this was associated with increased right ventricular hypertrophy and 
pulmonary vascular remodelling. 
Immunohistochemical analysis of diseased lungs demonstrated dominancy of the 
CD206+ macrophages suggesting that M2- like macrophage population may drive this 
PAH phenotype. Differentiation towards M2 phenotype has been also observed in vitro 
using primary cells obtained from MacLow mice. Furthermore, by tracing the origin of the 
effector macrophages responsible for the development of MacLow- induced PAH using 
different chimeric mice, it seems that the major contributor cells originate within the lung 
tissue and that male bone marrow cells were not sufficient to induce disease in female 
recipient. Finally, culturing of bone marrow-derived macrophages and alveolar 
macrophages showed unique characteristic differences in term of their polarization, 
expression of DTA and expression of leukotriene B4 following stimulation with 
doxycycline. The data suggested that alveolar macrophage might be resistant to the 
doxycycline-induced depletion which may lead to activation of the alveolar macrophages 
following loss of the interstitial subtype.        
In conclusion, loss of CD68+ macrophages in MacLow mice led to the development of 
PAH spontaneously in male and not female mice, and the pathogenesis might involve 
activation of alveolar macrophages. Also these data further highlight the gender 
imbalance in PAH and add immune cells to this paradigm.  
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1  General introduction 
1.1 Pulmonary hypertension 
Pulmonary Hypertension (PH) was first reported in 1891 by the German physician 
Dr Von Romberg, he described the pathology from patient autopsy as pulmonary 
vascular lesions with unknown etiology and referred to the case as ‘pulmonary 
vascular sclerosis’ (Romberg, 1891). After the introduction of the catheterization 
technique for measurement of pulmonary blood pressure in patients, PH is 
defined as an elevation of mean pulmonary artery blood pressure (mPAP) of ≥ 
25 mmHg at rest, recorded by heart catheterization (Galiè et al., 2009, Galie et 
al., 2010, Hoeper et al., 2013a). According to the latest classification agreed by 
the WHO in the 5th world symposium of pulmonary hypertension (WSPH) PH can 
be classified into five main classes based on their causes and pathology which 
are: Pulmonary Arterial Hypertension, Pulmonary Hypertension due to left heart 
disease, Pulmonary Hypertension due to Lung disease and/ or hypoxia, chronic 
thromboembolic Pulmonary Hypertension (CTEPH) and PH with unclear 
multifactorial mechanisms (Simonneau et al., 2013).  
1.2 Pulmonary arterial hypertension  
1.2.1 Disease definition and classification  
Pulmonary arterial hypertension (PAH) is a complex, rare syndrome 
characterized by the increased vascular resistance of the pulmonary artery due 
to narrowing of the vascular lumen. Haemodynamically, PAH is defined by mPAP 
of higher than 25mmHg in rest and above 30mmHg in exercise (Kiely et al., 2013) 
associated with a pulmonary vascular resistance of more than 3 Wood units and 
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the end-expiratory pulmonary artery wedge pressure of ≤ 15mmHg (Hoeper et 
al., 2013b).  
The restricted blood flow within the pulmonary artery alongside with the elevated 
pulmonary pressure and the resistance will lead to the weakening of cardiac 
muscles and in most of the cases to right heart failure and death.  
According to the classification of the 5th WSPH, group 1 PAH is further subdivided 
into idiopathic pulmonary arterial hypertension (IPAH), heritable PAH, drug and 
toxin-induced PAH and PAH associated with other conditions such as HIV 
infection, connective tissue disease, schistosomiasis and congenital heart 
diseases. In addition, there is also a persistent pulmonary hypertension of the 
new-born which classified under PAH category (Table 1.1) (Simonneau et al., 
2013).  
PAH has a prevalence range of 15-50 person / a million of the population ( 
average age of 50 years), and the prevalence is higher in specific patients groups, 
notably (5-10%) in those with congenital heart diseases, (9%) in those with 
systemic sclerosis and (0.5%) in those with HIV (Kiely et al., 2013).   
Gender bias has been also implicated in PAH. According to the REVEAL registry, 
the female to male ratio of having PAH is 4.3:1 and 4.1:1 of IPAH. Although the 
prevalence was higher in women, men showed higher mPAP and poorer 
prognosis compared to the women, who have higher survival rate (Badesch et 
al., 2010).   
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Table 1.1. An updated classification of Pulmonary Arterial Hypertension modified in the 
5th WSPH in Nice, France 2013. 
1. Pulmonary arterial hypertension 
1.1 Idiopathic PAH 
1.2 Heritable PAH 
1.2.1 BMPR2 
1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3 
1.2.3 Unknown 
1.3 Drug and toxin-induced 
1.4 Associated with: 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension  
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1’ Pulmonary veno-occlusive disease and/ or pulmonary capillary hemangiomatosis 
1’’. Persistent pulmonary hypertension of newborn (PPHN)  
     
BMPR2 = bone morphogenic protein receptor type ll, ALK-1 = activin receptor- like kinase 1, ENG 
= endoglin, CAV 1= caveolin-1, HIV= human immunodeficiency virus.  
 
1.2.2 Pathobiology and pathophysiology of pulmonary arterial 
hypertension 
It is still not completely clear how the disease initiates, however it has been 
hypothesized that an injury to the vessel wall of the distal pulmonary arteries 
(such as viral infection, shear stress, mechanical stretching, hypoxia, 
inflammation or another unknown insult) alongside with environmental and 
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genetic factors can trigger pathological changes (Galie et al., 2010). Several 
mechanisms including different pathways and molecules have been proposed to 
be involved in the pathogenicity of PAH, but again the full mechanism of the 
disease progression is still unclear. 
The pathogenicity of PAH includes multifactorial, complex processes that cause 
vasoconstriction, vascular wall remodelling and thrombosis, these processes 
eventually lead to stiffening of the vasculature, narrowing of the lumen, increased 
vascular resistance, increased blood pressure, increased right ventricle workload 
and consequently heart failure. The following sections will introduce the main 
cellular and molecular pathways that have been shown to be involved in the 
development of PAH.  
1.2.2.1  Genetic factors associated with pulmonary arterial hypertension   
It is well recognised by now that the major heritable risk factor for the 
development of PAH is the altered bone morphogenetic protein receptor type 2 
(BMPR2) signalling, via mutation in the BMPR2 gene, a member of the growth 
factor receptor family of transforming growth factors-β (TGF-β) (Nichols et al., 
1997, Deng et al., 2000, Simonneau et al., 2013). In the heritable/ familial subtype 
of PAH approximately 80% of the cases carry a germline mutation in BMPR2 
(Machado et al., 2009). However, the prevalence of PAH among the BMPR2 
mutation carriers is less than 20%, and patients with IPAH can have a reduced 
expression of BMPR2 even though no mutations detected (Morrell et al., 2009, 
Machado et al., 2009, Pfarr et al., 2013, Pousada et al., 2014). This suggests that 
other environmental/ host factors are required (second hits) to fully establish the 
disease state.  
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The importance of environmental factors in addition to impaired BMPR2 
signalling is also evidenced by data collected from BMPR2 deficient animal 
models. For examples, heterozygous BMPR2 mutant do not develop PH 
spontaneously while when exposed to inflammatory stress (Song et al., 2005) or 
serotonin (Long et al., 2006) the disease susceptibility increased. In addition, 
conditional ablation of BMPR2 in endothelial cells (ECs) (Hong et al., 2008) or 
overexpression of a dominant negative BMPR2 in smooth muscle cells (SMCs) 
(West et al., 2005) only 30% of mice showed evidences of increased right 
ventricular systolic pressure (RVSP). However, recent mouse model using 
heterozygous knock-in allele (BMPR2+/ R899X) bearing the R899X stop codon in 
exon 12 (a bmpr2 mutation associated with human PAH), the animals developed 
spontaneous increase in RVSP which was reversed by BMP9 treatment (Long et 
al., 2015).    
Within the lung, BMPR2 is highly expressed on vascular endothelium of 
pulmonary arteries and to less extent in smooth muscle cells and fibroblast 
(Atkinson et al., 2002). In ECs, the response to BMPs is dependent on specific 
BMP ligand; as BMP4 and BMP6 activates proliferation, migration and tubular 
formation of ECs, the BMP9 on the other hand, act to inhibit ECs proliferation and 
promote monolayer integrity in cultured ECs (Long et al., 2015).   
Reduction in BMPR2 signalling in ECs may compromise the endothelial barrier 
and consequently this makes the underlying SMCs exposed to mediators and 
growth factors stimulating proliferation.  
Mutations in other genes such as Activin- Like receptor Kinase-1 (ALK-1), 
endoglin (ENG), Caveolin-1 (CAV1), potassium channel subfamily K member 3 
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(KCNK3) and SMAD9 have been also discovered in families with PAH 
(Simonneau et al., 2013, Austin and Loyd, 2014).  
1.2.2.2  Endothelial cell dysfunction in pulmonary arterial hypertension    
The endothelium of the blood vessel is a thin layer of ECs forming an interface 
layer between the circulating blood and the rest of the vessel wall layers (figure 
1.1). The endothelium function to control vessel haemostasis and tone, white 
blood cells infiltration and hormone trafficking. PAH featured by ECs apoptosis 
leading to intima disruption and leakage of different mediators to the underlying 
SMCs (Morrell et al., 2009). Dysfunction of ECs assimilates in the imbalanced 
production of vasodilators versus vasoconstrictors, SMC growth inhibitors versus 
growth stimulators and antithrombotic and thrombotic factors (Humbert et al., 
2008). 
The balance between vasodilators/ growth inhibitors such as nitric oxide (NO) 
and prostacyclin, and between vasoconstrictors/ co-mitogens such as endothelin-
1 and thromboxane A2 is essential to maintain vascular tone.  Patients with PAH 
have shown an elevated level of vasoconstrictors (endothelin) (Giaid et al., 1993) 
and a reduction in vasodilators (NO and prostacyclin) (Christman et al., 1992). In 
addition, increased Thromboxane A2 (also cause vasoconstriction, platelet 
activation and aggregation) have been detected in patient’s samples (Christman 
et al., 1992). 
Endothelin-1 (ET-1) is a key vasoconstrictor that work through ETA and ETB 
receptors. The ETA receptor found on vascular SMCs while the ETB found on 
SMCs and ECs (Seo et al., 1994). Normally, ET-1 level in plasma is low, however, 
in PAH patients the circulating level of ET-1 shown to be elevated and associated 
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with right arterial pressure and PVR (Giaid et al., 1993, Cacoub et al., 1997). 
Drugs that antagonise the effect of ET-1 such as Bosentan and Macitentan have 
been approved for clinical use in PAH and showed improved clinical outcomes 
(Rubin et al., 2002, Sitbon et al., 2003, Renshall et al., 2018). 
NO is also important regulator of vascular tone that shown to be reduced in PAH. 
NO produced in ECs from L-arginine substrate by endothelial nitric oxide 
synthase (eNOS). Reduced NO level in PAH could result from either reduced 
expression of eNOs, NO inactivation by superoxide anion or eNOs inhibition 
(Takemoto et al., 2002, Xu et al., 2004). In addition, IPAH patients showed an 
increased level of the eNOs inhibitor, known as ADMA (asymmetric 
dimethylarginine) in the plasma and in pulmonary artery endothelium (Pullamsetti 
et al., 2005). 
Furthermore, deficiency of prostacyclin (cardio-protective hormone), prostacyclin 
synthase and increased thromboxane are reported in PAH (Christman et al., 
1992). In animal models, prostacyclin overexpression protect against hypoxia-
induced PH (Geraci et al., 1999), while prostacyclin-receptor knock-out mice 
develop severe hypoxia- induced PH (Hoshikawa et al., 2001).        
In addition, in IPAH patients, ECs have been shown to produce excess leptin (the 
‘satiety hormone’ that controls hunger and feeling of satiety) (Huertas et al., 
2012). the high leptin plasma level of IPAH patients has been correlated to the 
exaggerated immune responses and the insulin resistance which are also 
features of PH (Huertas et al., 2012). 
Taken together, the ECs dysfunction seems to have an integral role in the 
structural changes that occur within the pulmonary vasculature.   
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1.2.2.3 Smooth muscle cell proliferation and migration in pulmonary 
arterial hypertension  
SMCs is the principal cells composing the media layer of vessel wall (figure 1.1). 
The up-normal proliferation of SMCs is a crucial pathological element in PAH. 
Many pathways shown to be fundamental in PAH are also involved in the 
proliferation and migration processes of SMCs such as the serotonin (or 5-
Hydroxytryptamine 5-HT) signalling pathways (Herve et al., 1995, MacLean et 
al., 2000, Eddahibi et al., 2001), prostacyclin pathway and  the expression of 
osteoprotegerin (OPG) (Lawrie et al., 2008). 
Serotonin is an important mediator that influences the pathogenicity of PH. It is 
synthesized by converting L-tryptophan to 5-hydroxy-L-tryptophan (5-HT) via the 
activity of tryptophan hydroxylase (TPH). It has been shown that some patients 
with IPAH can have a high plasma level of serotonin (Herve et al., 1995). Also, 
pulmonary arterial endothelial TPH1 expression is increased in PAH patients and 
the derived serotonin can have paracrine effect on the underlying pulmonary 
artery SMCs (Eddahibi et al., 2006) .Serotonin exert a constricting effect on SMCs 
via binding to the 5-HT receptor and a mitogenic effect that is mediated by the 5-
HT transporter (5-HTT). There are three major subtype of 5-HT receptors; 5-HT1, 
5-HT2 and 5-HT3 (van den Berg et al., 2004). The response of pulmonary artery 
to serotonin is mediated mainly by the 5-HT1B receptor (Macintyre et al., 1992, 
MacLean et al., 1996a, Rondelet et al., 2003). In experimental PH, the pulmonary 
arterial response to the 5-HT1B receptor are amplified and receptor antagonism 
or deletion reverse the PH (MacLean et al., 1996b, Keegan et al., 2001). 
Furthermore, the disruption of the 5-HTT gene in animal models resulted in less 
severe hypoxia-induced PH phenotype when compared to control (Eddahibi et 
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al., 2001), while the overexpression the 5-HTT gene led to a spontaneous 
increase in the right ventricle pressure and exaggerated hypoxia-induced PH in 
female mice (MacLean et al., 2004).   
As described above, prostacyclin is an important cardioprotective hormone which 
has been found to be reduced in PAH (Christman et al., 1992). Prostacyclin is 
produced by the endothelium of blood vessel and when coupled to its receptor it 
induces the formation of the cyclic adenosine monophosphate (cAMP). In 
vascular SMCs, cAMP mediates relaxation and inhibits the proliferation of the 
cells, thus the therapeutic utility of prostacyclin to treat PAH has been worked on 
extensively (Ruan et al., 2010, Safdar, 2011, Mitchell et al., 2014, Pluchart et al., 
2017).   
OPG is a regulatory protein with a main function of regulating osteclastogenesis. 
However, OPG can also bind to the tumour necrosis factor related apoptosis-
induced ligand (TRAIL) to inhibit TRAIL-induced apoptosis (Emery et al., 1998). 
OPG expression and release is mediated by serotonin, BMPs and interleukin-1 
(IL-1) and shown to be highly expressed within pulmonary vascular lesions and 
in patient's serum of IPAH (Lawrie et al., 2008). In addition, stimulation of human 
pulmonary artery SMCs with OPG induce proliferation and migration, OPG mRNA 
found to be 2-fold higher in pulmonary artery SMCs from IPAH patients compared 
to control and that high serum level predict poor survival (Condliffe et al., 2012). 
So OPG could provide an effective biomarker and a therapeutic target (Lawrie et 
al., 2008, Condliffe et al., 2012). The expression of TRAIL was also found to be 
elevated in patients with IPAH, TRAIL was shown to stimulate remodelling of 
pulmonary vascular cells and its blockage prevented  PAH development in an 
animal model (Hameed et al., 2012). 
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In conclusion, An impaired balance between proliferation and apoptosis favours 
proliferation, resulting in muscularisation or thickening of the pulmonary vessel 
wall which is a hallmark pathogenic feature in PAH (Rabinovitch, 2008). 
1.2.2.4 The adventitia remodelling in pulmonary arterial hypertension 
Although the ECs and SMCs have received much attention from vascular 
biologists, the adventitial layer has also been noted to have a role in the 
pathogenicity of PAH and the associated remodelling. Fibroblasts are the key 
cells in the connective tissue that form the adventitia layer of the vessel wall 
(figure 1.1), they produce the tropocollagen and the ground substances that fill 
the spaces between cells of connective tissue (Stenmark et al., 2011). Activation 
of fibroblasts in response to injury or stress results in fibroblast proliferation, 
migration, and differentiation. In response to hypoxia, fibroblasts have shown the 
capability of proliferation with high propensity and differentiation into 
myofibroblast which can then either accumulate in adventitia or migrate to the 
other layers of the vessel wall. Activated fibroblast are also involved in inducing 
inflammatory cell recruitment, increasing the release of the extracellular matrix 
(ECM), and production of angiogenic chemokines to support neovascular growth 
(Stenmark et al., 2005, Li et al., 2011). In addition, recent publications have 
described adventitial fibroblast population in chronic hypoxic models of PH that 
possess pro-inflammatory phenotype (defined by high expression of pro-
inflammatory markers such as IL-1β, CCL-2, GM-CSF, IL-6, CXCL12 and CCL-
5), this phenotype was suggested to be a result of the epigenetic modification 
brought by histone-modifying enzymes specifically class I histone deacetylase 
HDACs (Li et al., 2011).  
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1.2.2.5  Inflammation in pulmonary arterial hypertension 
Inflammation is another key feature of the PAH pathology. Excessive recruitment 
of different inflammatory cells such as dendritic cells, B cells, T cells and 
macrophages has been detected in the vascular lesions in patients and in animal 
models of PAH (Frid et al., 2006, Savai et al., 2012). Stacher et al reported that 
most of the pulmonary vascular remodelling and haemodynamic parameters in 
PAH are correlated with infiltration of perivascular inflammatory cells and that 
persistent inflammatory processes contribute to pulmonary vascular diseases 
(Stacher et al., 2012). Moreover, other studies showed that BMPR2 mutation also 
correlates with advanced inflammatory pathology, suggesting that in 
experimental PH the immune alteration is a cause rather than a consequence of 
the disease since inflammation precedes vascular remodelling (Tamosiuniene et 
al., 2011, Rabinovitch et al., 2014). 
In this research thesis, inflammation in PAH is the main aspect of interest and will 
be discussed in detail in following sections.                                                                                                  
1.2.2.6    Other mediators and growth factors 
As discussed above, excessive proliferation is a key pathogenic feature of PAH, 
and different growth factors shown to be involved. Platelet-derived growth factor 
(PDGF), vascular endothelial growth factor (VEGF) and epidermal growth factor 
(EGF) are of the major growth factors which have been linked to the exaggerated 
proliferation, migration and apoptosis-resistance of pulmonary vascular cells in 
PAH (Humbert et al., 1998, Eddahibi et al., 2000, Cohen et al., 2003).  
PDGF is a peptide growth factor considered as a potent mitogen for the VSMCs 
as its deletion or disruption of its signalling cascade attenuates neo-intimal 
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formation and inhibits SMC proliferation and migration (Boucher et al., 2003, 
Caglayan et al., 2011). It has been shown to have a role in fibro-proliferative 
disorders including PAH (Humbert et al., 1998). Recent approaches using 
primary cell culture and experimental PH showed the effectiveness of PDGF 
receptor inhibitors (such as imatinib) in attenuating proliferation (Lanner et al., 
2005, Schermuly et al., 2005, Perros et al., 2008). Clinical trial has also shown 
the effectiveness of imatinib in patients, however, severe adverse effects were 
reported that limited its applicability (Ghofrani et al., 2005, Ghofrani et al., 2010, 
Hoeper et al., 2013a) 
VEGF is also a powerful angiogenic growth factor which is released at the site of 
injury by the platelets to promote wound healing and endothelial repair in 
combination with other platelets-derived mitogens such as PDGF. Platelets 
contents of VEGF has been found to be elevated in patients with severe PAH 
while the PDGF content do not change (Eddahibi et al., 2000). However, the 
exact mechanistic role of VEGF in the development of PAH remains unclear 
particularly since treating rodents with VEGF receptor blocker (SU5416 or 
SUGEN) in presence of a second hit such as chronic hypoxia causes angio-
obliterative PAH and right heart failure (Taraseviciene-Stewart et al., 2001). 
Some researchers suggest that VEGF exert either angiogenic or antiangiogenic 
functions depending on the type of receptor, the ligand and the duration of ligand-
receptor binding (Ferrara et al., 2003) 
Finally, EGF and its receptor EGFR are also emerging as important players in 
PAH pathology. The inhibition of EGFR attenuates PAH in the monocrotaline rat 
model (Merklinger et al., 2005). Furthermore, clinically approved EGF inhibitors 
such as gefitinib (Cohen et al., 2003) and erlotinib (Cohen et al., 2005) are also 
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available to treat some type of cancers. Despite this information, therapeutic use 
of EGF inhibitors in experimental PAH still did not show any effectiveness in 
targeting the disease (Dahal et al., 2010). 
 
Collectively, different cell types contribute to the progression of the pulmonary 
vascular remodelling associated with PAH including ECs, VSMCs, fibroblasts and 
inflammatory cells. The uncontrolled proliferation and migration lead to medial 
thickening, increased vascular resistance, increased right ventricular afterload 
and eventually right ventricular failure and death.               
1.2.3 Treatment of pulmonary arterial hypertension 
PAH is a multicomponent syndrome that involves different pathological pathways, 
treatments available tend only to improve the patient's symptoms and quality of 
life. However there is no cure for PAH, and in many cases, lung transplantation 
is the final option. 
Currently used drugs aim to reduce the vascular resistance of the vessels via 
targeting the three major pathological causes of vasoconstriction; nitric oxide, 
prostacyclin and endothelin-1 (figure 1.1). Mainly, there are four groups of drugs 
used in PAH treatment: 
- Prostacyclin and its analogues: epoprostenol, treprostinil, beraprost, 
iloprost and the oral drug selexipac. 
- Phosphodiesterase-5 inhibitor: sildenafil, vardenafil and tadalafil. 
- Endothelin receptor antagonist: bosentan, macitentan and 
ambrisentan. 
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- And guanylate cyclase stimulator: riociguat.                                                                                
The effectiveness of the prescribed therapeutic regimen can be assessed by the 
‘6-minute walk' test, where the distance walked in 6 minutes is measured.    
Phosphodiesterase-5 inhibitors are important clinically used drugs that show 
effectiveness and improved clinical outcomes in PAH patients (Galiè et al., 2009). 
Phosphodiesterase-5 is the degrading enzymes that inactivate NO and shown to 
be elevated in PAH patient’s lungs and heart (Corbin et al., 2005, Nagendran et 
al., 2007). Interestingly, sex may influence the effectiveness of 
phosphodiesterase-5 inhibitors as male showed better outcomes in the 6-
minutes’ walk test compared to female (Montani et al., 2009).     
The endothelin system can be targeted effectively by blocking both endothelin 
receptors, Bosentan and Macitentan are both dual ETA/ETB receptor antagonists 
approved for clinical use in PAH and showed improved clinical outcomes (Rubin 
et al., 2002, Sitbon et al., 2003, Renshall et al., 2018)  
In addition to the groups described above, blocking calcium influx into PASMCs 
provide a scope to promote vasodilation. Indeed, high-dose calcium channel 
blockers such as nifedipine and diltiazem can be only recommended for patients 
following a positive acute vasoreactivity test (Kiely et al., 2013).  
It should be noted here that there is evidence in the literature to show that anti-
inflammatory and immunosuppressive agents could improve PAH (Meloche et 
al., 2013). In addition, some of the currently used medications may have, to some 
extent, an immune-modulatory activity that participates in their efficiency (Cohen-
Kaminsky et al., 2014). This indicates that novel drugs specifically targeting the 
immunological component of the disease could be considered. 
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Ongoing work on developing novel antibodies targeting different pathological 
pathways in PAH is underway such as the vasoactive intestinal peptides (VIP), 
Rho kinases, Apelin and anti-OPG antibody.  In summary, the facts describe the 
severity of PAH as a life-shortening disease, patient’s quality of life will change 
dramatically after diagnosis and the accelerated pathogenesis of the disease will 
make them (even in young age) incapable to finish the six-minute walking test. 
Therefore, it is urgent first to validate the available treatment options and try to 
use and deliver them properly, and secondly to investigate new therapeutic 
targets that aim to selectively inhibit the vascular remodelling.          
                                
 
Figure 1.1- Pathobiology of the three layers of the vessel wall and the blood with the 
related therapy: Increased thickness of different layers of the vessel wall and severe 
reduction of the vascular lumen. Currently, available treatment aims to target the main 
pathological causes of vasoconstriction. Reused with permission from (Galie et al., 2010). 
MFB= myofibroblast, PDGF= platelet-derived growth factor, B-FGF= basic fibroblast growth 
factor, VIP= vasoactive intestinal peptide, TxA2= thromboxane A2, MMP= matrix-
metalloprotienase, K+ = potassium.   
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1.3 Inflammation in diseases  
Inflammation is an aspect of the protective immune response of the body against 
any type of harmful stimuli, the reaction involves vasodilation, increased blood 
flow, the release of molecular mediators, release of extravascular fluids and the 
recruitment of immune cells (Ferrero-Miliani et al., 2007). Inflammation occurs to 
minimize cell injury, clear the dead cells and potentiate tissue repair. 
Inflammation can be either acute or chronic. The acute inflammatory process is 
the quick, initial response of the body to harmful stimuli, it involves the increased 
movement of white blood cells from the blood into the site of injury. On the other 
hand, the chronic inflammation has a longer duration and can cause a 
progressive shift in the type of cells present at the site of inflammation and 
destruction of the tissue from the inflammatory process (Pullamsetti et al., 2011). 
Normally the inflammatory response is self-limiting, however, in many disorders, 
the inflammatory processes become continuous leading to chronic inflammation. 
1.3.1 Role of inflammation in pulmonary arterial hypertension 
As discussed above, impaired inflammation and altered immune responses are 
important aspects in the pathology of PAH. Excessive infiltration of inflammatory 
cells such as mast cells, dendritic cells (CD209+), T cells (CD3+), cytotoxic T cells 
(CD8+), macrophages (CD68+), macrophages/Monocytes (D14+) and helper T 
cells (CD4+) has been detected in the vascular lesion in clinical and experimental 
PAH (Frid et al., 2006, Savai et al., 2012, Stacher et al., 2012, Vergadi et al., 
2011).     
In addition, a vascular injury normally promotes an immune response in which 
natural killer cells (NK cells) and Tregs prevent the prolonged inflammation (Gill, 
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2010). Coordination between adaptive immunity (T and B lymphocyte) and innate 
immunity (NK cells and macrophages) is essential to suppress the reparative 
immune response when the danger has been eliminated. Treg cells regulate 
other T cells function as well as monocyte, macrophage, NK cells and B cells 
function. The altered Treg function has been observed in PAH patients 
(Tamosiuniene et al., 2011, Huertas et al., 2012). Also, congenital defects cause 
an absence of Treg cells in the athymic rat model led to massive inflammatory 
cell infiltration (B cells, mast cells and macrophages) into the lung after a vascular 
injury resembling the lesions seen in PAH patients, an effect which was prevented 
by Treg reconstitution (Tamosiuniene et al., 2011).    
Furthermore, different inflammatory cytokines and chemokine such as 
interleukin-1β, IL-6, IL-8, MCP-1, CCL5/RANTES and TGF-B are shown to be 
elevated in PAH. Some of these cytokines mediate specific recruitment of 
leukocytes into the vascular compartment and are correlated with poor prognosis 
(Tuder et al., 2013). Evidence has been provided to show that pulmonary 
vascular cells, as well as inflammatory cells, are important source of local 
cytokines and chemokines, which lead to recruitment of different inflammatory 
cells and eventually cause pulmonary vascular remodelling (figure 1.2) 
(Pullamsetti et al., 2011).  
Cytokines are multifunctional inflammatory mediators that can cause increased 
proliferation and contractility of vascular cells. IL-1 is pro-inflammatory cytokine 
secreted from macrophages, monocytes and vascular cells, the IL-1 level is found 
to be elevated in the patient's serum (Humbert et al., 1995) and the high level 
correlated to poor prognosis. It has been proposed that it has a role in mediating 
proliferative response in pulmonary vasculature's SMC and fibroblast (Steiner et 
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al., 2009). In the monocrotaline mouse model of PAH and in the IL-1 knockout 
mouse, the disease was attenuated following treatment with IL-1 receptor 
antagonist which emphasizes the implication of this cytokine in PAH pathology 
(Lawrie et al., 2011). 
Furthermore, IL-6 is another important cytokine that has a role in the 
pathogenesis of PAH and shown to be elevated in patients serum (Humbert et 
al., 1995). In experimental PH, lung specific overexpression of IL-6 transgenic 
mice display spontaneous PH and exaggerated hypoxia-induced PH (Steiner et 
al., 2009), while IL-6 deficient mice showed resistance to hypoxia-induced PH 
(Hashimoto-Kataoka et al., 2015). Recombinant IL-6 can cause mild remodelling 
when given to rodents, and can further exaggerate the response in the presence 
of hypoxia (Golembeski et al., 2005). Furthermore, IL-6 can induce fibroblast 
growth factor-2 via KLF-5 transcription factor (Kruppel- like factor) and this may 
lead to pulmonary artery SMCs proliferation. In addition, blockage of IL-6 using 
receptor blocker prevents the hypoxia-induced PH and blocks the downstream 
IL-21 signalling, this was shown by suppression of IL-21 accumulation and the 
suppression of TH17 cell accumulation (TH17 is the source of IL-21) (Hashimoto-
Kataoka et al., 2015). Thus IL-6 and the downstream IL-21 signalling could 
provide potential therapeutic for treating PAH. 
 
General introduction 
 
19 
 
 
 
 
Figure 1.2- Schematic illustration of inflammation-mediated vascular remodelling: As a 
response to noxious  stimuli (such as infection or inflammation), cells within pulmonary 
vasculature start to produce inflammatory mediators that attract the inflammatory cells ( mast 
cell, B-cells, macrophages, T-cells, Treg-cells and Dendritic cells), these could further release 
inflammatory mediators and growth factors. These processes collectively may lead to 
vascular remodelling via collagen deposition, matrix remodelling, vascular cell proliferation/ 
migration and thrombosis.  Reused with permission from (Pullamsetti et al., 2011). 
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Macrophages are another inflammatory cell that have had the attention of 
different research groups in attempts to understand the role of infiltrated 
macrophages to the pulmonary arterioles. Frid et al. (2006) have shown that the 
number of leukocyte/monocyte markers is increased by 50% in rat and bovine 
models of hypoxia-induced PH when compared to controls, and after tracing their 
origin they found that these cells are blood-borne cells (Frid et al., 2006). They 
suggested that the changes associated with hypoxia-induced PH such as the 
proliferation of adventitia, deposition of collagen and accumulation of smooth 
muscle-like cells (known as myofibroblast and express α- smooth muscle actin) 
are not only caused by the resident adventitial fibroblast, but also the recruited 
monocyte/ macrophage cells may directly contribute. 
Macrophages are the cell of interest in this current work, thus the following section 
will include basic background related to monocyte and macrophage populations, 
focusing on macrophage function, subtype and their role in diseases which will 
lead onto my aims and hypotheses.  
1.3.2  Monocytes 
Monocytes are large, phagocytic white blood cells, which have an important role 
in the immune system and expansion of lymphocytes. Monocytes are generated 
from haematopoietic stem cells in the bone marrow and released into the 
circulation where then can either migrate to tissues to develop into macrophages 
(this cell lineage referred to as monocyte/macrophage) or stored in body tissue 
mainly the spleen, which acts as a reservoir for immature monocytes (Hettinger 
et al., 2013, Ziegler-Heitbrock et al., 2010b). 
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Although monocytes has been considered as the precursors for tissue 
macrophages and dendritic cells, some tissue macrophages and dendritic cells 
shown to be originated independently of monocytes (Geissmann et al., 2010). 
In murine blood cells, monocytes can be distinguished from lymphocytes and 
granulocytes by their high expression of CD115 (M-CSF receptor) (Geissmann 
et al., 2008).  
In human, monocytes were initially grouped into two subsets based on expression 
of the CD16 antigen; the CD14+CD16- and CD14+CD16+ monocyte subsets 
(Passlick et al., 1989). Later on, monocytes have been further segregated into 
three subsets according to the expression of the surface markers CD14 and 
CD16: CD14 ++ CD16 – [CD16-] cells or the classical monocyte, CD14 ++ CD16+ 
[CD16+] cells or the intermediate monocyte and CD14+CD16++ the non-classical 
monocytes (Ziegler-Heitbrock et al., 2010a). In mice, monocytes can be similarly 
subdivided but with different markers: classical monocytes Ly6C++CD43+, 
intermediate monocytes Ly6C++CD43++ and the non-classical monocytes 
Ly6C+CD43++ (Ziegler-Heitbrock et al., 2010b, Wong et al., 2012). 
Recent studies have advanced the knowledge regarding the three monocyte 
subsets. Apart from their gene expression, monocyte subpopulations reveals 
distinct functions, cytokine profiles and definite relationships. For instance, about 
85% of all monocyte are classical monocytes and they have superior phagocytic 
properties, while the intermediate monocytes possess only 5% of total monocytes 
and their described functions include T-cell proliferation and stimulation and 
superior ROS production (Wong et al., 2012).                                                                                                 
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1.3.3  Macrophages 
Following monocyte migration from the blood to the tissues, monocytes 
differentiate into dendritic cells or macrophages by aid of colony stimulation 
factors GM-CSF and M-CSF. Macrophages were first introduced in the 19th 
century by Elie Metchnikoff who described macrophages-phagocytic activity 
(Metchnikoff, 1893). Later on, this concept extended to include broader 
description of macrophages; macrophages described as phagocytic, antigen 
presenting cells (APC), mainly mononuclear (multinuclear in bone), which play 
different roles in innate and acquired immunity (Duffield et al., 2005). 
Macrophages shown to perform different functions including presenting the 
degraded protein to T-cells, tissue repair and reorganization. Also macrophages 
participate in lymphocyte activation and shown to have microbiocide activity 
(Epelman et al., 2014).  
Macrophages named according to their anatomical location, for example: 
osteoclast in bones, Kupffer cell in the liver, alveolar macrophages in the lung 
and the microglia in the brain (Duffield et al., 2005, Gheryani et al., 2013). 
Macrophages, as well as monocytes, neutrophils, dendritic cells and mast cells, 
express cell surface receptors such as the Toll-like receptors (TLRs) and 
scavenger receptors, these receptors specifically detect signals arising normally 
from non-healthy tissue or invading organisms and so-called ‘professional 
phagocytic cells’ (Murray and Wynn, 2011). 
Macrophages can be distinguished from other cells by their expression of unique 
surface markers such as F4/80 and CD68 (table1.2). Moreover, whole genome 
analysis revealed further heterogeneity and overlapping within macrophages 
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population. Based on the gene expression profile, chemokine expression profile 
and response to different stimulus macrophage subsets were introduced. 
 
Table 1.2. Examples of murine macrophages-surface markers that commonly used in 
research 
Cell surface 
marker 
Expression Example reference  
 
CD11b All myeloid lineage (Hettinger et al., 2013) 
CD68 Most tissue macrophages (Gheryani et al., 2013, 
Higashi-Kuwata et al., 
2010) 
CD86 Most tissue macrophages 
Suitable for M1 macrophages 
(Talati et al., 2014) 
CD204 Scavenger receptors 
Suitable for M2 macrophages 
(Higashi-Kuwata et al., 
2010, Talati et al., 
2014) 
CD206 Mannose receptor 
Suitable for M2 macrophages 
(Moreno et al., 2014) 
F4/80 Most tissue macrophages in the 
mouse. 
Predominantly expressed on 
eosinophils in human. 
(Gheryani et al., 2013) 
Ly6C+ Inflammatory monocytes (Hettinger et al., 2013) 
NHC II Professional Antigen Presenting 
Cells. 
Suitable for M1 macrophages 
(Talati et al., 2014, 
Moreno et al., 2014) 
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1.3.3.1  Macrophage subset 
Classically activated macrophages (M1): This macrophage population stimulated 
by TLRs-ligand such as polysaccharide and interferon gamma (Mosser and 
Edwards, 2008). The M1 macrophages produce pro-inflammatory cytokines and 
reactive nitrogen and oxygen intermediates. The M1 macrophages mediate the 
defensive mechanisms against invading pathogens such as bacteria and viruses 
and possess some anti-tumour activity (Sica and Mantovani, 2012).  
Commonly defined markers for M1 macrophages include inducible nitric oxide 
synthase, MHC class II, IL-12β and co-stimulatory molecules as CD86, which can 
be detected and quantified by immunostaining and PCR (Higashi-Kuwata et al., 
2010, Moreno et al., 2014). 
Alternatively activated macrophages (M2): This macrophage subset is the anti-
inflammatory macrophages that are activated by IL-4 or IL-13 (Stein et al., 1992). 
The M2 macrophages participate in debris scavenging, regulate wound healing, 
have immune-regulatory functions and promote tumour progression (Jensen et 
al., 2009, Weisser et al., 2012, Gheryani et al., 2013). The M2 macrophages 
express mannose receptor CD206, arginase 1 (arg-1), IL-4 receptor α-chain 
amongst others (Moreno et al., 2014, Sica and Mantovani, 2012).    
 
Biswas and Mantovani have described a functional macrophage subtype that 
shares some features with M2 cells such as the expression of mannose receptor, 
but differ in other properties such as chemokine expression repertoire when 
induced by different signals as IL-10 or molecules released from the immune 
complex. They refer to this subtype as M2-like macrophages (Biswas and 
Mantovani, 2010). Furthermore, in some instances, the literature shows a slightly 
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different classification scheme for macrophages: some research articles 
categorize them as [M1] classically activated, [M2] alternatively activated and the 
[regulatory] anti-inflammatory macrophages, where the major feature of the 
regulatory macrophages is their promotion of immunosuppression and high 
production of IL-10 and low IL-12 (Vergadi et al., 2011). 
Different researchers use different types of cell marker to distinguish 
macrophages from other cells and/or macrophage subsets from each other. 
Moreover, expression of a combination of specific macrophage markers in a 
specific manner can be used to identify different macrophage subpopulation. For 
example, in a study by Moreno et al, a combination of CD11b+CD45hi was used 
for the identification of monocyte-derived macrophages, CD11b+CD45lo for 
microglia, CD206+Arg+Ym1+ for M2 and Ly6chiMHCII+CD86+iNOS+ for M1 
macrophages. To do so they used either flow cytometry, RT-PCR or 
immunofluorescent labelling (Moreno et al., 2014). However, in a study by Talati 
et al another combination of cell markers were used to distinguish between lung 
macrophages using cell sorting and immunohistochemical staining. They used 
CD45+ CD68low CD11+ Gr1- for interstitial macrophages, CD45+ CD68hi CD11c+ 
F4/80+  for alveolar macrophages, F4/80+ MHCII+ CD86+ for M1 and f4/80+ 
CD204+ for M2 macrophages (Talati et al., 2014). 
1.3.3.2  Macrophages in disease 
In case of tissue injury or stress, the resident macrophages might be insufficient 
to control the damage, so the circulating monocytes recruit to the damaged organ 
or tissue and differentiate into macrophages. These newly recruited 
macrophages are pro-inflammatory and secrete inflammatory mediators 
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including IL-1, IL-12, IL-23, nitric oxide and  TNF-α (Murray and Wynn, 2011). 
However, inflammatory macrophages can initially be beneficial since they clear 
the debris, but they could also cause collateral damage to the tissue because of 
the toxic activity of the oxygen and nitrogen species they produce (Fang, 2004). 
Thus, excessive release of these mediators must be controlled quickly or it 
becomes pathogenic and contributes to the progression of many diseases.  
To protect tissue integrity macrophages undergo apoptosis or switch their 
phenotype to the anti-inflammatory M2 phenotype (Arnold et al., 2007). The 
presence of two macrophage subtypes and/or switching of macrophages 
between inflammatory and anti-inflammatory has a great impact on the 
progression of many chronic diseases such as cancer (Jensen et al., 2009), 
fibrosis (Duffield et al., 2005) and atherosclerosis (Martinet et al., 2007). 
Macrophages are versatile and possess various, and sometimes opposing 
functions. For example, in a skeletal muscle regeneration study, macrophage 
activation was traced using latex beads to label the monocytes in CXCR1GFP/+ 
mice. The study showed that the recruited monocytes were only CXCR1lo/ Ly-
6C+, but were also a pro-inflammatory and non-dividing. Later on, these cells 
switched within the muscle to become anti-inflammatory CX3CR1hi/Ly-6C- cells, 
which then differentiate to F4/80hi macrophages (Arnold et al., 2007). In addition, 
in vitro experiments showed that the switch from pro-inflammatory to anti-
inflammatory macrophages is induced by phagocytosis of tissue debris and 
releasing TGF-β1 (Arnold et al., 2007).     
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1.3.3.3  Macrophages in pulmonary arterial hypertension 
In PAH, excessive infiltration of macrophages and high levels of IL-6 and IL-1 
have been detected in patients (Frid et al., 2006). These findings suggest that 
macrophages may play a key role in the remodelling processes associated with 
PAH. However, their exact role remains unclear. 
Vergadi has investigated the link between macrophage phenotype and hypoxia-
induced PH, using a bi-transgenic mouse model where doxycycline induces lung-
specific expression of heme-oxygenase-1 (HO-1). The study showed that HO-1 
has a protective function via an immunomodulatory pathway since 
overexpression of HO-1 inhibited macrophage recruitment and alternative 
activation in response to hypoxia, this suggested that early macrophages 
recruitment and activation are essential for later development of hypoxia-induced 
PH (Vergadi et al., 2011). Furthermore, the temporal profile of broncho-alveolar 
lavage fluid (BALF) cell content showed that the number of monocyte/ 
macrophage reach the peak after two days of hypoxia and then dropping 
significantly in the control animal, while overexpression of HO-1 suppressed the 
accumulation of macrophages at all-time interval investigated (Vergadi et al., 
2011). 
Moreover, in the same study, analysis of BALF- isolated alveolar macrophages 
by PCR and immunofluorescent staining showed upregulation of M2 macrophage 
markers (such as Arg-1 and Fizz 1) in hypoxic mice, whereas no changes in M1 
marker were detected. Overexpression of HO-1 suppressed the M2 alternatively 
activated marker in the transgenic animal. Their data strongly suggested that the 
M2 macrophage phenotype is the dominant polarized form of alveolar 
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macrophages in hypoxia-induced PH (Vergadi et al., 2011). Vergadi study 
presented a link between M2 macrophages and the development of PH, 
particularly since M2 macrophages have been shown to be involved in the 
pathogenesis of other diseases including lung disease (Lewis and Murdoch, 
2005, Mosser and Edwards, 2008) but further work is required to investigate the 
underlying mechanism of action of these subsets. 
In severe PAH, plexiform lesions (complex mass of vascular formation originated 
from the pulmonary artery) are common and have also shown to be rich in 
macrophages (Sakao et al., 2009, Jonigk et al., 2011, Vergadi et al., 2011), but 
again, the exact role of macrophages within these lesions is not yet known. In 
addition, plexiform lesion have been shown to contain high numbers of 
macrophages expressing leukotriene A4 hydrolase (LTA4H) (Tian et al., 2013). 
LTA4H is the biosynthesis enzyme of leukotriene B4 (LTB4) and high levels of 
LTB4 have been detected in PH patient’s plasma (Tian et al., 2013). LTB4 derived 
from macrophages has shown the ability to induce apoptosis in pulmonary artery 
ECs and cause proliferation of SMCs possibly by inhibition of endothelial 
Sphingosine-kinase/ endothelial nitric oxide synthase pathways (Tian et al., 
2013).  
In order to study the function of macrophages in different inflammatory based 
diseases, researchers aimed to deplete macrophages in vivo using different 
approaches to investigate macrophages distinct role in case of their absence.   
1.3.3.4  Macrophage depletion models 
Many methods have been utilised to deplete specific cells in order to investigate 
their functions. The oldest approaches involve the use of toxic chemicals such as 
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silica and asbestos (Kagan and Hartmann, 1984), however, many unwanted toxic 
effects hinder these approaches. Early genetic approaches such as the knockout 
of colony-stimulating factor-1  in mice (op/op mutant mice (Yoshida et al., 1990)), 
resulted in  severe macrophage loss especially in bones (leading to congenital 
osteopetrosis), skeletal deformity, growth abnormality, poor fertility and weak 
immunity. These severe abnormalities shortened the lifespan of the animals and 
hindered further pathological studies (Stanley et al., 1997). 
To improve specificity of cell depletion, recent models have been generated using 
gene targeting and genetic engineering technologies. Still, most of these models 
carry some level of toxicity or lacking of specificity. Some of these models are: 
liposome-mediated depletion (Vanrooijen and Sanders, 1994), transgenic FAS-
induced apoptosis (Burnett et al., 2004), transgenic expression of the diphtheria 
toxin receptor (Duffield et al., 2005), pharmacological- initiation of cell death in 
atherosclerosis (Martinet et al., 2007) and the  use of gadolinium chloride (GdCl3) 
(Singh et al., 2004).  
Among the most commonly used approaches in research is the liposome-
mediated depletion model. The model (also called macrophage suicide model) 
involves the use of liposome encapsulated drug dichloromethylene 
diphosphonate (CL2MDP) to cause macrophage death due to disturbances in 
cell metabolism following phagocytosis of the liposome (Vanrooijen and Sanders, 
1994). This approach has managed to some extent to be specific to 
macrophages, however, it targets all the phagocytic cell including dendritic cells 
(Weisser et al., 2012). Also, some safety issues are still a concern since the 
‘bystander effect' was not controlled. The bystander effect becomes apparent 
when the macrophages died and their toxic content (lysosomal enzyme, 
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proteases and cytokines) are released, this may lead to an inflammatory 
response, lymphocyte recruitment and pH changes (Rogers et al., 2014).  
The transgenic expression of the diphtheria toxin receptor is another commonly 
used approach for cell depletion in rodents. The ablation system adopted in this 
model relies on expression of human diphtheria toxin receptor (DTR; also known 
as human heparin binding-EGF) under the control of CD11b followed by 
diphtheria toxin (DT) administration (Duffield et al., 2005). The DT in vitro cleaves 
to DT-A and DT-B chains, DT-B chain binds to the heparin-binding EGF and 
internalize the A chain to the cell by endocytosis. DT-A chain causes the toxicity 
via inhibition of protein synthesis. Mice lack the hb-EGF binding receptor and thus 
are insensitive to DT (Duffield et al., 2005). This model showed effectiveness in 
deleting the CD11b cells, however, DT is a highly toxic molecule and any non-
specific expression would be lethal (Rogers et al., 2014).      
1.3.3.5  MacLow mouse model for macrophage depletion 
To deplete a vital cell such as a macrophage, it is important to adopt a depletion 
model with the least side effects and to overcome the limitations associated with 
the common depletion models such as specificity, toxicity, longevity and 
complexity (described above). The MacLow model newly developed in Sheffield, 
is a macrophage ablation model, based on the cell specific induction of 
macrophage ablation in mice using doxycycline (Gheryani et al., 2013).  
It has been shown that conditional cell elimination can be achieved when the 
expression of DTA gene is regulated by tetracycline responsive element in 
conjunction with using cell-specific promoter (Lee et al., 1998). In the MacLow 
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mouse model the CD68 promoter (macrophage-specific encoding gene) was 
used to selectively deplete macrophages in vivo (Gheryani et al., 2013).      
The model demands generation of a double-transgenic mouse containing CD68-
rtTA-eGFP and tetDTA transgenes which then treated with doxycycline to induce 
the expression of diphtheria toxin in CD68 positive cells. The first transgene 
expresses the reverses tetracycline transcriptional activator (rtTA) under the 
control of a CD68 promoter, in addition to IRES (internal ribosome entry site) and 
enhanced green fluorescence protein eGFP. The second transgene express 
diphtheria toxin A-chain (DTA) downstream of tetracycline responsive element 
TRE (figure 1.3). 
Using the MacLow mouse model, up to a 40% reduction in macrophage number 
within the liver was achieved after 48h of doxycycline injection, whilst up to 50% 
reduction was achieved following continuous two weeks doxycycline treatment in 
diet (Gheryani et al., 2013). Moreover, extending the experimental duration to six 
weeks did not show any further reduction in macrophage number, but 
interestingly the remaining macrophage population in doxycycline-treated double 
transgenic animals were smaller and had reduced cytokine production in 
response to LPS (Gheryani et al., 2013).     
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The advantages of MacLow mouse model over other macrophage ablation model 
can be summarized as follow: 
1- In contrast to other knockout methods, the double transgenic animals in this 
model were healthy and suitable for further pathological investigation. 
2- No external diphtheria toxin is used, so no potential toxicity. 
3- Unlike other models that use complex and expensive materials with a 
complex delivery system, MacLow model involves the use of doxycycline 
which is safe, readily available and easily administered reagent.  
4- The macrophage specificity is a major benefit of this model, since only cell 
expressing CD68 were depleted.                                                       
In my previous work undertaken for completion of my MSc degree (Zawia, 2011) 
I utilized the MacLow mice to correlate macrophages and vascular remodelling in 
hypoxia-induced PAH. MacLow mice were fed either doxycycline containing diet 
or normal chow for 2 weeks to induce macrophage ablation, and then PAH was 
Figure 1.3- MacLow mouse model: a diagram of the transgenes used to produce the double 
transgenic animal, rtTA= reverse tetracycline transactivator, PA= poly A tail, EGFP= 
enhanced green fluorescent protein, hCD68= human CD68 promoter, DTA= diphtheria toxin 
A-chain. Reused with permission (Gheryani et al., 2013) 
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induced by the insult of hypoxia (10% Oxygen) for another 2 weeks with 
continuous doxycycline administration (parallel groups were left in the normal air 
as controls). The findings showed that reducing the number of CD68+ 
macrophages did not protect against hypoxia-induced PAH, but it also showed 
an interesting trend (not significant) whereby an unexpected increase in the right 
ventricular end systolic pressure (RVESP) of the normoxic control group 
(specifically male mice) was seen after the loss of macrophages (figure 1.4). 
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For the current research, undertaken for completion of my PhD, I intended to 
pursue this work further and explore the modulatory mechanism of macrophages 
using the same MacLow animal model.  
Figure 1.4- loss of CD68+ macrophages did not protect against hypoxia-induced PAH:  
the graph shows the right ventricle systolic pressure (mmHg) measured by closed chest 
cardiac pressure-volume catheterization.  Error bars represent mean ±SD, * P< 0.05. modified 
from (Zawia, 2011) 
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1.4  Hypothesis of the study 
I hypothesized that macrophage depletion in MacLow mouse will reduce/ protect 
the mice from induced PAH.    
1.5  Aim of the study 
The main goal of this research was to determine the role of macrophages in the 
pulmonary arterial hypertension and whether they are required for the pulmonary 
vascular remodelling (and/ or reverse remodelling). 
The objectives include: 
- To confirm that loss of macrophages can cause sex- specific 
spontaneous PAH phenotype as suggested by my previous work. 
- To trace the origin of lung macrophages during the disease and 
whether the majority of macrophage population are lung resident 
macrophages or blood- borne cells.  
- To determine if a particular macrophage subset is dominant in the 
MacLow- induced PAH phenotype. 
- To investigate whether MacLow-derived macrophages have unique 
characters compared to control macrophages.  
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2  Materials and methods  
2.1 Animal work 
2.1.1 Generation of the double transgenic mouse (MacLow 
mouse) 
To generate the double transgenes CD68-rtTA- EGFP/ tetDTA (CDTD or the 
MacLow mouse) the heterozygous single transgenic mouse CD68-rtTA-EGFP 
(CD) was crossed with a homozygous tetDTA (TD) transgenic line (see section 
1.3.3.5 for the generation of the single transgenes). The line was maintained by 
crossing the heterozygous (CDTD) with the homozygous tetDTA (TD) at the 
biological service unit of the University of Sheffield. Mice were kept in high health 
state facilities in a controlled environment with a 12 hour light/ dark cycle, and 
with free access to food and water ad libidum. All animal works were approved 
by both the University of Sheffield Ethicals committee and the UK Home office 
regulation (project licence number 40/3517 and 70/8910) under the Animal 
Scientific procedure act (1986).    
The genotype of the double transgenic mice generated was assessed by using 
polymerase chain reaction PCR. For a rapid DNA extraction for genotyping, 
mouse ear clips were incubated in 150 µl of DNA extraction solution that consists 
of 300 µg/ml proteinase K (Proteinase K from Tritirachium album supplied by 
SIGMA) in Tail Lysis Buffer (see appendix II for recipe) at 55⁰C overnight, then 
the reaction was heated up to 100 ⁰C for 12 minutes to inactivate the proteinase 
K in the extraction buffer. For the genotyping PCR, primer pairs used were the 
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CD68 GT F 5′-GACGTAAACGGCCACAAGTT-3′ and CD68 GT R 5′- 
TGCTCAGGTAGTGGTTGTCG-3′ primer pair to amplify the 526 bp fragment 
within the CD transgene. And TetDTA F1 5′-TCGTACCACGGGACTAAACC- 3′ 
and TetDTA R1 5′-ACTTGCTCCATCAACGGTTC -3′ primer pair to amplify the 
299 bp fragment of the DTA transgenes. The PCR reaction mixture consisted of   
9 µl master mix (containing 3 µl of the 5X Go Taq Flexi buffer with dye, 1.5 µl of 
the 10X dNTPs, 0.12 µl Promega GoTaq® G2 Flexi DNA polymerase and 3.48 
µl millicurie water) 2 µl of each primer and 2 µl of the DNA sample to make a final 
volume of 15 µl. Samples containing a known DNA were used as a positive and 
a negative control, a no-template control that contains no DNA was used as a 
negative control as well.   
The reaction was first heated to 94 ⁰C for 4 minutes, followed by 30 amplification 
cycle each consists of: denaturation at 94 ⁰C for 30 seconds, annealing at 57 ⁰C 
for 30 seconds and extension at 72 ⁰C for 30 seconds, finally the reaction 
preserved at 72 ⁰C for 10 minutes using MyCycler TM Thermal Cycler, USA. 
Resulted products were then visualized using gel electrophoresis, the gel was 
made as 0.8% w/v agarose gel (Fisher BioReagent®) in 1X LTB buffer (see 
appendix II for recipe) containing 5 µl of 10 mg/ml ethidium bromide (SIGMA). 
The gel ran at 100 V for 30 minutes in 1X LTB buffer. A DNA marker 
(GeneRuler™ 1 Kb DNA ladder) containing a set of DNA fragments of known 
sizes was loaded alongside the sample to confirm the size of the DNA in test 
samples.   The bands were visualized using BioDoc-it image system with the UV 
transilluminator UVP (figure 2.1). Mice shown to be a non-double transgenic 
(CD68 negative) were either kept to use as controls in some studies or culled if 
not required. 
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2.1.2  Induction of macrophage ablation  
To induce macrophage ablation in MacLow mice, animals were treated with 
doxycycline either orally (with food) or by intraperitoneal injection as stated in 
each study. In the doxycycline time- point study, a single intraperitoneal injection 
of doxycycline (doxycycline hyclate, 002R27, Sigma-Aldrich) in a dose of 80 
mg/kg body weight was given to mice which then culled at different time points. 
Figure 2.1- Generation of MacLow mouse: Representative images of agarose gel showing 
PCR amplification of DNA extracted from mouse ear clips for genotyping. An example of PCR 
gel that shows the positive samples for the CD68 genes (2, 3, 4, 5 and 6) appeared in 546bp 
bands (a). And an example of PCR gel that shows positive samples having the tetDTA genes 
appeared in 299bp bands (b).  
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Doxycycline hyclate was dissolved in water for injection to make up an injection 
volume of about 200µl for each animal.  
On other longer-term studies, doxycycline was given as doxycycline containing 
diet (contains 625 mg/kg, ENVIGO laboratories Inc, Madison, USA), where 5 
grams of diet allocated to each mouse for each day. Doxycycline has poor 
stability in light and in water so the diet was replaced with fresh every 2-3 days to 
ensure the activity of the drug.  
2.1.3  Bone marrow transplant procedure and generation of the 
chimeric mice  
To generate the targeted chimeric mice, a donor inoculum was given to a pre-
irradiated recipient mouse, the inoculum used contains hematopoietic stem cells 
harvested from the bone marrow of the donor mouse with known genotype. For 
the bone marrow transplant procedure (BMT) all mice were kept in individually 
ventilated caging (IVC) under the barrier area in the biological service unit in 
Hallamshire hospital, mice were fed standard chow and given acidified drinking 
water (see appendix II for recipe) one day before the transplant to minimized the 
risk of infection. 
On the day of transplant, recipient mice were given a lethal single dose of whole-
body irradiation equals to 10 Gy (1000 rad) using a CIS IBL 437 Cs-137 irradiator 
(BM0435/CA5869). The time of exposure was calculated using the dosing guide 
provided with the machine. Following the irradiation, mice were placed in 35 ⁰C 
incubator for 1 hour before receiving donor bone marrow cells. 
Donor mice (aged 5-7 weeks) were euthanized by cervical dislocation. From each 
mouse, both legs were harvested intact in a clearly labelled petri dish on ice. It 
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was essential to maintain aseptic conditions during the whole procedure by 
spraying the mouse periodically with 70% ethanol. Under the fume hood, bones 
were cleaned up from fur and muscles as much as possible before placing them 
in cold media (RPMI- 1640 media ‘phenol red-free' contains 10% v/v HI FBS). 
Epiphyses removed using sterile scissors and the bone marrow flushed with 26-
27 G syringe contains 2 ml media, cells were passes through 40 µm cell strainer 
then centrifuged at 4 ⁰C 500 Xg for 5 minutes. Pellets re-suspended in Hank's 
buffered salt solution (HBSS) containing 10% v/v heat- inactivated fetal bovine 
serum (FBS) and counted with a haemocytometer using 1% v/v acetic acid to 
lyse the red blood cells. Cell suspension left on ice ready for tail vein injection, 
each mouse produces an average of 15-25 X106 cells/ ml. 
For efficient and fluent tail vein injection procedure, recipient mice were sedated 
with subcutaneous injection of Hypnorm® solution and sent back to the incubator 
for few minutes before injection. Each mouse received between 5 and 6 x 106 
cells in 100-200 µl cell suspension the left in the incubator to recover from 
sedation for 2-3 hours. Mice were closely monitored daily for the first two weeks 
for any sign of non-engraftment. This protocol was established and optimized 
according to the results of two pilot studies that I performed to enhance the 
survival rate (see chapter 4, section 4.3.1). Using this optimized protocol, we get 
a survival rate of 100% in our experiments and a successful engraftment of the 
donor bone marrow.    
2.1.4  Echocardiography  
To assess the changes in shape, size and functions of the heart following PAH 
induction echocardiography was performed, echocardiography is a non-invasive 
technique that uses the ultra-sound waves to produces a moving image of the 
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heart and the associated vessels (Singh and Goyal, 2007). The readings were 
taken at the baseline, midpoint and at the end of the study using the Vevo 770 
system (Visual Sonics, Toronto, Canada) and the RMV 707B scan head.  Mice 
were immediately weighed, then anaesthesia induced by 5 % v/v isoflurane, 2 L/ 
min oxygen. The anaesthetised mouse was then placed on the platform with a 
heating lamp directed to it to minimise heat loss, the mouse needs to be flat down 
with limbs secured well and with cushions on sides to prevent sliding. General 
anaesthesia was confirmed by loss of pedal reflex.    
Biological parameters such as temperature, heart rate and respiratory rate were 
recorded constantly during the procedure with the accompanied Visual Sonic 
temperature control and ECG amplifier.  Anaesthesia maintained by 0.5- 2 % v/v 
Isoflurane through oxygen using facemask and manipulated to keep the heart 
rate within the range of 450- 500 bpm as possible. The chest area was shaved 
properly and pre-heated ultrasound gel was applied before starting taking 
readings 
The right ventricle cavity dimensions were taken from the right long axis view by 
M-Mode of the free wall, while left ventricle functions were assessed at 2 
dimensions, the left long axis view and the short axis view by M-Mode at the level 
of papillary muscle. For the calculations of cardiac output Doppler pulse wave of 
the aortic valve from the right axis view and the left ventricle outflow tract diameter 
(LVOT diameter) from the left axis view were taken. The pulmonary artery flow 
measurements (pulmonary artery acceleration time PAAT, ejection time PAET 
and velocity timed interval VTI) were also recorded from the short axis view at the 
level of the pulmonary valve. 
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The analysis was performed using the Vevo 770, version 3.0; visual sonics 
software, measurements were taken offline when the cardiac cycle did not 
correspond with inspiration phase. 
2.1.5  Cardiac catheterization 
At the end stage studies and following echocardiography, left and right ventricular 
catheterisation was performed using a closed chest method. The technique 
involves insertion of a thin flexible tube called a catheter into the blood vessel and 
guided to the heart, despite its invasiveness it is required to definitively diagnose 
PAH as it gives important information about the dynamic inside the heart. Left 
and right ventricles were reached through the right internal carotid artery and the 
right external jugular vein respectively (figure 2.2), Isoflurane-induced 
anaesthesia was maintained throughout the procedure (0.5- 2 % v/v Isoflurane). 
First, to expose the jugular vein, a small incision was made in the neck to the right 
of the midline, then the tissue surrounding the vein were dissected carefully using 
fine curved forceps. The clear vein ligated with one suture distal to the heart and 
another loose suture proximal to the heart. Millar SPR-1030 1F catheter (Millar 
Instruments Inc, Houston, TX, USA) inserted through the vein by the aid of a bent 
25G needle to help to pull up the vein and inserting the catheter simultaneously. 
After this stage, the loose proximal suture can be tied off slightly and the recording 
can be started using the PowerLab system version 7 (AD Instruments, Oxford, 
UK), the catheter advanced carefully until reaching the right ventricle. The right 
ventricle haemodynamic parameters are taken when normal and stable RV 
tracing established. The tracing recorded for about a minute to allow multiple data 
extraction points then the catheter pulled carefully and the vein tied properly.    
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Similar principles were applied to cannulate the right internal carotid artery for the 
measurements of left ventricle loop haemodynamic using Millar SPR-1035 1F 
catheter (Millar Instruments Inc, Houston, TX, USA). If the systemic pressure was 
needed, the catheter pulled out slightly from the left ventricle to the aorta and the 
aortic pressure recorded. Data recorded using the Lab Chart Pro software 
(version 7.0, AD instrument, Oxfordshire, UK).      
 
 
2.1.6  Blood collection and tissue harvesting 
In the majority of the studies, blood collected from anaesthetized animals by 
cardiac puncture. Cardiac puncture is an effective technique to obtain a large 
volume of peripheral blood with a good quality from mice under deep terminal 
Figure 2.2- Ventricular pressure measurements: a) Diagram shows catheter inserted into 
right ventricle via jugular vein to record right ventricular pressure measurement (RVP) and a 
trace of the RVP. Y axis in mmHg. b) Diagram shows catheter inserted into left ventricle via 
right carotid artery to record left ventricular pressure measurement (LVP) and a trace of the 
LVP. Y axis in mmHg.    
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anaesthesia. Animals were placed on their back on flat stage or preheated mat, 
blood collected directly from the heart using 20 G needle, preferably from the left 
ventricle where the needle inserted through the left side of the chest just down 
the sternum, the blood then is withdrawn slowly to prevent heart collapsing. 0.1– 
1 ml blood can be drawn up from the heart depending on mouse age and size 
and whether the heart was beating or not. 
Cardiac puncture has not been used when lungs need to be lavaged for bronchial 
fluid collection, as heart and lungs must be undamaged and puncturing the heart 
may lead to leakage of blood into the peritoneal cavity. Therefore, blood was 
collected from the posterior vena cava, this was reached by cutting through the 
abdomen then the intestine and liver pushed gently to expose the vena cava 
where the blood can be withdrawn.    
The collected blood was then used to isolate the peripheral blood mononuclear 
cells (PBMC) or for serum separation. To isolate the PBMC, blood collected in 
tubes containing sodium citrate (3.8 % w/v, approximately 130 µl is required for 
each ml of blood) and placed on ice to preserve the integrity. For serum isolation, 
blood collected in empty covered tubes and left to clot at room temperature. 
After culling the mouse, a transverse incision was made below the diaphragm 
after peeling back chest skin, then by holding up the zyphoid process (the 
cartilaginous lower part of the sternum) a tiny hole was made in the diaphragm 
and the whole rib cage traced and removed carefully without piercing the lungs.     
Saline-filled syringe injected into the right ventricle to wash off the remaining 
blood in the heart and lungs. To expose the trachea a midline incision at the neck 
was made then the heart and both lungs were harvested en bloc, the right lung 
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was tied off and snap freeze in either RNAlater ® (R0901- 500ML SIGMA) and/or 
liquid nitrogen. The left lung was perfusion- fixed with slowly injected 10% 
formalin at 20-22 cm height via the trachea, 2 inches polyethylene tube (PE-90 
tubing from Becton Dickinson) fitted with 20G needle was used for lung perfusion.  
Heart and left lung then placed in formalin for 24 hours for fixing.  Liver and spleen 
were also harvested in formalin containing tubes for 24 hours fixation. 
Femur and tibia bones were collected with care in sterile petri-dish on ice for bone 
marrow cell harvesting, bones should stay intact as the cutting may compromise 
the sterility of bone marrow. Tissue kept in formalin for 24 hours then moved to 
sterile phosphate buffered saline (PBS) and stored in cold place to be processed 
for paraffin fixation and immune- staining. 
2.1.7  Isolation of mouse mononuclear cells for flow cytometry 
analysis 
In each experimental group, blood was pooled from the treated mice to make a 
volume of 3-5 ml of whole blood to perform density gradient isolation of 
mononuclear Cells (MNC). Blood diluted with equal volume of sterile PBS which 
then overlaid carefully into equal volume of density gradient medium Histopaque® 
1077 (10771, Sigma- Aldrich). The preparation then centrifuged at 400 Xg for 30-
40 minutes at 18- 20 ⁰C with no brakes to not compromise the layers generated. 
The MNC layer will be the cloudy layer in the middle which can be transferred by 
sterile Pasteur to another fresh centrifuge tube for washing. To wash, 3 ml of PBS 
was added then the sample centrifuged at 500 Xg for 5 minutes at 18- 20 ⁰C, the 
supernatant discarded.         
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For flow cytometry analysis, MNCs were counted using haemocytometer and 
then spliced between two tubes each containing 1 x 106 cell, one tube was the 
unstained control tube and the other stained with anti-mouse CD115 (Alexa Fluor 
® 488 anti-mouse CD115, BioLegend) according to manufacturer instructions 
(detailed in section 2.4.1).  
2.1.8  Isolation of serum for biochemical analysis 
After collecting the whole blood from each mouse in a cover tube, blood left to 
clot undisturbed at room temperature for at least 15 minutes, the clot was then 
removed by centrifuging the sample at 1000- 2000 rpm in a refrigerated 
centrifuge. Following centrifugation, the liquid component (serum) was 
transferred immediately into clean polypropylene tube using a Pasteur pipette 
and stored at -80 °C.    
2.1.9  Harvesting bone marrow cells 
After isolating the tibia and femur bones into a sterile petri dish, the bones were 
cleaned from fur and muscles in a sterile condition, then placed in DMEM 
(Dulbecco’s Modified Eagle’s Medium with glucose and L-glutamine, Lonza 
bioWhittaker®). Epiphyses removed using sterile scissors and forceps and the 
bone flushed with a 26G syringe filled with 5 ml DMEM to extrude bone marrow 
out to a petri dish. Cells were homogenized by plastic pipette or 26G syringe and 
counted using haemocytometer, then centrifuged at 300 Xg for 5 minutes. Pellets 
re-suspended in either culture medium for culturing or in freezing medium 
(containing 90% FCS, 10% dimethyl-sulfoxide DMSO) and frozen in cryovials at 
-80 ⁰C for storage. 
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2.1.10  Collection of broncho- alveolar lavage fluid 
To collect the broncho- alveolar lavage fluid (BALF) from mice, the mice were 
culled by anaesthetic overdose (pentobarbital 100-150µl intraperitoneal 
injection). The neck and thoracic cage exposed using a fine scissor and the 
tissues surrounding the trachea were dissected, rib cages traced partially to 
expose the heart and lungs.  With caution not to pierce the organs, a piece of 
thread passed underneath the trachea then 24G cannula inserted into the trachea 
in a distance about 2- 3 mm from its proximal end, the thread then tied off properly 
around the cannula after withdrawing the needle. After setting up the cannula 1 
ml of cold normal saline injected slowly into lungs which confirmed by lung 
inflating, then the fluid collected back into the syringe resulting in lung shrinking. 
This wash repeated for 5 times to collect approximately 4 ml lavage fluid in 15 ml 
falcon tube on ice, tubes then centrifuged at 450 Xg for 5 minutes. The 
supernatant transferred to cryovials for freezing at -80 ⁰C, while the pellets re-
suspended in either 100 µl cold media (RPMI medium 1640 contains 10% FBS, 
100 IU/ ml penicillin and 100 IU/ ml streptomycin) for culturing and preparation of 
cytospin slides, or in cold PBS for flow cytometry analysis. The yield was then 
counted with a haemocytometer (EVOS XL Core, life technologies® 
haemocytometer).     
To prepare a cytospin slide, an apparatus consists of a microscopic slide 
mounted with filter card and cytospin funnel into a metal holder was used. 100µl 
cell suspension was loaded into the funnel and centrifuged for 6 minutes at 250 
Xg using cytocentrifuge. The slide was then removed from the holder and left to 
dry for few seconds before fixation with few drops of methanol. To stain the cells, 
the slide was dipped into Eosin stain for few seconds, drained on a tissue then 
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stained with methylene blue for few seconds and finally washed with water. After 
air drying the slides mounted with DPX. 
2.1.11 Assessment of right ventricular hypertrophy 
Heart and left lung were perfusion fixed via the trachea at 20 cm using 10% 
formalin, the heart was dissected in a way that the atria, aorta, and the pericardial 
fat were all separated, and then the right ventricular free wall dissected from the 
left ventricle plus the septum and dried off. The right ventricular hypertrophy index 
(RVH index) was calculated by dividing the weight of the right ventricular (RV) 
over the weight of left ventricular free wall plus septum (LV+S). 
2.2  Immunohistochemistry 
2.2.1 Tissue preparation for immunohistochemical staining 
Liver, lung and spleen were harvested and stored for paraffin fixation as in section 
(2.1.6). Each tissue was embedded and cut into 3-4 pieces according to the 
sample size, the pieces were then placed in the standard size plastic cassette for 
dehydration. Cassettes were transferred through ascending concentrations of 
ethanol (starting from 50% v/v, 70%, 90% and 100%v/v for 1 hour each) then 
moved to a mixture of 50:50 xylene: ethanol followed by two changes of 100% 
xylene for 1 hour each before placing in molten wax for overnight (60⁰C oven), 
these steps were performed either manually or by using LEICA TP 1020 wax 
tissue processor automated system. 
For tissue embedding using paraffin wax, the LEICA EG 1150 (H) and (C) 
embedding stations were used as a working station. Using a proper size mould, 
each piece of tissue was placed on the flat side facing the bottom of the mould, 
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and then the warm wax used to fill the mould. Mould covered immediately with 
the labelled plastic lid and left to dry. 
Embedded tissues were left to dry overnight before cutting the sections. On the 
day of sectioning, tissue blocks removed from their mould and placed on ice for 
1 hour. A five micrometre thick sections were cut using Leica RM2135 microtome 
(Leica microsystems, Wetzlar, Germany). Sections floated out on 37⁰C water 
inside water bath to flatten the sections then mounted on Polysine TM slides and 
left to dry on 40⁰C oven overnight, at this stage the slides were ready for staining.  
For the preparation of frozen lung sections, snap frozen lung tissue were 
sectioned using a cryostat (a -20 ⁰C freezer enclosing a microtome). Tissue was 
moulded using embedding compound (CRYO-M-BED, Bright) then frozen with 
aid of freezing spray (Cryospray 134A, Bright) onto the specialized metal grid or 
the specimen chuck that supplied with the cryostat (LEICA CM3050 S). 5µm thick 
sections were cut and transferred within 1 minute to a room temperature slide as 
the section melted onto the surface. The slides were stored in -20⁰C freezer for 
future staining.      
2.2.2  Immunohistochemical staining 
2.2.2.1 Staining of tissue macrophages   
Lung, liver and spleen paraffin sections were immuno-stained with: anti- F4/80 
antibody as a pan-macrophage marker to estimate the level of ablation, and with 
anti-iNOS antibody and Anti-CD206 as M1 and M2 markers respectively. Lung 
paraffin sections were also stained with anti-IL-4 antibody to detect IL-4 
expressing cells.     
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For the immunohistochemical staining a standard protocol was followed for all of 
the antibodies, the protocol started with dewaxing and re-hydration steps by 
immersing the slides in 100% v/v xylene for 10 minutes moving through graded 
alcohol to water (100% v/v xylene, 100% v/v ethanol, 100% v/v ethanol, 90% v/v 
ethanol, 70% v/v ethanol and 50% v/v ethanol for 1 minute each). 3% hydrogen 
peroxide was then used for 10 minutes to block endogenous peroxidases 
followed by rinsing with water.      
For antigen retrieval, heat- mediated antigen retrieval (also known as heat-
induced epitope retrieval HIER) was performed using 1:10 dilution of 10mM 
citrate buffer at PH6 for 20 minutes at 95⁰C.  
To improve antibody penetration, it was important (except for anti- F4/80 
antibody) to use Triton X-100 on the slides for 10 minutes as a popular detergent 
used for this purpose. 
To block any non- specific binding of the secondary antibody and to exclude the 
false positive staining, 1% w/v milk blocking buffer (MARVEL original dried 
skimmed milk, Premier foods Ltd, UK / from a supermarket) was used for 30 
minutes before adding the primary antibody. 
Excess milk drained out without washing and a primary antibody was added and 
left for overnight at 4⁰C in a humidity chamber. Antibodies used were either: anti- 
F4/80 antibody (1:100 dilutions; Abcam, ab6640), anti-iNOS antibody (1:100 
dilutions; Abcam, ab15323), anti-CD206 (1:100 dilution; R & D systems, AF2535) 
or anti-IL-4 (1:150 dilution; Biorbyt, orb360766). Antibodies were diluted to the 
appropriate concentration using PBS in final volume enough to cover the slides 
(100 µl/ slide). Slides were then washed with PBS for 3 times 5 minutes each 
before incubating with the appropriate secondary antibody for 30 minutes (see 
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Appendix III for the types and dilutions used) followed by 3 washes with PBS. 
Control sections were included for each antibody application to confirm the 
absence of false positive staining; these were either by carrying out the protocol 
without adding the primary antibody or without adding the secondary antibody.  
The slides were incubated with Vectastain Elite ABC kit working reagent (Vector 
Laboratories) for 30 minutes, then washed further with PBS before incubation 
with DAB substrate (SIGMAFAST ™ 3,3’- Diamino-benzidine; SIGMA) for 3-8 
minutes and rinsing quickly with water. 
Finally, the slides were counterstained by Carazzi’s Haematoxylin for 1 minute 
then washed in water and dehydrated back through the graded alcohols (50% v/v 
ethanol, 70% v/v ethanol, 90% v/v ethanol, 100% v/v ethanol, 100% v/v ethanol) 
to 100% v/v xylene for 1 minute each. The slides were mounted with DPX and 
left to dry overnight. Histological images were visualized using Zeiss multi-slides 
scanning microscope (Imager.Z2, CarlZeiss limited) using Axiocam 506 colour 
camera. Slides were scanned sequentially using X20 magnification objective lens 
and saved to be analysed with the accompanying software. 
2.2.2.2 Staining of pulmonary blood vessels 
To assess the vascular remodelling, lung sections were stained against alpha- 
smooth muscle actin as a marker for smooth muscle, with Alcian blue Elastin Van 
Gieson (ABEVG) to assess the percentage of muscularised pulmonary arterioles, 
and with Von Willebrand to assess the state of endothelial cells.   
The same standard protocol detailed above was followed to stain the blood 
vessels in the lung sections. The protocol started with dewaxing and re-hydration 
steps by immersing the slides in 100% v/v xylene for 10 minutes moving through 
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graded alcohol to water (100% v/v xylene, 100% v/v ethanol, 100% v/v ethanol, 
90% v/v ethanol, 70% v/v ethanol and 50% v/v ethanol for 1 minute each). Then, 
3% hydrogen peroxide was used for 10 minutes to block endogenous 
peroxidases followed by rinsing with water.      
Antigen retrieval step was used in case of the vWF staining only, no- heat antigen 
retrieval was utilized. The no-heat method (also called proteolytic induced epitope 
retrieval (PIER)) depends on the enzyme digestion where 0.1% trypsin in TBS 
was used for 10 min at 37 ⁰C. 
To block any non- specific binding of the secondary antibody 1% w/v milk blocking 
buffer (MARVEL original dried skimmed milk, Premier foods Ltd, UK / from a 
supermarket) was used for 30 minutes before adding the primary antibody. 
Excess milk drained out without washing and the primary antibody added. The 
primary antibodies used to stain the blood vessels were: alpha- smooth muscle 
actin (1:150 dilution; Dako Mouse monoclonal anti-human- α- SMA antibody, 
M0851) and with vWF (1:300 dilution; Dako rabbit anti-human vWF, A0082). The 
primary antibody was left for 1 hour at room temperature in a humidity chamber. 
The antibodies were diluted to the appropriate concentration using PBS in 
sufficient final volume to cover the slides (100 µl/ slide). Slides were washed with 
PBS for 3 times 5 minutes each before incubating with the secondary antibody 
for 30 minutes (see appendix II for the types and dilutions used) followed by 3 
washes with PBS. Control sections were also included for each antibody 
application to confirm the absence of false positive staining. 
The slides were then incubated with Vectastain Elite ABC kit working reagent 
(Vector Laboratories) for 30 minutes and washed further with PBS before 
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incubation with DAB substrate (SIGMAFAST ™ 3,3’- Diamino-benzidine; SIGMA) 
for 3-8 minutes and rinsing quickly with water. 
Finally, the slides were counterstained by Carazzi’s Haematoxylin for 1 minute 
then washed in water and dehydrated back through the graded alcohols (50% v/v 
ethanol, 70% v/v ethanol, 90% v/v ethanol, 100% v/v ethanol, 100% v/v ethanol) 
to 100% v/v xylene for 1 minute each. The slides were mounted with DPX and 
left to dry overnight. 
For Alcian blue Elastin Van Gieson (ABEVG) staining, slides were dewaxed and 
re-hydrated as above, then oxidized with 0.25% w/v potassium permanganate for 
3 minutes. Sections were rinsed with water for 3 minutes and then bleached with 
oxalic acid for another 3 minutes and washed again. The slides then stained with 
Carazzi’s haematoxylin for 2 minutes to stain the nuclei before been differentiated 
in 1% acid alcohol for few seconds. Hot running tap water used to wash the slides 
for 5 minutes then stained with Alcian blue stain (1% in 3% acetic acid, PH 2.5) 
for 5 minutes. Slides were rinsed in water first then rinsed with 95% industrial 
methylated spirits (IMS) before they transferred to the Miller Elastin stain for 30 
minutes. The slides then rinsed and differentiated in 95% IMS followed by a brief 
rinse in water before the Curti’s modified Van Gieson was added for 6 minutes. 
Finally, after rinsing the slides with water they were dehydrated back through the 
graded alcohols 70% v/v ethanol, 100% v/v ethanol and 100% v/v xylene then 
mounted with DPX (see Appendix III for more information about the antibodies 
used and preparation of buffers).       
Histological images were visualized using Zeiss multi-slides scanning 
microscope (Imager.Z2, CarlZeiss limited) using Axiocam 506 colour camera. 
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Slides were scanned sequentially using X20 magnification objective lens and 
saved to be analysed with the accompanying software.      
2.2.3  Immunohistochemical analysis 
To determine the level of macrophage ablation, the number of the remaining 
macrophages within the tissues was calculated by counting positively stained 
cells for the anti-F4/80 antibody (pan-macrophage marker), anti-CD206 (M2 
marker) and anti- iNOS (M1 marker) remained within the liver, lung and spleen of 
treated mice. Six fields of view with a high density of stained cells were recorded 
under X20 objective. The average number of macrophages per field of view was 
normalized to the average of the control group.    
2.2.4  Analysis of vessel wall remodelling 
To determine the effect macrophage ablation had on the pulmonary arteries, two 
parameters were measured to quantify and assess the degree of remodelling 
within these vessels. The first includes calculating the ratio of the media to the 
cross-sectional area (media/ CSA) of the whole vessel in sections stained with α- 
smooth muscle actin staining (identifying vascular smooth muscle cells). The 
second parameter assess the degree of muscularisation in sections stained with 
Miller Elastin stain (ABEVG), this was performed by classifying the vessels to 
muscularised (has double elastic lamina) and non- muscularised (one thin elastic 
lamina layer), then expressed as a percentage of muscularised vessels to total 
pulmonary vessels.   
For both of the parameters, around 50-100 vessel were scored in each mouse, 
and the vessels were divided according to their size into 3 categories: small or 
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distal pulmonary arteries with an outer diameter of less than 50µm, medium 
pulmonary arteries with a diameter between 50-100 µm and large pulmonary 
arteries having an external diameter more than 100µm. 
 Analysis performed using Zeiss multi-slides scanning microscope accompanied 
ZEN software. 
2.2.5 Immunofluorescence staining 
For the Immunofluorescence detection of SMA in the formalin- fixed, paraffin-
embedded lung tissue, The slides were de-waxed and re-hydrated by immersing 
in 100% v/v xylene for 10 minutes moving through graded alcohol to water (100% 
v/v xylene, 100% v/v ethanol, 100% v/v ethanol, 90% v/v ethanol and 70% v/v 
ethanol for 1 minute each). 3% v/v hydrogen peroxide were then used for 10 
minutes to block endogenous peroxidases followed by rinsing with water.      
To block the non-specific binding of the antibody, the slides were incubated in 
blocking solution (5% v/v goat serum, 1% w/v BSA in BPS-T (0.05% v/v tween 
20 in PBS)) for 1 hour at room temperature. Excess blocking solution was drained 
out without washing and the primary added (1:150 from Dako Mouse monoclonal 
anti-human- α- SMA antibody) and left for overnight at 4 ⁰C in a humidity chamber.  
The antibody was diluted to the appropriate concentration using the blocking 
solution in sufficient final volume to cover the slides (100µl/ slide). Slides were 
then washed with PBS-T for 5 times 5 minutes each before incubating with the 
secondary antibody. The secondary antibody used was goat anti- mouse Alexa 
555 at 1:200 dilution in PBS. The slides incubated in the secondary antibody for 
1 hour at the room temperature in dark then washed with PBS-T and mounted 
with Vectashield® with DAPI mounting media ( by Vector laboratories). Slides 
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were sealed with nail polish and kept in dark. Negative control slides that 
incubated with either no primary antibody, no secondary antibody or none of them 
were also included. 
To examine the co-distribution of macrophages in smooth muscle cells in one 
paraffin section, the double immunofluorescence staining was carried out using 
two primary antibodies (anti-F4/80 for macrophages and anti-SMA for smooth 
muscle cells) raised in different species in a mixture. The same protocol 
described above was performed using primary antibodies mixture that contains 
anti-F4/80 (rat monoclonal; Abcam, ab6640) at 1:100 dilutions with anti- SMA 
(mouse monoclonal; Dako, M0851) at 1:150 dilution in PBS-T. The secondary 
antibodies mixture solution used contains (Goat anti- rat Alexa 488 and Goat anti-
mouse Alexa 555) at 1:200 dilution each. 
To examine the proliferation capacity of macrophages in frozen lung section, the 
double immunofluorescence staining was carried out using the two primary 
antibodies (anti-F4/80 for macrophages and PCNA for proliferating cells) raised 
in different species in a mixture. For double immunofluorescence staining of 
frozen lung section, the slides were fixed with ice- cold acetone for 10 minutes 
then washed with PBS-T for 3 times for 5 minutes each. To block the non-specific 
binding, the slides incubated in blocking buffer (1% w/v BSA, 5% v/v goat serum 
in PBS-T) for 1 hour at room temperature. Excess blocking solution was drained 
out without washing and the primary antibodies mixture that contains rat 
monoclonal anti-F4/80 (Abcam, ab6640) at 1:150 dilution with the monoclonal 
mouse anti-PCNA (Dako; M0876) at 1:125 dilution was added and left for 
overnight at 4⁰C in a humidity chamber.  The antibody was diluted to the 
appropriate concentration using the blocking solution in sufficient final volume to 
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cover the slides (100µl/ slide). Slides were washed with PBS-T for 5 times 5 
minutes each before incubating with the secondary antibody. The secondary 
antibodies used were the goat anti-mouse Alexa 555 and goat anti-rat Alexa 488 
in a mixture at 1:200 dilution in PBS. The slides were incubated in the secondary 
antibodies solution for 1 hour at the room temperature in dark then washed with 
PBS-T and mounted with Vectashield® with DAPI mounting media (by Vector 
laboratories). Slides were sealed with nail polish and kept in dark. Negative 
control slides that were incubated with either no primary antibodies, no secondary 
antibodies or none of them were also included. 
2.2.6 Immunofluorescence analysis  
Immunofluorescence images were visualized using Zeiss multi-slides scanning 
microscope (Imager.Z2, CarlZeiss limited) using the MRm camera and the 
appropriate filter for each fluorophore. Slides were scanned using X20 
magnification objective lens and saved to be analysed with the accompanying 
software. 
2.3  Culturing of mouse primary cells 
2.3.1 Culturing of bone marrow- derived macrophages 
Frozen or fresh bone marrow- derived macrophages (BMDMs) were thawed or 
suspended in DMEM culture medium containing 100IU/ml Penicillin/ 
Streptomycin antibiotics, 10% FBS, 20ng/ml M-CSF (gibco® by life technologies), 
cells were then incubated in a humidified incubator with 5% CO2 at 37⁰C, after 3 
days of growing the media discarded and the cells washed with PBS before 
adding a fresh media. At day 7 mature BMDM were obtained and they were ready 
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for splitting as required (figure 2.3). As macrophages adhere strongly to the flask, 
room-temperature trypsin was used to incubate the cells twice at 37⁰C (5 minutes 
each) before scrapping them gently of the flask. Formation of the mature BMDM 
was evaluated using flow cytometry analysis and fluorophore-conjugated 
antibodies to detect cells expressing F4/80 and CD68. 
To study cells polarization and differentiation, cells were seeded at 2 X105 /ml 
and on the following day they stimulated with either LPS (100 ng/ml; cell- signal®) 
with IFNγ (50ng/ml; R&D system) for M1 activation, IL-4 (10 ng/ml; R&D system) 
for M2 activation, or doxycycline (1µg/ml, 5µg/ml, 10µg/ml and 40µg/ml). After 48 
hours cell phenotype was investigated using flow cytometry. 
For the viability assay, cells were seeded in 96-well plate at a density of 20,000 
cells per well. The viability assay performed at the zero time then the cells treated 
with a fixed dose of doxycycline and their viability assessed again at the different 
time point (see section 2.7) 
For immunocytochemical staining, cells were seeded in 6 well plate at 0.5 X106 
cell/ well before stimulating with doxycycline (see section 2.5.2).  
The morphological investigation was performed using approximately 8 X106 cell 
in each well of 6- well plate and then differentiated into the different macrophage 
populations as described above. Images were taken by EVOS XL Core, life 
technologies® haemocytometer, with 20X magnification.  Conditioned media was 
also collected from each cell type generated and stored at -80⁰C freezer for future 
work. 
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2.3.2 Culturing of alveolar macrophages  
Fresh cells from BALF were cultured using warm RPMI media (contains 10% 
FBS, 100 IU/ml Penicillin/ Streptomycin) after passing through a 35µl cell strainer. 
Collected cells were confirmed to be mainly alveolar macrophages (AMs) using 
flow cytometry analysis (figure 2.4). 
About 0.5 X106 cell/ml were placed per well into 6 well plate, then allowed to 
adhere inside the incubator for 2 hours.  Cells were stimulated with either LPS/ 
INFγ, IL-4 or doxycycline as above. After 48 hours, cell phenotype and their 
polarization following stimulation were investigated using flow cytometry and 
immunocytochemistry. 
For the viability assay, cells were seeded in 96-well plate at a density of 20,000 
cells per well. The viability assay performed at the zero time then the cells treated 
with a fixed dose of doxycycline and their viability assessed again at the different 
time point (see section 2.6). 
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For immunocytochemical staining, cells were seeded in 6 well plate at 0.5 X106 
cell/ well before stimulating with doxycycline (see section 2.5.2).  
Figure 2.3- Culturing of bone marrow-derived macrophages: Diagram describes, in brief, 
the process of collecting and culturing of mouse bone marrow cells. Myeloid progenitor cells 
harvested from the bone then cultured in M-CSF containing media for 7 days to differentiate 
to mature bone marrow-derived macrophages (BMDM), mature BMDM formation confirmed 
by flow cytometry.   
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The morphological investigation was performed using approximately 8 X106 cell 
in each well of 6- well plate and then differentiated into the different macrophage 
populations as described above. Images were taken by EVOS XL Core, life 
technologies® haemocytometer, with 20X magnification. 
Conditioned media was also collected from each cell type generated and stored 
at -80⁰C freezer for future work. 
 
 
Figure 2.4- Culturing of Alveolar macrophages: a diagram describes, in brief, the process 
of collecting and culturing of alveolar macrophages. Broncho-alveolar lavage fluid (BALF) 
collected from mouse lung and passed through a cell strainer, cells confirmed to be alveolar 
macrophages by flow cytometry. 
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2.4 Flow cytometry analysis 
2.4.1 Flow cytometry analysis of mouse blood  
For flow cytometry analysis of the mouse blood, MNCs were spliced between two 
tubes (1 x 106 cell each), one tube was left unstained as a control while the other 
was stained with anti-mouse CD115 (Alexa Fluor ® 488 anti-mouse CD115, 
0.5mg/ml, BioLegend). 2µl of the antibody was used for each 1 million cell, 
incubated on ice in the dark for 20- 40 minutes. Following incubation, both tubes 
were washed twice with 2ml washing buffer (PBS) and centrifuged at 500Xg for 
5 minutes. Pellets were re-suspended in 300µl PBS and kept on ice until the time 
of flow cytometry analysis. BD LSR II flow cytometer was used (BD Biosciences, 
Pharmingen) for flow cytometry. Blood monocyte was identified on the basis of 
their size and granularity using the forward and side light scatter plot. For each 
sample, a minimum of 10,000 events was recorded, and the data analysed with 
FlowJo software version 10.2. 
2.4.2 Flow cytometry analysis of mouse primary cells 
For flow cytometry analysis of mouse BMDM and BALF, cells were collected by 
detaching from the flask using warm trypsin and scrapping as previously 
described. Cells then washed with PBS and stained with the antibodies. The 
antibodies used were: APC anti-mouse F4/80. FITC anti-mouse CD68, PE anti-
mouse CD206 (MMR) and the Pacific BlueTM anti-mouse all from Biolegend®, 
(more information about the antibodies used in appendix IV). Negative unstained 
controls or the proper isotypes were run in parallel to each antibody. 1µl of each 
antibody was used for each 1 million cell, incubated on ice in dark for 20-40 
minutes. Following incubation, both tubes washed twice with 2ml washing buffer 
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(PBS) and centrifuged at 500Xg for 5 minutes. Pellets were re-suspended in 
300µl PBS and kept on ice until the time of flow cytometry analysis. BD LSR II 
flow cytometer was used (BD Biosciences, Pharmingen). For each sample, a 
minimum of 10,000 events was recorded, and the data analysed with FlowJo 
software version 10.2. 
2.5 Immunocytochemistry  
2.5.1  Cells preparation for immunocytochemistry 
In a sterile tissue culture hood, glass coverslips (18mm X 18mm, Zeiss) were 
sterilized by dipping in 70% v/v ethanol, slips were left to dry out then placed in 
sterile 6 well plates. 2 ml cell suspension (mature BMDM or fresh BAL cells) 
containing 0.2 – 0.4 X 106 cells were added over each coverslip in the plate, then 
placed in the incubator for 24 hours before been stimulated according to the 
experiment design.  
2.5.2  Immunocytochemical/ immunofluorescence staining 
Culture medium from each well was aspirated and the cells gently rinsed twice 
with PBS at room temperature. For the immunofluorescence staining, general 
protocol was adopted. In brief, cells were fixed by incubation in 4% v/v 
paraformaldehyde in PBS for 10 minutes then rinsed three times with PBS. To 
permeabilize the cells, cells were incubated for 15 minutes in 0.1% v/v Triton X-
100 in PBS at room temperature. Again cells were washed gently three times with 
PBS. Cells were then incubated in blocking buffer (1% BSA in PBS contains 0.1% 
v/v tween 20) for 1 hour before adding the primary antibody.   
Materials and methods 
 
63 
 
The primary antibody used was the anti-5 lipoxygenase antibody (Abcam, 
ab39347) in a dilution of 1:100 in the blocking buffer, the final volume should be 
should be sufficient to cover the whole coverslip (minimum of 500µl per well). 
Cells incubated with the primary antibody overnight at 4⁰C in dark then washed 
three times with PBS. The secondary antibody was diluted in the blocking buffer 
away from light to the appropriate concentration (1:200 of Goat anti- rabbit IgG 
Alexa Fluor® 555, Abcam), cells were incubated with the secondary antibody for 
1 hour in dark at room temperature.  
To confirm the absence of autofluorescence and the non-specific binding, a 
parallel protocol was carried out without adding the primary antibody or without 
adding the secondary antibodies to the cells as negative controls.   
Cells were rinsed thoroughly with PBS three times/ 5 minutes each away from 
light. Enough microscope slides were labelled and one drop of mounting medium 
(Vectashield with DAPI) was added to each slide, then each coverslip was 
carefully mounted on the slide with the cell- side face down and left to dry for few 
minutes. Nail polish was used to seal the edges of the coverslips to the slides 
and the slides visualized using the fluorescence channel with the appropriate 
filters of the Zeiss multi-scanning microscope. Analysis was performed using FiJi 
image processor software (ImageJ 1.51; USA). 
2.6 Cell viability assay  
To examine the effect of doxycycline on cell death in vitro, cell viability analysis 
was performed using the ApoTox-GloTM Triplex assay kit (Promega, Madison, 
USA). This assay is a three in one technique that allows assessment of viability, 
cytotoxicity and caspase activation (a hallmark of apoptosis) in a single assay, 
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also to determine the mechanism of cell death. The kit includes three substrates; 
a viability substrate (glycyl-phenyl-alanyl-aminofluorocoumarin; GF-AFC) which 
is a cell-permeable peptide that cleaved by the live- cell protease when entering 
the intact cell and generates fluorescent signals correlate to the number the living 
cells. A cytotoxicity substrate (bis-alanylalanyl-phenylalanyl-rhodamine 110; bis-
AAF-R110) which is a cell-impermeable peptide that cleaved by the dead-cell 
protease and generates fluorescent signals correlate to a number of cells that lost 
their cell membrane. 
Both of the fluorogenic products (AFC and R110) can be detected simultaneously 
as they have different excitation and emission spectra thus both of the substrates 
can be added at the same time. And the caspase -3/7 luminogenic substrate, 
which added lastly to the cells as it leads to cell lysis, caspase cleavage and 
generation of a glow-type luminescent signal from the luciferase, this signal is 
proportional to the caspase activity.  
In this experiment, mature BMDM or BAL cells derived from MacLow and control 
mice were tested. The aim was to detect the cell viability, cytotoxicity and the 
probable apoptosis (caspase activity) following doxycycline treatment at the 
different time point to compare between the MacLow vs control derived cells and 
BMDM vs AM in term of effect of doxycycline as an inducer of cell death. The 
cells were seeded in a 96-well plate at a density of 20,000 cell per well with the 
appropriate media for a 100µl final volume. The viability assay performed at day 
zero following the manufacturer protocol. In brief, at the first part of the assay 
20µl of the reagent mixture contains the viability and cytotoxicity substrates was 
added to each well, then mixed by orbital shaker (500rpm for 30 seconds) 
followed by 30 minutes incubation at 37⁰C. The fluorescence measured at an 
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excitation wavelength of 400nm and an emission of 505nm for the viability and 
485 nm excitation/ 520 nm emission for the cytotoxicity. On the second part, 100µl 
of the Caspase-Glo® 3/7 reagent added to each well, then mixed at 500rpm for 
30 seconds followed by 30 minutes incubation at 37⁰C, then the luminescence 
measured.        
Following the zero time viability assay, doxycycline was added at a concentration 
of 5 µg/ml, and the assay performed again after 2,4,5 and 7 days. The 
fluorescence/ luminescence was measured by the advanced spectral scanning 
multimode reader, the Varioskan Flash (Thermo Scientific).  
2.7 Dot blot technique for detection of protein expression 
Dot blot technique is used for detecting and identifying the expression of 
Diphtheria Toxin A protein (DTA) in cell lysate after inducing its synthesis with 
doxycycline (figure 2.5). The technique is different from western blot in that the 
protein samples are not separated electrophoretically but instead spotted directly 
onto the membrane.   For the preparation of cell lysate, BMDM or BAL cells 
derived from MacLow mice were stimulated with 5 µg/ml doxycycline or left with 
no stimulation for 48 hours. The cells were washed with ice-cold PBS then lysed 
using 1:100 protease and phosphatase inhibitor cocktail in RIPA lysing buffer 
(see appendix V for recipe), the flask left on ice for 20 minutes before storing in 
the -80ºC freezer. The lysed cell were then scrapped from the flask and 
transferred to Eppendorf tube for further analytical experiments.  
For the dot blot experiment, a nitrocellulose membrane (Amersham™ protran ™ 
0.45µm NC) was prepared by drawing a grid using a pencil to identify the samples 
region, then a narrow- mouth pipette tip was used to spot 2µl of each sample onto 
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the centre of the grid. The membrane left to dry for few minutes then soaked in 
the blocking buffer (30% Odyssey® blocking buffer; LI-COR® diluted in PBS) to 
block the none specific sites for 1 hour in a rocker. With no washing, the 
membrane incubated in 1:2000 of the primary antibody (anti- DTA antibody; 
Abcam, ab8308) diluted in 30% blocking buffer for 1 hour. The membranes were 
washed 3 times using the washing solution (0.05% v/v Tween 20 in PBS) for 5 
minutes each before incubating with the secondary antibody (1:10000 of Goat 
anti-mouse; Dyssey®) diluted in 30% blocking buffer for 1 hour in a rocker. Finally, 
the membranes were washed 3 times for 5 minutes each using the washing 
solution then visualized by the LI-COR ® reader using the proper channels.   
 
 
Figure 2.5- Expression of Diphtheria toxin A DTA: a diagram describes the rationale of 
DTA expression in culture. Doxycycline induces the expression of DTA under control of a 
CD68 promoter.  The resulted DTA was detected using the dot blot technique. 
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2.8  Statistical analysis 
All statistics were performed using GraphPad prism version 7.2 (GraphPad 
software, SanDiego, California USA). Statistical comparison between the 
different groups was established by the use of one- way analysis of variance 
(ANOVA) followed by Bonferroni post- hoc analysis. When comparing between 
groups that have two or more independent variables, the two-way ANOVA was 
used. Unpaired t-test was used when comparing only two independent groups. 
Values are presented as mean ± SEM, and differences of P< 0.05 values were 
taken as significant. 
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3  Impact of CD68+ cell depletion on the 
development of pulmonary arterial 
hypertension 
 
3.1 Introduction 
Inflammation in PAH has been an area of great interest in experimental research 
during the last decade. The presence of different inflammatory cells such as mast 
cells, lymphocytes, dendritic cells and macrophages around the vascular lesions 
point towards their contribution in disease pathology, however, their definitive role 
is still unclear. It is important to understand the different immune pathways 
associated with PAH to support the argument about the utility of designed 
immune-therapy for patients with PAH. 
A study by Savai and colleagues showed in an elegant way that the CD68+ 
macrophages were significantly higher in lungs of IPAH subjects compared to 
donor's lungs, they also showed that these cells accumulated in large numbers 
in the adventitial layer of small, medium and large pulmonary arteries of IPAH 
lungs. Furthermore, they showed that by blocking the recruitment of the 
inflammatory cells (including CD68+ macrophages) they could attenuate the PH 
phenotype in monocrotaline rat model (Savai et al., 2012).    
In my research, I am using the MacLow mouse model for specific macrophage 
ablation to investigate the role of macrophages in PAH. The MacLow mouse 
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model utilizes the tet-on system to switch on the expression of DTA in the CD68 
positive cell following doxycycline treatment leading to 50% loss of tissue 
macrophages (Gheryani et al., 2013, Rumney et al., 2017). 
This chapter will address the first objective of this research, which is to investigate 
whether loss of macrophages can actually cause a spontaneous PAH phenotype 
in MacLow mice as suggested by my previous findings (refer to figure 1.4). First, 
a doxycycline time- point study was conducted to determine the duration of action 
of doxycycline as a gene inducer and the level of ablation caused by a single 
dose of doxycycline was determined. Then, a longer- term macrophage depletion 
study (MacLow- induced PAH study) was conducted to determine the effect of 
long-term depletion on the development of PAH. The depletion of M1 and M2 
subsets after doxycycline treatment was also investigated.  
3.2 Material and methods 
3.2.1 Doxycycline time- point study design 
Sixteen age- and sex- matched adult MacLow mice were used in this study, 
animals were divided into four groups of four (two males and two females). In 
addition, single transgenic tetDTA mice were also used as controls in each group. 
All animals were injected with a single intraperitoneal injection of doxycycline (80 
mg/kg body weight) and then a single group was sacrificed at zero, 24 hours, 72 
hours and 7 days after injection (figure 3.1-a).  
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3.2.2 MacLow- induced pulmonary arterial hypertension study 
design 
Four groups of mice (two male groups and two female groups) were used in this 
study. A male and a female group (n= 8 per group) 12- 14 week age MacLow 
mice were used as treatment groups, parallel groups of age and sex- matched 
single transgenic mice were used as control groups. All the groups were treated 
with doxycycline in the diet for six weeks, mice were maintained in a normal 
environment with a 12 hour light/ dark cycle, normal air (21% oxygen) and normal 
humidity. Doxycycline was given in a dose of 80 mg/kg body weight in doxycycline 
containing diet (contains 625 mg/kg doxycycline) (figure 3.5-a).    
Mice were weighed weekly for first 3 weeks, then on every other day for the 
remaining 3 weeks, the echocardiographic analysis was performed to monitor the 
disease development at the 3 weeks midpoint, disease progression assessed at 
the endpoint using echocardiography, closed chest cardiac and lung 
immunostaining. 
3.2.3  Echocardiography and cardiac catheterization  
Following six weeks of doxycycline treatment, non- invasive assessment of the 
disease was performed using echocardiography under anaesthesia as described 
in section 2.1.4. Then the closed chest cardiac catheterization was used to take 
the pressure- volume measurements from both sides of the heart as described in 
section 2.1.5. 
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3.2.4  Histological analysis  
Tissues were harvested, fixed, processed, and stained according to the standard 
laboratory procedure described in sections 2.1.6 and 2.2.  
3.2.5  Statistical analysis 
All statistics were performed using GraphPad Prism version 7.2 (GraphPad 
software, SanDiego, California USA). Statistical comparison between the 
different groups was established by the use of one- way analysis of variance 
(ANOVA) followed by Bonferroni post- hoc analysis. Two- way ANOVA was used 
when comparing groups with two or more variables. Values are presented as 
mean ± SEM, and differences of P< 0.05 values were taken as significant.   
3.3 Results 
3.3.1 Doxycycline time-point study 
To assess the duration of action of doxycycline as a gene inducer and determine 
the level of macrophage depletion caused after one dose of doxycycline, a single 
intraperitoneal injection (i.p) of doxycycline was administered to MacLow and 
control groups. Total tissue macrophages, as well as M1 and M2 macrophages 
subsets and blood monocytes, were assessed at zero, 1, 3 and 7 days following 
the injection.  
3.3.1.1  Reduction of F4/80 + macrophages within different tissues 
following doxycycline injection 
To determine the level of macrophage ablation, the number of macrophages 
remaining following doxycycline injection was calculated by counting cells stained 
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positively for the anti-F4/80 antibody (pan-macrophage marker) in the liver, lung 
and spleen of injected mice. In the MacLow mouse model the targeted cells are 
CD68 positive macrophages, however, no difference was observed previously in 
term of macrophage quantification between the use of anti-F4/80 and anti-CD68 
antibodies (Gheryani et al., 2013, Rumney et al., 2017), thus anti-F4/80 was 
chosen as the staining protocol as it was more reliable. Six fields of view with a 
high density of stained cells were quantified under X20 objective. The average 
number of macrophages at each time point was normalized to the day zero count.    
The results showed that single i.p injection of doxycycline caused an approximate 
30-40% reduction in the total number of F4/80+ macrophages within the lung, 
liver and spleen of MacLow mice, however the reduction was not significant. The 
percentage of reduction of F4/80 positive macrophages within the liver showed a 
significant decrease at day 3 in MacLow group compared to day zero (figure 3.1). 
The pattern of reduction was similar between the three tissues investigated (lung, 
liver and spleen) where the reduction of macrophages occurs within the first 3 
days following the injection, then the number rises again to baseline levels. The 
control mice showed no clear pattern in their macrophage count over the 7 days. 
It was recommended to increase the power of the study (by increasing the 
number of mice in each group) to get clear statistical analysis, However, this was 
hindered by ethical restrains as the i.p injections of doxycycline were causing pain 
and distress to the mice.   
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Figure 3.1- Macrophage quantification after a single dose of doxycycline: a) Schematic 
of the study design of doxycycline time- point study displaying the different time-points 
selected for macrophage quantification following a doxycycline i.p injection (80 mg/kg body 
weight). b) Graphs with the corresponding representative histological images show the 
difference in number of macrophages (arrow-head) over time within lung, liver and spleen 
normalised to day zero time. Tissues stained with anti- F4/80 antibody (stained brown). Scale 
bar = 100µm.  n= 4/ MacLow group, n= 3/ control group. **P<0.005 using the two-way 
ANOVA. 
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3.3.1.2 Reduction of M1 and M2 macrophages within different tissues 
following doxycycline injection 
To further investigate whether the MacLow model has a dominant effect on one 
macrophage subset over another, two cell markers were used to quantify the cells 
remaining within the tissues after doxycycline injection. For the M2 subset 
(alternatively activated macrophages) antiCD206 antibody was used, while anti-
iNOS antibody was used to identify and count the M1 subset (classically activated 
macrophages).  
The analysis of positively stained cells for both antibodies showed no significant 
differences in any of the time point compared to zero time. However, the 
doxycycline injection shown to cause 20-30% reduction in cell count within the 
first 3 days in both subsets in all tissues investigated, but again the reduction was 
not significant (figures 3.2 and 3.3). This suggests that the induced ablation of 
macrophages with doxycycline might affect both M1 and M2 subsets. There was 
an unexplainable increase in a number of CD206 + macrophages within the livers 
of the MacLow mice after 1 day of the injection.  
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Figure 3.2- M2 macrophage quantification after a single dose of doxycycline: Graphs 
with the corresponding representative histological images show the difference in a number of 
CD206+ macrophages (arrow-head) over time within lung, liver and spleen normalised to day 
zero time. Tissues stained with anti- CD206 antibody (stained brown). Scale bar = 100µm.  
n= 4/ MacLow group, n= 3/ control group. Data analysed with two-way ANOVA. 
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Figure 3.3- M1 macrophage quantification after a single dose of doxycycline: Graphs 
with the corresponding representative histological images displaying the change in numbers 
of iNOS+ macrophages (arrow-head) over time within lung, liver and spleen normalised to day 
zero time. Tissues stained with anti- iNOS antibody (stained brown). Scale bar = 100µm.  n= 
4/ MacLow group, n= 3/ control group. Data analysed with two-way ANOVA. 
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3.3.1.3  Reduction in blood monocyte following doxycycline injection  
To determine if the number of circulating monocytes changed over the time 
course and if their numbers were affected by the alteration in macrophage 
number. Flow-cytometry using anti- CD115 antibody (to detect murine 
monocytes) was performed. Blood was pooled from all mice (n=4)  in each group 
of MacLow mice into one sample, then peripheral blood mononuclear cells 
isolated and stained with Alexa Fluor® 488 anti-mouse CD115 (refer to sections 
2.1.7 and 2.4). Because the minimum amount of blood required to isolate blood 
monocyte is 3-4 ml, no data were acquired from the control groups at any time 
point.   
Interestingly, the data shows that the number of circulating monocyte was 
massively depleted within the first three days of the injection, with a peak at 24 
hours (more than 50% reduction) then the level increased continuously to above 
the baseline count (figure 3.4). The pattern of reduction was consistent with that 
of tissue macrophages. However, none of these data was statistically analysed 
as the samples had to be pooled. 
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Figure 3.4- Flow cytometric analysis of the circulating monocyte after a single dose of 
doxycycline: a) representative examples of the flow cytometric plot of peripheral blood 
mononuclear cells stained with Alexa Fluor ® 488 anti-mouse CD115. The plot shows 
approximately 4.8% of the total parent cells at zero time are CD115 positive (left plot) whereas 
this drops to 1.9 % after 24 hours of doxycycline injection (right plot). b) A graph showing the 
pattern of reduction of monocyte count in the blood of MacLow mice over the period of 7 days 
after the doxycycline injection. Each point represents the result from a pooled blood sample from 
the MacLow group. n=4. 
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3.3.2  MacLow- induced pulmonary arterial hypertension 
To determine the effect of long-term loss of macrophages (specifically lung 
macrophages) in MacLow mice, mice were treated with doxycycline for six weeks 
with no other insult, and then the development of the PAH phenotype was 
assessed.  
3.3.2.1  Confirmation of macrophage depletion in MacLow mice 
To confirm depletion of macrophages in the MacLow model, the number of 
macrophages within the livers was calculated. 5 µm paraffin-embedded liver 
sections were stained with anti-F4/80 antibody, and then macrophages were 
counted as previously described (sections 2.2.2 and 2.2.3). The results showed 
a significant reduction (approximately 35- 40%) in the total macrophage numbers 
in male and female MacLow groups compared to the corresponding controls 
(figure 3.5). although the expected level of depletion is 50 % reduction (Gheryani 
et al., 2013, Zawia, 2011), the obtained level of macrophage reduction was still 
acceptable and statistically significant. In addition, the data showed no difference 
between males and females in term of their loss of macrophages after the six 
weeks doxycycline treatment. 
3.3.2.2  Assessment of PAH in MacLow mice 
3.3.2.2.1 Haemodynamic evaluation 
Following doxycycline treatment, disease progression was first assessed by the 
different haemodynamic parameters (gathered from the heart catheterization and 
echocardiography) as well as the right ventricle hypertrophy value (Fulton index). 
Interestingly, male MacLow mice but not female displayed a spontaneous 
disease phenotype after doxycycline administration with a significant increase in 
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their right ventricular end- systolic pressure (RVESP) compared with the controls 
(66.1 mmHg vs 24.5 mmHg respectively) (figure 3.6-a). This effect was also seen 
in most of the other haemodynamic parameters measured from the right side of 
the heart such as the contractility assessment (dp/dt max) and the arterial 
elastance (Ea) (see appendix I), with no effect on the measurements from the 
left-side of the heart especially the left ventricular end- systolic pressure (LVESP) 
(figure 3.6-b). No change was detected in the left ventricle internal diameter 
(LVID) nor the cardiac index between the groups (figure 3.6- d,e).       
To investigate whether this increase in pressure has led to right ventricular 
hypertrophy (RVH), the RVH index was calculated. RVH value represents a 
hallmark of right ventricular hypertrophy and was assessed on the basis of the 
ratio of RV free wall weight to the left ventricle free wall weight plus septum. The 
results show a significant increase in the RVH value of male MacLow mice 
compared to the control group (figure 3.6-f). No weight changes between the 
different groups were noted. 
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Figure 3.5- Confirming macrophages depletion in the liver after doxycycline treatment: 
a) Experimental time-line; MacLow and control mice treated with doxycycline on diet for six 
weeks, the disease was monitored at week 3 by echocardiography and assessed at the end-
point by echocardiography and cardiac catheterization. b)  Quantification of the number of 
macrophages remaining within the liver after six weeks treatment with doxycycline. Positively 
stained cells (stained brown) were counted in 6 fields of view at X20 magnification. c) 
Representative histological image of liver sections stained with anti-F4/80 antibody. Data 
analysed using a one- way ANOVA with Bonferroni post hoc test. Error bars represent mean 
±SEM, n= 7- 8/ group.  *P <0.05, **P< 0.01. (♂) males, (♀) females.  
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Figure 3.6- Haemodynamic of the PAH phenotype in MacLow mice:  a) Right ventricle 
systolic pressure. b) Left ventricle systolic pressure. c) Right ventricle internal diameter in 
diastoli. d) Left ventricle internal diameter in diastoli. e) Cardiac index (cardiac output/ body 
weight), f) Right ventricle hypertrophy index. Measurements (a,b) taken using closed chest 
cardiac pressure volume catheterization. Measurements (c-e) taken using Vevo 770 
echocardiography equipment. Data analysed by one- way ANOVA with Bonferroni post hoc 
test. Error bars represent mean ±SEM, n= 5-8/ group. *P <0.05, ****P< 0.0001. (♂) males, 
(♀) females. 
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3.3.2.2.1 Analysis of vessel wall remodelling 
The degree of remodelling in the pulmonary arteries was assessed by two 
measurements; the increase in thickness of different sized pulmonary arteries 
and by counting the number of muscularised vessels as a proportion of total 
vessels. The increase in media thickness was calculated by dividing the area of 
the media by cross-sectional area (CSA) of the whole artery (media /CSA) in 
sections stained with α- smooth muscle actin staining (figure 3.7). The media 
/CSA of the small pulmonary arterioles (less than 51 µm) in male MacLow group 
showed a significant increase compared to the male control group as well as both 
females groups (figure 3.8- a). No significant differences were seen in the 
medium (51-100 µm) or large (>100 µm) sized vessels between MacLow and 
control male groups, although the difference was significant when male MacLow 
mice were compared to the female groups (figure 3.8- c,e).   
Staining with vWF antibody showed the state of the endothelium in pulmonary 
vessels. A slight increase in thickness of the endothelial layer was seen in 
MacLow male mice compared to control (figure 3.7)  
The percentage of muscularised vessels within the lung was calculated in elastin 
van Gieson stained sections.  The results showed a significant increase in the 
percentage of smaller muscularised vessels sized less than 51µm in the diseased 
MacLow male group when compared to all other groups (figure 3.8-b), other size 
categories did not show a significant difference between any of the groups (figure 
3.8-d,f).  
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Figure 3.7- Remodelling of pulmonary arteries in MacLow male mice compared to 
controls: Representative histological images of lung sections shows the pulmonary vascular 
lesion in MacLow male mice compared to male controls. Sections stained with α- smooth 
muscle actin (SMA) to demonstrate the increase in medial wall thickness (the brown stained 
layer), or with Alcian blue Elastin van Gieson (ABEVG) to calculate the percentage of 
muscularised vessels (elastic lamina shown in purple), or with Von Willebrand factor (vWF) to 
assess the state of endothelial cell layer (stained brown). Images taken and analysed using 
Zeiss multi-slide scanning microscope at X20 magnification, scale bar= 50 µm. 
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Figure 3.8- Analysis of the degree of remodelling in lung sections: a,c,e) bar graphs 
represent Media to cross sectional area (CSA) of three different sized groups (10-50 µm, 51-
100µm and >100µm respectively), data analysed using a one- way ANOVA with Bonferroni 
post hoc test.  b,d,f) graphs represent pulmonary vascular remodeling by percentage 
muscularised vessels of three different sized groups of vessels (10-50 µm, 51-100µm and 
>100µm respectively) data analysed using two- way ANOVA. In all data n= 8 / group.  *P 
<0.05, **P< 0.01, ***P< 0.001. (♂) males, (♀) females. 
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3.3.2.3  Analysis of lung macrophages  
Analysis of the macrophage population within the lungs was performed using 
immunohistochemical staining of 5 µm thick paraffin sections. To assess the level 
of ablation of total macrophage, anti-F4/80 antibody was used (figure 3.9). The 
results showed a significant 30-40 % reduction in total macrophage number within 
the lung of MacLow mice when compared to controls (figure 3.10-a).  
To further analyse the two-macrophage subsets, anti- iNOS and anti- CD206 
antibodies were used to label M1 and M2 macrophages respectively (Figure 3.9). 
As expected, there was a significant reduction in iNOS+ macrophages in male 
and female MacLow mice after the six weeks doxycycline treatment (Figure 3.10-
b). However, the reduction in CD206+ macrophages was not significant in male 
MacLow groups, as there was no difference compared to the controls (Figure 
3.10-c). Female MacLow group showed a trend of reduction in the percentage of 
CD206+ macrophages, this reduction in M2 population was highly comparable to 
the reduction in M1 population in MacLow female groups. Though, the reduction 
was significant (P< 0.05) when compared to the female control group using the t-
test.     
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Figure 3.9- Lung macrophages in MacLow male mice compared to controls: 
Representative photomicrographs of   lung sections stained with antibodies against F4/80 
(total macrophages), iNOS (for M1 macrophages), CD206 (for M2 macrophages) and 
counterstained with haematoxylin. The images show the difference in macrophage 
populations (stained brown- arrow-head) that remain within the lung of MacLow male 
mice compared to control males after six weeks doxycycline treatment. Image taken 
using Zeiss multi-slide scanning microscope at X20 magnification, scale bar= 50 µm.  
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Figure 3.10- Analysis of macrophage subsets in lung sections: Quantification of the 
number of macrophage remaining within the lung after six weeks treatment of doxycycline. 
Positively stained cells were counted in 6 field of views / tissue at X20 magnification. a) 
Quantification of total macrophage using F4/80 antibody. b) Quantification of M1 macrophage 
subset using iNOS antibody. c) Quantification of M2 macrophage subset using CD206 
antibody. Data analysed using a one- way ANOVA with Bonferroni post hoc test. n=7-8 / 
group.  *P <0.05, **P< 0.01. (♂)  males, (♀) females. 
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To examine the co-distribution of macrophages within pulmonary blood vessels 
of male groups, double immunofluorescent staining with anti-F4/80 and anti-SMA 
was performed (refer to section 2.2.5 for protocol). Qualitative assessment of the 
histological images showed the accumulation of F4/80 positive macrophages 
within the muscularised smooth muscle actin- expressing cells of the small sized 
vessels in MacLow male mice, this accumulation was not seen in the control 
group (figure 3.11).       
Taken together, the MacLow- induced PAH phenotype was associated with peri-
vascular macrophage accumulation and increasing M2 population (CD206+ 
macrophages) within the lungs. 
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3.3.2.4  Analysis of circulating blood monocyte  
To relate the changes in haemodynamic and vessel remodelling to the alteration 
in monocyte/ macrophage cell counts. Blood was collected by cardiac puncture 
and pooled into a single blood sample for each group (n=5). Following density 
gradient centrifugation, blood monocytes were isolated and stained with Alexa 
Fluor ® 488 anti- mouse CD115 (refer to sections 2.1.7 and 2.4). As with the time- 
point study, the monocyte number was also reduced in MacLow mice after 
doxycycline treatment. Moreover, the reduction was larger in the diseased male 
MacLow group than the females (Figure 3.12), this may suggest that the PAH 
phenotype in MacLow male mice was also associated with a reduction of blood 
monocyte. However neither of these observations were statistically analysed as 
there was only one blood sample in each group. 
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Figure 3.12- Flow cytometric analysis circulating monocyte after six weeks doxycycline 
treatment: graph represents the number of CD115+ cells obtained from one pooled blood 
sample for each group (5 mice/ group). Peripheral blood mononuclear cells (PBMC) isolated 
and stained with Alexa Fluor ® 488 anti- mouse CD115 then analysed by flow cytometry.  
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3.4 Discussion 
Data presented in this chapter further support the modulatory role of 
macrophages in PAH pathogenicity, and emphasise the notion that the switch in 
macrophage polarity is important in the disease development. The findings did 
not support my primary hypothesis, as the specific depletion of macrophages in 
MacLow mice did not protect against induced vascular remodelling. On the 
contrary, macrophage loss actually led to the development of PAH 
spontaneously. Additionally, the results showed a unique and interesting sex-
specific PAH phenotype induced by the loss of macrophages in male mice 
suggesting a correlation between sex and macrophages in PAH.    
In the MacLow- induced PAH study described here, males but not females 
MacLow mice possessed a significant increase in their RVESP, RVH index and 
vascular remodelling when compared to controls after the loss of CD68+ 
macrophages. This PAH phenotype correlated mainly to the macrophage 
depletion in tissues (particularly the lungs) in addition to the male sex 
susceptibility.   
Moreover, all study groups were given doxycycline for the same period of time to 
preclude the argument that doxycycline itself may cause these changes, 
especially since tetracyclines have previously been shown to inhibit collagenolytic 
enzymes (such as matrix metalloproteinases MMPs), which may lead to inhibition 
of the degradation of connective tissue (Vieillard-Baron et al., 2000). 
No previous literature has demonstrated that macrophage depletion leads to the 
development of PH in animal models. In contrast, previous ablation strategies  
that aimed to deplete the monocyte/ macrophage cell lineage in rodents such as  
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liposome containing clodronate (Cl2MBP) or the use of gadolinium chloride 
(GdCl3), showed that the depletion of the mononuclear cells (referred to as 
fibrocytes) following the clodronate liposome injection in male rats attenuates the 
hypoxia- induced pulmonary artery adventitial remodelling (Frid et al., 2006). 
Importantly,  the Cl2MBP liposome when administered as an intravenous 
injection is unable to cross the barrier of the vascular endothelial, so was not even 
taken- up by the tissue resident phagocytic cells (Vanrooijen and Sanders, 1994). 
A similar phenomenon occurs with the GdCl3 injection as the drug aggregates 
into large particles which are then taken-up by circulating phagocytes only (Singh 
et al., 2004).   
Moreover, therapeutic inhibition of the stromal cell derived factor SDF-1 
(important chemokine for the recruitment of inflammatory cells) in the 
monocrotaline rat model of PH blocks the pulmonary vascular infiltration of 
CD68+, CD3 and mast cells, this was also associated with reduced pulmonary 
vascular remodelling (Savai et al., 2012). 
Again, another study by Zaloudikova used intra-tracheal chlodronate liposome to 
investigate whether the ablation of alveolar macrophages can attenuate hypoxia-
induced PH in male rats. The findings showed that repeated chlodronate 
treatment leads to significant reduction in the mean pulmonary artery pressure 
after hypoxia compared to untreated controls (Zaloudikova et al., 2016). 
Interestingly, none of these studies reported any spontaneous increase of the 
pulmonary pressure or associated remodelling in their normoxic controls after 
macrophage depletion. As macrophages are extremely versatile, it is likely that 
each of the macrophage depletions strategies described above targets specific 
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macrophage populations depending on the drug and the route of the drug 
delivery.  
For instance, within healthy lungs, heterogeneous macrophage populations were 
detected; lung macrophages were classified as resident alveolar macrophages 
(AM), and tissue interstitial macrophages (IM). The alveolar macrophages reside 
within the airways, while the tissue macrophages are located within the lung 
without contacting the airway sacs. In response to inflammation, additional 
macrophages are recruited to the lungs (referred to as recruited macrophages) 
from circulating monocytes (McCubbrey et al., 2016). Each of these population 
could respond differently to the doxycycline-induced depletion. However, further 
work will be required to address the speculations. A brief summary of 
macrophages development and differentiation is shown in Figure 3.13.  
Another important observation in the MacLow- induced PAH model, was the bias 
toward the CD206+ population (resembling the alternatively activated M2 
subtype) within the lungs of the diseased male mice following six weeks 
doxycycline treatment. It has been shown previously that in hypoxia- induced PH, 
hypoxia causes polarization of alveolar macrophages toward M2 phenotype, this 
was associated with the development of hypoxia- induced PH in vivo and 
proliferation of pulmonary artery smooth muscle cells in vitro (Vergadi et al., 
2011).    
A possible explanation of the accumulation of M2 macrophages within the lung 
following doxycycline treatment is that the M2 macrophages are resistant to the 
MacLow ablation model, although the female groups showed a trend toward 
reduction in this population and the M2 population was reduced after a single 
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doxycycline injection in both sexes of MacLow mice. Another possible 
explanation is that this population developed via differentiation of the surviving 
macrophages to clear up the dead cells, as one of the M2 macrophages functions 
is debris scavenging (Weisser et al., 2012). Further studies are required to 
determine the specific mediators that may be contributing factors in signalling 
cascade of M2 activation leading to development of PH. Further work will be 
described in the next chapters to address this observation. 
In addition, blood monocyte in MacLow mice were also affected by the 
macrophage depletion. Analysis of blood monocyte by flow cytometry showed a 
pronounced drop in blood monocyte count following a single doxycycline injection 
as well as following the six weeks doxycycline treatment. However, the exact 
mechanism of this reduction is unclear. It could be that monocytes migrate 
excessively from the peripheral blood to tissues to compensate for the loss of 
tissue macrophages. Or and most likely, that monocytes are also targeted in 
MacLow depletion model, as all monocyte/ macrophage myeloid lineage shown 
to express the CD68 antigen (Hume, 2011, Iqbal et al., 2014, McCubbrey et al., 
2016).  
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Finally, the incidence of PAH in female patients is higher than in males, however, 
men showed the higher mean pressure of the pulmonary artery and higher risk 
Figure 3.13- Schematic illustration of macrophage development and differentiation: 
Monocytes are first derived from the differentiation of bone marrow myeloid progenitor cells 
in presence of the colony stimulation factors (CSF), then circulate in bloodstream for 
several days before enter the tissues and being differentiated to macrophages. When 
tissue macrophages depleted for any reason, newly recruited macrophages infiltrate to 
restore local macrophage population. The acquired differentiated phenotype of 
macrophages reflects the micro-environmental signals in which macrophages reside: 
macrophages differentiate to classically activated (M1) macrophages in presence of 
Lipopolysaccharide (LPS) and interferon gamma (IFN-γ) or to alternatively activated (M2) 
macrophages in presence of interleukin-4 (IL-4). Within the lungs, the tissue-resident 
macrophages can be further classified depending on their location within the lung tissue 
to either alveolar or interstitial macrophage. Markers used to identify monocyte/ 
macrophage populations shown in brackets.  
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of death compared to the female (Badesch et al., 2010). It was interesting to see 
that in the MacLow model only the male mice developed the spontaneous PAH 
phenotype following macrophage depletion. Females in animal models have 
been shown to be more protected against the induced forms of PH, this is thought 
to be due to the protective effect of sex hormones such as oestrogen (known as 
Oestrogen paradox phenomenon). The role of oestrogen in clinical PAH is still 
not completely known, but in animal models, oestrogen has been shown to be 
beneficial and has a cardiovascular protective function (Umar et al., 2011). The 
implication of sex differences in the MacLow mouse model will be investigated 
further in chapter 6. 
The following chapter investigates whether bone marrow-derived cells or the 
tissue resident macrophages are critical for the development of PAH in male 
MacLow mice. 
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4   The role of circulating versus tissue resident 
cells in the development of pulmonary arterial 
hypertension in male MacLow mice 
4.1 Introduction 
In chapter 3, I demonstrated that loss of macrophages in MacLow mice can cause 
a sex- specific spontaneous PAH phenotype, this was associated with increased 
vascular remodelling and a prevalence of M2 macrophages within the lungs. 
There is accumulating evidence in the literature showing the ability of circulating 
progenitor cells to migrate to the lung and to contribute to the pathology of 
hypoxia- induced PH (Davie et al., 2004, Hayashida et al., 2005, Raoul et al., 
2007). The aim of this chapter was to investigate whether bone marrow- derived 
cells or tissue resident cells were the critical cells for the development of PAH in 
male MacLow mice.  
To trace the origin of cells (whether bone marrow or tissue resident), different 
chimeric mice can be generated by the process of bone marrow transplantation 
(BMT). The principle of BMT procedure depends on injecting bone marrow 
hematopoietic stem cells from donor mice (donor inoculum) into the bloodstream 
of recipient mice with supressed immunity, then the donor cells reconstitute the 
immune system. The total body irradiation (TBI) is the most commonly used 
immune-suppression method. TBI suppress the immune system of the recipient 
mice and prevent graft rejection as it kills the hematopoietic progenitor cells and 
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the proliferating immune- competent in the recipient (Cui et al., 2002, Duran-
Struuck and Dyskoz, 2009).  
Leading to the aim of this chapter, the BMT procedure was adopted as a tracing 
strategy to investigate the contribution of bone marrow- derived cell in PAH 
development. 
Various studies have reported some differences in radio-sensitivity between mice 
strains, and as there was no previous literature describing a protocol for the 
generation of MacLow chimera, it was essential to perform two pilot studies using 
a small number of mice before determining the best irradiation regimen for 
optimization of the BMT protocol. Furthermore, it became apparent using already 
developed fate-mapping techniques that most tissue-resident macrophages can 
self- maintain via proliferation without replenishment from blood monocyte 
(Gundra et al., 2014, Ginhoux and Jung, 2014). It has been also shown that IL-4 
can enhance this increase in numbers of tissue macrophages above the 
homeostatic level, through proliferation rather than infiltration (Jenkins et al., 
2013, Jackson-Jones et al., 2016). Thus, the probable proliferation capacity of 
macrophages in MacLow- induced PAH model, and the expression of IL-4 within 
the diseased lungs was also investigated.    
4.2  Methods 
4.2.1 Pilot study 1 
In this study, four age-matched male mice (9 weeks old) were used as recipients, 
and two male mice (5 weeks old) were used as cell donors (recipient to donor 
ratio = 2:1), the chimaeras generated described in the table (4.1). 
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Table 4.1. MacLow/ control chimeras generated from bone marrow transplantation for the 
pilot studies 
Chimera Donor Recipient (n) 
1 Control MacLow (2) 
2 MacLow Control (2) 
 
For the BMT procedure, a standard protocol which has been successfully used 
in our department was followed (Chamberlain et al., 2006, Evans et al., 2009, 
West et al., 2014, Hameed et al., 2012). In brief, all mice were kept in individually 
ventilated caging (IVC) under barrier condition in the biological service unit at the 
Hallamshire hospital, mice were fed standard chow and started drinking acidified 
water one day before the transplant to minimized the risk of infection (see 
appendix II for recipe). 
On the day of transplantation, recipient mice were given a fractionated dose of 
whole body irradiation (5 Gy twice with 4 hours interval) before injecting donor 
bone marrow. Donor mice were euthanized by cervical dislocation, femurs and 
tibias removed in sterile PBS on ice. After removing the skin and fur from the 
bone it was washed with 70% v/v ethanol for 1 minute then the marrow cavity 
was flushed with 26-27 G syringe containing 2 ml media (RPMI- 1640 media 
contains 10% v/v FBS) under aseptic condition. Cells were passed through 40 
µm cell strainer then centrifuged at 4 ⁰C 500 Xg for 5 minutes before been re-
suspended in Hank’s buffered salt solution (HBSS).   
After the second dose of radiation, recipient mice were left in an incubator at 35⁰C 
for one hour prior to injection. A maximum of 200µl of bone marrow cell 
suspension containing approximately 2 X 106 cells were injected through the tail 
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vein. Following BMT mice were monitored daily for any signs of illness, and 
weighed every two days to monitor changes in body weight.   
This strategy was not successful as all mice showed signs of distress and pain 
within the first two weeks post-transplant, therefore, the procedure was 
terminated. For qualitative assessment of donor cell re-constitution in the 
recipients, the legs of culled mice were harvested directly and the bone marrow 
cells were flushed and prepared as described in section (2.1.9), the DNA was 
extracted from the bone marrow cells to run a genotyping PCR as described in 
sections (2.1.1).       
4.2.2 Pilot study 2  
Based on the fact that different strains of mice have different sensitivities to 
radiation thus may require different irradiation dose and frequencies (Duran-
Struuck and Dyskoz, 2009), a modified irradiation strategy was followed in the 
second pilot study to enhance the survival. The MacLow line was originally 
derived from an FVB background and it has been reported that the FVB mice 
were successfully transplanted previously using 10-22 Gy as a single dose 
(Crawford and Gordon, 2005). Therefore, in the second pilot study the recipient 
mice were irradiated with a single dose of 10 Gy before receiving the donor 
inoculum and the same chimeras described in the table (4.1) were generated. 
Furthermore, aseptic steps were modified when preparing the donor cell 
suspension, to avoid the excessive use of ethanol on the intact bones, using heat-
inactivated FBS and phenol free media for flushing the marrow to minimise 
negative effects on the reconstitution of the cells after injection.             
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Finally, for efficient and fluent tail vein injection procedure, recipient mice were 
sedated with subcutaneous injection of Hypnorm® solution few minutes before 
receiving the injection. Each mouse received between 5 and 6 x 106 cells in 100-
200 µl cell suspension then kept warm to recover from sedation for 2-3 hours.   
If any mouse showed signs of distress, pain or a loss of weight of greater than 
10% of body weight over two consecutive days it was sacrificed. When mice 
reached the end of the study (70 days post-transplant) or culled on welfare 
grounds the legs were harvested and bone marrow cells were collected. For 
qualitative assessment of donor cells re-constitution, the DNA was extracted from 
the bone marrow cells to run a genotyping PCR. The modified strategy followed 
for the second pilot study was successful and 3 out of 4 mice survived and 
reached the endpoint of the study. 
4.2.3 Generation of male MacLow chimeric mice and induction 
of pulmonary arterial hypertension 
Leading to the main aim of this chapter, male chimeric mice were generated by 
the process of BMT, the procedure was performed using the optimized protocol 
from pilot study 2 (the full modified protocol is detailed in section 2.1.3). Age-
matched male mice (8-10 weeks) were used as the recipient to generate the 
chimeras described in the table (4.2). The MacLow donor BM cells were 
transplanted into a genetically different pre-irradiated control recipient (allogenic 
graft), and the control BM cells were transplanted into pre-irradiated MacLow 
recipient. In addition, two groups received genetically identical graft (syngeneic 
graft) of MacLow- derived BM into MacLow mice and control BM into control mice 
as a positive and negative control groups respectively (figure 4.2-a).  Mice were 
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left to recover for 30 days after the transplant, then the PAH was induced using 
doxycycline treatment to induce macrophage depletion (doxycycline containing 
diet) for another six weeks with no other insult. Mice were kept under aseptic 
condition and given acidified drinking water for the whole period of the study (10 
weeks in total).      
Table 4.2. MacLow/control chimeras generated from bone marrow transplantation for the 
PAH study 
Chimera Donor Recipient (n) 
1 control MacLow (5) 
2 MacLow Control (5) 
3 MacLow MacLow (8) 
4 control Control (5) 
 
4.2.4 Echocardiography and cardiac catheterization  
Following six weeks of doxycycline treatment, non-invasive assessment of the 
disease was performed using echocardiography under anaesthesia as described 
in section 2.1.4. Then the closed chest cardiac catheterization was used to take 
the pressure-volume measurements from both sides of the heart as described in 
section 2.1.5. 
4.2.5 Histological analysis  
Tissues were harvested, fixed, processed, and stained according to the standard 
laboratory procedure described in sections 2.1.6 and 2.2.  
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4.2.6 Statistical analysis 
All statistics were performed using GraphPad Prism version 7.2 (GraphPad 
software, SanDiego, California USA). Statistical comparison between the 
different groups was established by the use of one- way analysis of variance 
(ANOVA) followed by Bonferroni post- hoc analysis. Values are presented as 
mean ± SEM, and differences of P< 0.05 values were taken as significant.   
4.3  Results 
4.3.1 Optimal protocol for bone marrow transplant procedure 
using the MacLow mice  
To determine the optimal strategy for the generation of MacLow chimeric mice, 
mice were either irradiated twice with 5 Gy in 4 hour interval and engrafted with 
approximately 2 X106 bone marrow cells (pilot study 1), or irradiated once with 10 
Gy and engrafted with approximately 5 X106 bone marrow cells (pilot study 2). 
The strategy used for pilot study 1 was severely toxic and all mice had to be culled 
within 14 days post-irradiation due to severe illness. In contrast, in the second 
pilot study, three out of four mice survived with little ill effect and reached the end 
point of the study (70 days post-transplant). As presented in figure 4.1-a, the 
genotyping PCR for the CD68 gene (should be present in MacLow mice and not 
the controls) in the bone marrow of the recipients showed a failure of 
reconstitution of the donor bone marrow cells in the first pilot study, as the 
MacLow recipient was still positive for the CD68 and the controls were still 
negative. While in the second pilot study, the MacLow recipients showed less 
presence of CD68 gene as the bands were dim and the bands were clearer in 
the controls. 
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Loss of body mass is an expected adverse effect of irradiation, and regain of any 
weight loss is a sign of successful engraftment. Figure 4.1-b showed the 
percentage of weight lost after BMT over time for both pilot studies, the graph 
represents the pattern of losing and then gaining weight for pilot study 2, whereas 
in pilot study 1 the weight loss was dropping until the study had to be prematurely 
terminated. Finally, the percentage survival of the two studies was compared in 
figure 4.1-c with the clear success of the strategy followed in pilot study 2 (75% 
survival). In conclusion, based on the outcomes of the two pilot studies and in 
order to generate the targeted male MacLow chimeric mice, the strategy followed 
on the second pilot study was adopted. 
MacLow and control mice underwent BMT to generate the chimeric groups 
showed in table 4.2, then PAH was induced by depleting macrophages with 
doxycycline treatment for six weeks. All mice reached the endpoint of the study 
(100% survival rate) and the pattern of their weight changes is displayed in graph 
4.2-b. All mice experienced some weight loss during the first week after the BMT 
procedure, then they gradually gained this weight back. No significant differences 
were detected at any point, however, the control recipient transplanted with 
MacLow graft failed to achieve their start weight but they had no sign of illness. 
To confirm the graft success, random bone marrow samples from the allogenic 
recipient groups were tested using the genotyping PCR as previously described.  
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Figure 4.1- Optimizing protocol for total body irradiation and generation of chimeric 
mice: a) Images of an agarose gel showing PCR amplification of the DNA extracted from the 
chimeric mice following pilot studies 1 and 2. The DNA extracted from the bone marrow for 
genotyping, positive samples have the CD68 genes appeared as a 546bp band, known CD68 
positive and negative templates were included as the positive and negative controls 
respectively. b) The graph shows the difference in weight loss of the chimeras from pilot 
studies 1 and 2 after the bone marrow transplant procedure. c) Comparison of the survival 
rate of the chimeric mice in pilot studies 1 and 2 at various intervals. n=4.  
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4.3.2 Confirmation of macrophage depletion in MacLow 
recipient mice 
To confirm efficient macrophage depletion, the percentage of macrophages 
depleted from the liver sections was assessed using immunostaining as 
previously described (see section 2.2.2). In brief, 5 µm sections of paraffin-
embedded liver were stained with anti-F4/80 antibodies, and then macrophages 
were counted and normalized to the negative control group (control BM into 
control mice). The results showed a significant reduction in F4/80 positive 
macrophages (about 35%) in both MacLow recipient groups compared to the 
control recipients (Figure 4.2). In addition, the data showed no difference in 
macrophage count between the MacLow recipients transplanted with either 
control (allogeneic graft) or MacLow (syngeneic graft) derived BM cells after 
doxycycline treatment. This suggests that doxycycline treatment can induce 
significant loss of liver macrophages in the MacLow chimeras regardless of the 
genotype of transplanted cells.   
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Figure 4.2- Confirming macrophages depletion in the liver after doxycycline treatment: 
a) Schematic of study design displaying the bone marrow transplant procedure followed by 4 
weeks recovery period before starting doxycycline treatment, the disease assessed at the 
end-point by echocardiography and cardiac catheterization. BM= bone marrow. b) Graph 
shows the difference in weight loss of the different groups after the bone marrow transplant 
procedure. BMT= bone marrow transplantation. c) Quantification of the number of F4/80+ 
macrophages remaining within the liver after six weeks treatment with doxycycline. Positively 
stained cells were counted in 6 fields of view at X20 magnification. BM= bone marrow. Data 
analysed using a one- way ANOVA with Bonferroni post hoc test. Error bars represent mean 
±SEM, n=5- 8/ group.  *P <0.05, **P< 0.01.  
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4.3.3 Assessment of PAH in male chimeric mice 
4.3.3.1  Haemodynamic evaluation 
Following macrophage depletion, disease progression was first assessed by 
measuring different haemodynamic parameters (gathered from the heart 
catheterization and echocardiography) as well as the right ventricle hypertrophy 
value. The results showed that transplantation of BM from MacLow mice into pre-
irradiated control mice was not sufficient to cause a significant increase in their 
RVESP compared to the positive control group (MacLow BM into MacLow mice) 
with 20.58 ±1.566 mmHg vs 28.94 ±2.192 mmHg respectively (figure 4.3-a). It 
was interesting to see that the control recipients transplanted with MacLow BM 
do not lose their tissue macrophages nor have increased pulmonary pressure 
following doxycycline treatment, this suggest that MacLow BM cells alone are not 
enough to induce the disease in control mice.  
In addition, no conclusion can be made regarding whether the MacLow recipients 
transplanted with control cells were protected or not against the disease 
development as the pressure readings were not significantly altered (23.26 ± 
0.6134 mmHg). However, the average RVESP is trending toward the normal 
pressure.  
This effect was also seen in other haemodynamic parameters measured from the 
right-side of the heart with no effect on the measurements from the left-side heart 
(see appendix I). No changes in the cardiac index were detected between the 
different groups (figure 4.3-b). Furthermore, the increase in RVESP after the loss 
of macrophages in the MacLow syngeneic chimeric group (around 29mmHg) was 
not as high as the spontaneous increase observed in the normal MacLow male 
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mice (about 66 mmHg) shown in chapter 3 (graph 3.6-a). This could as a result 
of irradiation that might be affecting the lung resident macrophages (Matute-Bello 
et al., 2004).        
To further investigate whether the increase in pressure has led to right ventricular 
hypertrophy (RVH), the RVH index was calculated. RVH value was assessed on 
the basis of the ratio of RV free wall weight to the left ventricle free wall weight 
plus septum. The results show no significant difference in the RVH value between 
the groups (figure 4.3-c), which again indicate that the disease phenotype was 
not aggressive enough to cause any effect on the heart.   
Taken together, the PAH phenotype showed only when the donor of the BM cell 
and the recipient are both MacLow mice, this suggests that both bone marrow-
derived macrophages and lung resident macrophages need to be depleted in 
order to develop PAH in male MacLow mice. 
Chapter 4 
 
111 
 
0
1 0
2 0
3 0
4 0
5 0
R
V
E
S
P
 (
m
m
H
g
)
*
M a c L o w  B M
to  M a c L o w
C o n tro l B M
to  M a c L o w
M a c L o w  B M
to  c o n tro l
C o n tro l B M
to  c o n tro l
0 .0
0 .5
1 .0
1 .5
C
a
r
d
ia
c
 i
n
d
e
x
(m
l/
m
in
/g
)
M a c L o w  B M
to  M a c L o w
C o n tro l B M
to  M a c L o w
M a c L o w  B M
to  c o n tro l
C o n tro l B M
to  c o n tro l
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
R
V
H
(R
V
/L
V
&
S
)
M a c L o w  B M
to  M a c L o w
C o n tro l B M
to  M a c L o w
M a c L o w  B M
to  c o n tro l
C o n tro l B M
to  c o n tro l
a)
b )
c )
 
 
 
Figure 4.3- Haemodynamic of the PAH phenotype in male chimeric mice:  a) Right 
ventricle systolic pressure (RVESP) taken by closed chest cardiac pressure-volume 
catheterization b) Cardiac index (cardiac output/ body weight) taken by Vevo 770 
echocardiography equipment, c) Right ventricle hypertrophy index (RVH). BM= bone marrow 
Data analysed by one- way ANOVA with Bonferroni post hoc test. Error bars represent mean 
±SEM, n= 5-8/ group.  *P <0.05.  
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4.3.3.2  Analysis of vessel wall remodelling  
PAH is usually associated with vascular remodelling, therefore the remodelling 
was assessed by calculating the increase in media thickness of the pulmonary 
arteries (by dividing the area of the media by cross-sectional area CSA of the 
whole artery in sections stained with α-smooth muscle actin staining), and by 
counting the number of muscularised vessels as a proportion of total vessels. The 
media /CSA of the small pulmonary arterioles (less than 51 µm) in the allogenic 
chimeras (control BM in MacLow and MacLow BM in control) showed no increase 
as that of the positive control group (figure 4.4-a)      
The positive control group (MacLow BM in MacLow) showed a significant 
increase in their media thickness compared to all other groups. No significant 
differences were seen in the medium (51-100 µm) or large (>100 µm) sized 
vessels between any of the groups.  
To calculate the percentage of muscularised vessels within the lung, the number 
of muscularised vessels (has double elastic lamina) in elastin van Gieson stained 
sections were divided by the total number of arteries under the same size range 
multiplied by 100. Although the results here should reflect and emphasise the 
Media/CSA calculation, no significant differences between the groups under any 
size category were detected, only a trend toward an increase was observed in 
the MacLow BM to MacLow group (figure 4.4-b,d,f). 
In summary, the overall remodelling in the chimeric MacLow mice was less 
pronounced than that seen in MacLow mice following macrophage ablation, this 
is consistent with the haemodynamic measurements as the disease phenotype 
was less severe in the chimeric mice.  
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Figure 4.4- Analysis of the degree of remodelling in lung sections: a,c,e) Bar graphs 
represent Media to the cross-sectional area (CSA) of three different sized groups (10-50 µm, 
51-100µm and >100µm respectively), data analysed using a one- way ANOVA with Bonferroni 
post hoc test.  b,d,f) Graphs represent pulmonary vascular remodelling by percentage 
muscularised vessels of three different sized groups of vessels (10-50 µm, 51-100µm and 
>100µm respectively) data analysed using two- way ANOVA with Bonferroni post hoc test. 
BM= bone marrow. In all data n= 3-6 / group.  *P <0.05.  
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4.3.4 Analysis of lung macrophages  
Analysis of lung macrophage subsets was performed using 
immunohistochemical staining of 5 µm thick paraffin sections of lung as 
previously described. To assess the level of reduction in total macrophages, anti- 
F4/80 antibody was used (figure 4.5) and then positively stained cells were 
counted and normalized to the negative control group (control BM into control 
mice). The results displayed in figure 4.6-a showed non-significant reduction in 
total macrophage numbers within the lung of both MacLow recipient groups when 
compared to control recipients.  
To further analyse macrophage subsets, anti-iNOS and anti-CD206 was used to 
stain and count M1 and M2 populations respectively (figure 4.6-b,c). The results 
showed no clear pattern of depletion of either of these populations. The M2 
population was still higher in the MacLow recipient given MacLow BM than control 
recipients given MacLow BM but again the differences were not significant. It was 
unclear why the depletion of lung macrophage in this study was not significant 
even though the numbers of liver macrophages were significantly reduced (figure 
4.2-c). Possibly, the irradiation is killing some of the resident lung macrophages 
(particularly the alveolar macrophages), and as they are long-lived, the recovery 
time was not long enough for the resident population to repopulate following the 
TBI (Matute-Bello et al., 2004).   
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Figure 4.5- Total lung macrophages in male chimeric mice: Representative 
photomicrographs of   lung sections stained with anti-F4/80 antibody (total macrophages), 
the images show the different in macrophage (stained brown- arrow head) remained within 
the lung of each group after six weeks doxycycline treatment. Image taken using Zeiss 
multi-slide scanning microscope at X20 magnification, scale bar= 50 µm.  
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Figure 4.6- Analysis of macrophage subsets in lung sections: Quantification of the 
number of macrophage remaining within the lung of the chimeric mice following doxycycline 
treatment. Positively stained cells were counted in 6 fields of views/tissue at X20 magnification, 
data of each group were normalized to the negative control group (control BM to control 
recipient) BM= bone marrow. a) Quantification of total macrophage number using F4/80 
antibody. b) Quantification of M1 macrophage subset using iNOS antibody. c) Quantification 
of M2 macrophage subset using CD206 antibody. Data analysed using a one- way ANOVA 
with Bonferroni post hoc test. Error bars represent mean ±SEM. n= 4-6/ group.  
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4.3.5 Analysis of circulating blood monocyte 
As described in sections 2.1.7 and 2.5, blood was collected by cardiac puncture 
from each animal and pooled for each of the groups. Following density gradient 
centrifugation blood monocytes were isolated and stained with Alexa Fluor ® 488 
conjugated anti-mouse CD115 antibodies. The number of blood monocyte in the 
MacLow recipients was about 30-40% less than control recipient group (figure 
4.7) which is comparable with the reduction in liver macrophages (figure 4.2). 
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4.3.6 Investigating lung macrophage proliferation and IL-4 
expression 
To investigate whether lung macrophages are capable of self-renewal via 
proliferation independently of blood monocytes, dual immunofluorescent staining 
for F4/80 with a cell proliferation marker; proliferating cell nuclear antigen (PCNA) 
Figure 4.7- Flow cytometric analysis of circulating monocyte: graph 
represents the number of CD115+ cells obtained from one pooled blood 
sample for each group (5 mice/ group). Peripheral blood mononuclear cells 
(PBMC) isolated and stained with Alexa Fluor ® 488 anti-mouse CD115 
then analysed by flow cytometry. 
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was performed (refer to the protocol in section 2.2.5). 5µm thick paraffin lung 
sections from MacLow and control mice that have been treated with doxycycline 
for six weeks was used. Qualitative assessment of the microscopic images (figure 
4.8) showed some double positive staining (arrowhead) of F4/80 positive cells 
(red) and PCNA positive staining (green) in MacLow lungs that was not found in 
the control lung. These positive signals suggest that the macrophages in 
diseased lung lesions have the capacity for proliferation to self-renew. However, 
whether this process was a consequence of the depletion and in order to maintain 
the homeostasis or a result of the disease is still undetermined.  
The images also suggest some differences between the MacLow and control in 
term of PCNA co-localization within the cells. In MacLow lungs there was an 
unexpected cytoplasmic expression of PCNA, The PCNA has a well-known 
function in DNA replication and repair, hence its nuclear localization. However, 
recent research has also detected PCNA in the cytoplasm which suggests it also 
has a crosslinking function in term of cell cycle and apoptosis, also it has been 
shown that mature human neutrophils express PCNA exclusively within the 
cytosol (Witko-Sarsat et al., 2010, Ohayon et al., 2016)    
Furthermore, it has been shown that the proliferation expansion of resident 
macrophages can be mediated by IL-4 signalling in parasitic infection (Jenkins et 
al., 2011, Jenkins et al., 2013). To determine whether expression of IL-4 is 
involved in MacLow model of PAH, IL-4 positive cells were counted in paraffin-
fixed lung sections from diseased male MacLow and from controls. The results 
presented in the figure 4.9 showed no difference between the diseased and 
healthy lungs regarding their IL-4 signalling which suggests that the process of 
macrophage proliferation was unlikely to be mediated by IL-4 signalling.    
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4.4  Discussion 
In chapter 3, I demonstrated that a loss of macrophages causes a spontaneous 
PAH phenotype in male MacLow mice. However, it was unclear how the disease 
developed or what was the origin of the responsible cells. The work in this chapter 
aimed to assess the contribution of bone marrow progenitor cells to the 
Figure 4.9- Expression of IL-4 within the lung: Control and MacLow male mice were treated 
with doxycycline for six weeks to induce PAH. a) Representative immunohistological staining 
of paraffin fixed lung sections using anti-IL-4 antibody (cells stained brown, arrow-heads). b) 
Quantification of IL-4 expressing cells in the lung sections from MacLow diseased male mice 
compared to controls. Sections were stained with anti-IL-4 antibody and the positively stained 
cells were counted in 8 fields of views/tissue at X20 magnification. n= 8/ group.  
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development of PAH in MacLow mice. It has been shown here using bone 
marrow transplantation that the lung resident macrophages, as well as bone 
marrow- derived cells, need to be depleted to induce the development of PAH.   
Assessing the increase in pressure in the chimeric mice following six weeks of 
doxycycline treatment showed that transplanting MacLow- derived progenitors 
into control animals was not enough to induce disease development, this 
emphasised the importance of the resident cells in driving the disease phenotype 
over the recruited cells.  It was also shown that MacLow recipient mice were still 
susceptible to macrophage depletion following doxycycline treatment regardless 
of the genotype of the donor cells. However, the level of macrophage depletion 
(particularly within the lungs) in the chimeric animals was not as high as in 
untransplanted MacLow animals in the previous chapter. 
The low level of reduction in lung macrophages obtained following the BMT 
procedure could be due to the effect of irradiation on the lung. It is still not 
completely known what happens in the lung after irradiation but it has been shown 
that irradiation can destroy the local stem cells residing in the alveolar spaces 
thus the total count of alveolar macrophages can fall following irradiation (Tarling 
et al., 1987). It has been shown that a 30 day recovery period following TBI (using 
9 Gy) is enough for the complete reconstitution of peripheral blood cells, however, 
only 47 % of the resident alveolar macrophages can repopulate in this period 
(Matute-Bello et al., 2004). However, it is important to also consider that different 
mouse strains respond differently to irradiation. 
Furthermore, it has been observed that the disease phenotype developed by the 
male chimeric mice was less aggressive than that developed in male MacLow 
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mice as shown by their pressure reading and the unchanged RVH. This suggests 
a positive correlation between the loss of lung macrophage and the increase in 
RVESP in MacLow mice, but again the reason for this is still not known.  
A study by Hayashida and colleagues  described the role of BM-derived cells in 
hypoxia-induced PH using BMT strategy, the diseased chimeric mice showed a 
significant increase in their RVESP, RVH and vascular remodelling following 
hypoxia exposure, the histological analysis also reported the ability of BM-derived 
GFP labelled cells to travel to the pulmonary arteries of the hypoxic mice 
(Hayashida et al., 2005). As the hypoxia model is mainly an inflammation based 
model, they expected to see a marked increase in the level of recruited cells from 
the blood to the vascular lesion. In MacLow-induced PAH shown here, the 
disease developed as a result of the loss of tissue macrophages and it seemed 
that the factors driving the disease did not originate in the blood. 
Another important observation from all of my studies using the MacLow mouse 
model is that the level of depletion observed in the lungs was always less than 
that seen in other organs (such as liver and spleen). To investigate whether the 
lung had some compensatory pathways to maintain homeostasis, dual 
immunofluorescent labelling using both anti-F4/80 antibodies (macrophage 
marker) along with anti-PCNA anti-bodies (proliferation marker) was performed. 
Interestingly, these experiments showed some double labelled cells only in 
MacLow lungs following macrophage depletion and not in any of the controls, this 
suggests that lung macrophages can self- renew via proliferation rather than 
recruitment from the blood. A study by (Hashimoto et al., 2013) also made it clear 
that monocytes do not contribute significantly to tissue macrophage repopulation 
in steady state using either the systemic administration of clodronate liposome or 
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the CD169-DTR mouse models of macrophage depletion (Hashimoto et al., 
2013).  
Finally, although IL-4 has been proposed to have a role in promoting mechanisms 
for local macrophage expansion following parasite infection (Jenkins et al., 2011, 
Jenkins et al., 2013), there was no increase in expression of IL-4 in MacLow lungs 
following depletion, this was consistent with the finding of (Hashimoto et al., 2013) 
who also could not detect an increase in expression of this cytokine within the 
lung after macrophage ablation. 
In conclusion, the tracing strategy followed here pointed to the importance of lung 
resident macrophages in the development of PAH. Lung macrophages can be 
further divided into two subpopulations according to their localization i.e: alveolar 
macrophages and interstitial macrophages. The following chapter aims to 
pinpoint the compartment within the lung by studying these populations 
separately in vitro and investigating some mechanistic pathways that might be 
involved in the developing the disease using in vitro assays.
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5  Characterization and polarization of MacLow- 
derived macrophages 
5.1  Introduction 
Tissue macrophages are a remarkably versatile and heterogeneous population 
of the immune cells, their heterogeneity and plasticity are important features to 
fulfil their tissue-specific functions. Within the lungs, at least two macrophage 
population are found, the alveolar macrophages (AMs) and the interstitial 
macrophages (IMs). Another population can also be recruited during 
inflammation referred to as recruited monocyte-derived macrophages 
(McCubbrey et al., 2016, Byrne et al., 2016). 
Following from the previous chapters, this chapter utilized an in vitro culture 
system to understand the underlying mechanisms that might be responsible for 
the development of MacLow-induced PAH in vivo. To investigate whether 
MacLow- derived lung macrophages have unique characteristics relevant to their 
respective roles, a side-by side comparison study of MacLow- derived 
macrophages with macrophages from control mice was performed. For better 
understand of lung macrophage heterogeneity, cells were cultured either from 
bone marrow progenitor cells (bone marrow-derived macrophages) or derived 
from the broncho-alveolar lavage fluid BALF (alveolar macrophages). The 
comparison study mainly focused on the macrophage’s morphology, polarization 
and differentiation in response to common stimuli, as well as their response to 
doxycycline.   
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In addition, leukotriene B4 (LTB4) has been shown as an important inflammatory 
mediator secreted by macrophages and has been implicated in PH pathogenicity 
(Wright et al., 1998, Tian et al., 2013, Qian et al., 2015). LTB4 biosynthesis is 
increased in pulmonary macrophages, the small pulmonary artery endothelial 
cells (Wright et al., 1998) and in the serum of patients with PAH (Tian et al., 2013). 
LTB4 is also shown increased in the BALF collected from experimental rats and 
its inhibition reverse PAH (Tian et al., 2013). Furthermore, it has been reported 
that LTB4 can induce apoptosis of pulmonary artery endothelial cells and 
proliferation of human smooth muscle cells (Tian et al., 2013). Thus expression 
of LTB4 in MacLow- derived macrophages was also examined.        
5.2  Material and methods 
5.2.1 Collection and culturing of mouse primary cells  
All of the cells used were murine primary cells obtained from either MacLow or 
control mice. Bone marrow cells were harvested from the tibia and femur as 
described in section 2.1.9, then cultured for 7 days in M-csf containing media to 
promote differentiation into mature macrophages (BMDM) as described in 2.3.1. 
Alveolar macrophages (AM) were obtained by collecting the broncho-alveolar 
lavage fluid (BALF) as described in 2.1.10.     
BMDMs and the AMs were then stimulated with either LPS/ INFγ, IL-4 or 
doxycycline. 
5.2.2 Detecting surface markers and protein expressions 
Following culture and stimulation, cells were phenotyped using flow cytometry 
(refer to the protocol on section 2.5). Antibodies used were: APC anti-mouse 
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F4/80, FITC anti-mouse CD68, PE anti-mouse CD206 and Pacific blue anti-
mouse CD86. Mature macrophages were defined as F4/80+ CD68+ cells; M1 
macrophages as F4/80+ CD86+ cells, whereas M2 macrophages as F4/80+ 
CD206+ cells.  
Expression of LTB4 was determined by detecting the expression of its 
biosynthesis enzyme the 5-lipoxygenase (5-LO) using IF/ICC (described in 
2.6.2.). Cell viability analysis was performed using the ApoTox-Glo TM Triplex 
assay kit (Promega, Madison, USA) as previously detailed in section 2.6. 
Expression of Diphtheria Toxin A (DTA) was detected by using the dot blot 
technique as detailed in section 2.7.     
5.2.3 Statistical analysis 
All statistics were performed using GraphPad Prism version 7.2 (GraphPad 
software, SanDiego, California USA). Statistical comparison between the 
different groups was established by the use of one-way analysis of variance 
(ANOVA) followed by Bonferroni post- hoc analysis. Two-way ANOVA was used 
in the time-point experiments when more than one variable need to be compared.  
Values are presented as mean ± SEM, and differences of P< 0.05 values were 
taken as significant. 
5.3 Results 
5.3.1 Characterization of MacLow bone marrow derived 
macrophage (BMDM)  
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5.3.1.1 Induction of BMDM formation 
In presence of M-CSF in the growth media, hematopoietic progenitor cells from 
the bone marrow were directed into a mature macrophage. Cells from MacLow 
and control mice were cultured in the growth medium for 7 days and the non-
adherent cells (dendritic cells) discarded. On day 7, the formation of mature 
BMDM and analysis of the purity of the population were evaluated using 
fluorophore-conjugated antibodies to detect cells expressing F4/80 and CD68. 
BMDMs were first gated on FSC and SSC to remove debris, then the non-treated 
macrophages (mature M) were defined as F4/80+ CD68+ subpopulation. The 
populations that resulted showed approximately 72-88% purity of the gated 
parent population (figure 5.2). The non-treated mature macrophages also 
showed some level of expression of CD86 (M1 marker) and CD206 (M2 marker).    
Morphological evaluation of the resultant cells showed that the non-treated 
mature BMDM possessed round with slightly elongated morphology (figure 5.1). 
No growth, shape or size differences were seen between the MacLow- derived 
cells and the controls.  
  
Figure 5.1- Morphological features of macrophage phenotypes: Morphological evaluation 
of the mature macrophages (Mature M) growing in culture media containing M-CSF at day 7. 
M1 macrophages resulted following stimulation with LPS/ IFNγ for 48hr and M2 macrophages 
following stimulation with IL-4 for 48hr. Images were taken at 20X magnification.   
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5.3.1.2 BMDM polarized activation 
Stimulation of M1 macrophages was induced by LPS/ INFγ for 48hr, while 
activation of M2 macrophages was induced by IL-4 for the same time. The 
activated macrophages were identified by flow cytometric analysis for expression 
of surface antigens (M1 as F4/80+ CD86+ cells and M2 as F4/80+ CD206+ cells)   
as shown in figure 5.3.  
The M1 population showed a similar level of co-expression of CD86+F4/80+ in 
the MacLow-derived BMDMs and controls (17.7 ± 5.047% and 16.9 ± 5.077% 
respectively). Similarly, in M2 population the co-expression of CD206+ F4/80+ 
was relatively identical and no significant differences detected (68.8 ±1.424% in 
MacLow macrophages vs 69.1 ± 2.073% in control macrophages).   
Morphological evaluation of the resulted cells showed that the LPS/IFNγ 
stimulated cells displayed some rounded shapes as the non-treated.  While the 
IL-4 stimulated cells had more pronounced elongation with the long protrusion 
(figure 5.1). These morphological features of the resulting cells are consistent 
with M1 and M2 morphology described in the literature, and again no differences 
in the size or shape of MacLow or control derived cells were detected.  
Taken together, no significant differences were noticed between the MacLow- 
derived BMDMs and the controls in term of their polarization toward the M1 and 
the M2 following activation.  
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Figure 5.2- Characterization and polarization of mature MacLow- derived BMDM: a) 
Representative flow cytometry scatter plots of bone marrow-derived macrophages (BMDM) from 
MacLow and control following culture using anti- F4/80 versus: anti-CD68, anti-CD86 and anti-
CD206. b) Summary data of flow cytometry results shown in (a) in each population before 
activation. Data analysed using a one-way ANOVA with Bonferroni post hoc test. Error bars 
represent mean ±SEM from 3 separate experiments.     
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Figure 5.3- Characterization and polarization of activated MacLow- derived BMDM: a) 
Representative flow cytometry scatter plots of bone marrow-derived macrophages (BMDM) from 
MacLow and control following culture and stimulation using anti- F4/80 versus: anti-CD86 and 
anti-CD206 for both M1 and M2 macrophages. b) Summary data of flow cytometry results shown 
in (a) in each population upon activation. Data analysed using a one- way ANOVA with 
Bonferroni post hoc test. Error bars represent mean ±SEM from 3 separate experiments.     
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5.3.1.3 Characterization and polarization of MacLow-derived BMDMs 
following doxycycline treatment  
To examine whether doxycycline can cause any other unique activation or 
skewing of macrophage phenotype, mature BMDMs were treated with different 
doses of doxycycline; 1, 5, 10 and 40 µg/ml for 48 hr (the same time required for 
full differentiation toward M1 and M2) then the expression of surface markers of 
M1 and M2 were investigated as previously shown.   
Interestingly, MacLow-derived macrophages stimulated with low doses of 
doxycycline (1 and 5 µg/ml) seemed to induce the skewing toward the 
alternatively activated M2 subtype as shown by its relative high frequent 
expression of CD206+F4/80+ compared to control cells (figure 5.4). However, the 
difference was not significant between the MacLow- derived cells and the controls 
at any concentration. In the higher doses of doxycycline the expression was also 
relatively high but with no difference between the MacLow and control derived 
cells, this was probably as a result of the pharmacological/ toxicological effect of 
doxycycline on macrophages regardless of their phenotype. Thus for all the 
subsequent experiments, a dose of not more than 5 µg/ml of doxycycline will be 
used.  
To confirm that the observed induction of CD206 level seen in MacLow- derived 
cells was a result of doxycycline, and whether the effect is reversible or not, 
mature BMDMs were first treated with  5 µg/ml of doxycycline for 48 hour, then 
the doxycycline removed the culture media and cell’s phenotype was tested after 
48 hour. The recovery samples showed that the effect was reversible as the 
expression of CD206 was largely inhibited (figure 5.4)    
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This suggesting that doxycycline can promote a shift or skew toward an M2-type 
macrophages cell type in MacLow- derived cells. This was also supported by the 
morphological assessment of doxycycline-treated cell as they were elongated 
and their morphology is highly resembling the M2 morphology (figure 5.5-a). 
Further analysis of the data showed that despite that difference was not 
statistically significant comparing the stimulated MacLow BMDM and the controls 
at any of the concentrations. However, by comparing the level of expression of 
CD206 after doxycycline treatment with that caused by IL-4 stimulation, the level 
was highly comparable and the increase led to a loss the significance seen in the 
control cell between the doxycycline-treated cell (1µg/ml dose) and IL-4 treated 
cells. Where in the MacLow cells there was a significant increase in expression 
of CD206 in the doxycycline-treated cell (5µg/ml dose) compared to untreated 
cells (figure 5.5).   
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Figure 5.4- Characterization and polarization of MacLow- derived BMDM following doxycycline 
stimulation: a) Representative flow cytometry scatter plots of bone marrow-derived macrophages 
(BMDM) from MacLow and control following stimulation with different concentrations of doxycycline, 
and after removing doxycycline from the media (recovery), the scatter plot present anti- F4/80 versus 
anti-CD206 fluorophores.  b) Bar graph summarize the flow cytometry results of doxycycline 
stimulation shown in (a), Data analysed using a one- way ANOVA with Bonferroni post hoc test. Error 
bars represent mean ±SEM from 3 independent experiments. 
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5.3.1.4  Effect of doxycycline on BMDM cell viability 
To examine the effect of doxycycline on cell death in vitro, cell viability analysis 
was performed using the ApoTox-Glo TM Triplex assay kit (Promega, Madison, 
USA) as previously detailed in section 2.6. This assay is a three in one technique 
that allows assessment of viability, cytotoxicity and caspase activation (a hallmark 
Figure 5.5- Skewing toward alternative activated macrophages: a) morphological feature 
of control and MacLow- derived BMDM following doxycycline treatment. b) Bar graph compare 
the expression of CD206+ F4/80+ of control and MacLow- derived BMDM after doxycycline 
and IL-4 treatment. Data analysed using a one-way ANOVA with Bonferroni post hoc test. 
Error bars represent mean ±SEM from 3 separate experiments.      
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of apoptosis) in a single assay. To assess cell viability in doxycycline-treated 
BMDM at the different time point, the live-cell protease activity was measured. 
The cell viability dropped significantly following 3 days of doxycycline treatment 
in MacLow-derived cells as well as the control cell. No significant differences were 
detected in cell viability between the MacLow and control derived cells at any of 
the time-point assessed (figure 5.6-a)   
To assess the cytotoxicity of doxycycline, the dead-cell protease activity was 
measured. Again, the cell toxicity did not significantly change over time although 
there was a trend of increased cytotoxicity in MacLow- derived cells within the 
first three days after doxycycline treatment compared to control cells (figure 5.6-
b). Ideally, viability and cytotoxicity are inversely correlated, however, it could be 
that the actual changes in cell membrane integrity had not occurred yet and this 
period will manifest as a decline in viability with no concomitant increase in the 
cytotoxic biomarker. Finally, to determine whether the cell death occurs via 
apoptosis, caspase 3/7 activity was measured.  The results do not show clear 
changes in the caspase activity in the MacLow and control derived BMDM 
following doxycycline treatment (figure 5.6-c), this suggests that it is unlikely that 
the cell died by apoptosis. 
Chapter 5 
 
136 
 
0 2 4 6 8
0
5 0
1 0 0
1 5 0
D a y s
C
e
ll
 v
ia
b
il
it
y
 F
lu
o
r
e
s
c
e
n
c
e
 (
%
)
M a c L o w
C o n tro ls
C e ll v ia b ility
0 2 4 6 8
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
C e ll c y to to x ic ity
D a y s
C
e
ll
 c
y
to
x
ic
ic
ty
 F
lu
o
r
e
s
c
e
n
c
e
 (
%
)
0 2 4 6 8
0
5 0
1 0 0
1 5 0
2 0 0
C a s p a s e  a c t iv ity
D a y s
C
a
s
p
a
s
e
 3
/7
L
u
m
in
e
s
c
e
n
c
e
 (
%
)
a )
b )
c )
 
 
Figure 5.6- Effect of doxycycline on BMDM cell viability: Mature BMDM derived from 
MacLow and control mice were treated with doxycycline (5µg/ml) then cell viability (a), 
cytotoxicity (b) and caspase activity (c) assessed using the ApoTox-Glo TM Triplex assay 
kit. Data presented as mean ± SEM collected from 3 independent experiment. Analysis 
performed using two-way ANOVA.    
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Collectively, this experiment showed that doxycycline can induce cell death in 
vitro to some extent and most likely via necrosis, however it was not clear whether 
this was due to the cytotoxic effect of doxycycline as a substance rather than as 
a gene inducer as the difference between the MacLow and control cells was not 
as pronounced as in vivo.     
5.3.2 Characterization of MacLow-derived alveolar macrophages 
(AM)  
BALF from MacLow and control mice were seeded in 24-well cell culture dishes 
to enable adherence of macrophages for at least 2 hours. The non-adherent cells 
were then discarded and the macrophages scraped to be characterized by flow 
cytometry based on their expression of surface markers. 
The resulting preparation showed that over 80% of the cells obtained were 
F4/80+ thereby identifying them as macrophages (figure 5.7). However, in 
contrast to the BMDM, the expression of CD68 was not clear and potent using 
the same protocol and the same antibody. It could be that the auto-fluorescent 
feature of macrophages interferes with the detection, however, this could give 
just a sight overestimation or underestimation of the reading. 
Although the expression of CD68 was low no difference was detected between 
the MacLow and control derived cells as well as the F4/80 expression. Since the 
MacLow system uses the human CD68 as promoter for the DTA expression, it is 
possible that the AMs are more resistant to the model if they express less CD68. 
Because of this, it was essential to investigate the effect of doxycycline on AM in 
vitro and identify whether AM and BMDM respond similarly or to a different extent 
in term of polarized activation and viability.      
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5.3.2.1 Characterization and polarization of MacLow- derived alveolar 
macrophages (AM) 
To further evaluate the effect of doxycycline on AMs polarization, the adherent 
AMs were treated with doxycycline (1 and 5 µg/ml) for 48 hours, then the cells 
scraped to be characterized by flow cytometry based on their expression of 
surface markers for M1 and M2 polarization.  
Following doxycycline treatment, macrophages from either MacLow or control 
exhibited no differences in expression of M1 marker CD86 or the M2 marker 
CD206, with 4.667 ± 0.938 and 14.03 ± 2.079 respectively in MacLow- derived 
cells, compared with 4.5 ± 0.5 and 15.67 ± 3.49 respectively in the control derived 
cells (figure 5.7). Also, no difference was detected between the two doses of 
doxycycline tested (data not shown).   
Moreover, to examine the effect of doxycycline on AMs following in vivo 
treatment, age- matched male MacLow and control mice were fed with 
doxycycline containing diet for 2 weeks to induce 50% loss of macrophage 
(Gheryani et al., 2013), then BALF was collected for cytospin preparation (see 
section 2.1.10).  Liver and lung were also harvested to confirm the loss of 
macrophage and the expression of DTA within the tissues (will be shown later in 
this chapter). Qualitative assessment of the cytospin slides showed that the 
number of AMs (the large mono-nuclear cell) was highly comparable between the 
MacLow and the control mice following doxycycline treatment (figure 5.8), also 
that the MacLow BALF preparation includes other inflammatory cells such as 
neutrophil (the multi-nucleated cells) and lymphocyte (large dark-staining 
nucleus) compared to the control preparation. It is appreciated that the 
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percentage yield of AMs from the BALF is highly dependent on the efficiency of 
the BALF collection technique, but this was taken into consideration when 
harvesting the cells and the same number of washes were performed from all 
mice harvested. These findings strongly suggest that the alveolar macrophages 
were resistant or affected to lesser degree by the doxycycline- induced depletion 
than other tissue macrophages. 
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Figure 5.7- Characterization and polarization of MacLow- derived AM: Representative 
flow cytometry scatter plots of alveolar macrophages (AM) following culture and stimulation 
using anti- F4/80 versus anti-CD68 (for non-treated), and anti-CD206 (for doxycycline-
treated). Data analysed using a one- way ANOVA with Bonferroni post hoc test. Error bars 
represent mean ±SEM. 
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5.3.2.2  Effect of doxycycline on alveolar macrophages viability 
To examine the effect of doxycycline on AM cell death in vitro, cell viability 
analysis was performed using the ApoTox-Glo TM Triplex assay kit as previously 
detailed. Cultured AM from MacLow and control mice were treated with 
doxycycline in vitro and the cell viability, cytotoxicity and caspase activity was 
Figure 5.8- BALF cytospin: Cytospin preparation of BALF from control and MacLow mice 
following 2 weeks doxycycline treatment in vivo. Magnification X20. 
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measured. The cell viability of both MacLow and control derived AMs dropped 
following three days of doxycycline treatment. However, the drop was highly 
comparable for both control and MacLow over the whole 7 days of the experiment 
and no significant differences recorded (figure 5.9).  On the other hand, the 
cytotoxicity profile showed a slight increase within the first three days followed by 
the steady-state curve for both MacLow and control cells with no statistically 
significant difference between the MacLow and control cells at any time point. 
Again no clear time-dependent caspase activation detected which suggest that 
apoptosis not involved in the process of cell death. 
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Figure 5.9- Effect of doxycycline on AM cell viability: Cultured AMs derived from 
MacLow and control mice were treated with doxycycline (5µg/ml) then cell viability (a), 
cytotoxicity (b) and caspase activity (c) were assessed using the ApoTox-Glo TM Triplex 
assay kit. Data analysed by two-way ANOVA and presented as mean ± SEM collected 
from 3 independent experiment.     
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5.3.3 Expression of Diphtheria toxin A chain (DTA)    
The MacLow mouse model utilized the Tet-on system for gene expression, 
whereby doxycycline can switch-on the expression of DTA protein leading to cell 
death, to determine whether DTA is detectable in vitro, dot blot technique was 
used (see section 2.7). Mature BMDM and cultured AMs from MacLow mice were 
either treated with doxycycline (5 µg/ml) or left with no stimulation for 48 hr. Cells 
were then processed for protein extraction and transferred onto a nitrocellulose 
membrane and stained with anti-DTA antibody. Liver tissue harvested from 
MacLow mouse that had been treated with doxycycline for two weeks was used 
as a positive control.  The expression of DTA was confirmed on the liver sample, 
and by comparing the BMDM and the AMs the blot showed that the expression 
of DTA in the AMs is less than that of BMDMs following doxycycline treatment in 
vitro (figure 5.10).  This finding further suggests that alveolar macrophages have 
a unique character and respond to the MacLow depletion system differently from 
other tissue macrophages.       
 
 
Figure 5.10- expression of diphtheria toxin A 
in MacLow- derived macrophages: Cultured 
AMs and mature BMDM derived from MacLow 
and mice were treated with doxycycline (5µg/ml) 
then the expression of DTA was assessed using 
dot blot technique. Image show nitrocellulose 
membrane visualized by the LI-COR ® reader 
using the proper channels.      
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5.3.4 Investigating 5-LO/ LTB4 signalling 
In macrophages, LTB4 is synthesized from arachidonic acid (AA) by the action of 
5-Lipoxygenase (5-LO) enzyme. Leukotriene A4 (LTA4) is produced which is 
then quickly hydrolysed to LTB4 by leukotriene A4 hydrolase (LTA4H) (figure 
5.11-a). 5-LO phosphorylation by p38 mitogen-activated protein kinase (MAPK) 
increases its enzymatic activity in vitro (Werz et al., 2000, Werz et al., 2002). 
LTB4 is shown to be overproduced by macrophages in PH (Tian et al., 2013). 
To investigate whether the biosynthesis of LTB4 in either BMDM or AM can be 
affected following doxycycline treatment in vitro, AM from BALF and BMDM from 
MacLow and control mice were cultured as previously described, then stimulated 
with 5µg/ml doxycycline for 48 hours. The cells were then fixed and 
immunofluorescent staining was performed using anti-5LO antibody (section 
2.6.2). Immunofluorescence analysis of 5-LO nuclear fluorescent intensity 
showed a significant increase in nuclear expression in MacLow-derived AM 
compared to control following doxycycline stimulation (figure 5.11). Conversely, 
5-LO nuclear fluorescence intensity was significantly lost in BMDM derived from 
MacLow compared to control BMDM following doxycycline treatment.   
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Figure 5.11- 5-Lipoxygenase /Leukotriene B4 signalling: a) Schematic of LTB4 production 
and secretion by macrophages.  b) Representative immunofluorescence images of alveolar 
macrophages (AM) and bone marrow-derived macrophages (BMDM) stained with 5-LO (red) 
with nuclei labelled with DAPI (blue), cells derived from either MacLow or control mice. c,d) 
Quantification graphs show the corrected total nuclear fluorescence of AM (c) and BMDM (d) 
corrected to the background. Images were analysed using FiJi software. Data analysed using 
a one- way ANOVA with Bonferroni post hoc test. Error bars represent mean ±SEM Bar graph 
represent mean ±SEM from 3 independent experiment. *P <0.05, **P<0.005. 
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5.4 Discussion 
Data presented in this chapter further highlights the heterogeneity and complexity 
of the lung macrophage population based on their origin and compartment. I 
showed here using an in vitro culture system that different lung macrophages 
have unique characteristics in term of cell viability, polarization, expression of 
DTA and expression of LTB4 following the addition of doxycycline. As the 
MacLow-BMDM showed a change in their phenotype toward the alternative 
activation state following doxycycline stimulation in vitro, while the MacLow- 
derived AMs showed less expression of DTA and therefore may be more resistant 
to killing following the addition of doxycycline.   
Various studies in animal models suggested a key role for lung macrophages in 
the pathogenesis of PAH, moreover, activation of AMs was highly associated with 
hypoxia-induced PH (Hayashida et al., 2005, Frid et al., 2006, Vergadi et al., 
2011) and depletion of AMs appears to attenuate hypoxic-PH (Zaloudikova et al., 
2016). However, the mechanism characterizing the functional phenotype relative 
to lung localization remains largely unclear. 
 In hypoxia-induced PH, a recent study has shown that AMs and IMs share a 
conserved pro-inflammatory programming at 4 days of hypoxic exposure, after 
which a contrasting phenotype appears by day 14 as the AMs promote their pro-
inflammation function, whereas the IMs demonstrated a unique anti-inflammatory 
programming state (Pugliese et al., 2017). 
A study by (McCubbrey et al., 2016)  used hCD68rtTA-GFP reporter mouse 
model for inducible targeting of CD11b+ lung macrophages to demonstrated that 
negligible activation occurs in AMs compared to IMs, they showed that 
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administration of doxycycline-induced tet-on reporter expression in the recruited 
and tissue macrophages but not in AMs during inflammation and homeostasis.  
The mechanism by which the macrophage inducing system fails to target AMs is 
not completely clear. However, our data demonstrated an AM phenotype with low 
expression of CD68 which is the promoter in the tet-on system used in both our 
MacLow model and the model used by McCubbrey et al. Another possibility is 
that doxycycline cannot access the alveolar spaces, although other studies 
showed that doxycycline as an antibiotic can be internalised by the AMs (Klimeš 
et al., 1999). An alternative possibility is that AMs produce yet unknown factor/ 
factors which are capable of interfering with doxycycline function. Further 
exploration of this will defiantly be required to fully address the underlying 
mechanisms.  
To isolate distinct lung macrophage population, BALF collection followed by lung 
digest and cell sorting with flow cytometry is highly recommended, as 
macrophages and monocyte can be separated into two compartments according 
to their marker expression: AM (CD64+,CD11chi, CD11blo) and IMs (CD64+, 
CD11clo, CD11bhi), then further comprehensive analysis of each subset can be 
performed. 
Analysis of BMDM polarization showed an interesting skewing toward the 
alternatively activated macrophage subtype (M2) following doxycycline 
stimulation,   this was also seen in vivo with the MacLow- induced PAH as it was 
associated with activation of M2 macrophages. Macrophages can sense and 
respond to the surrounding condition and can alter their phenotype to meet the 
specific needs of the circumstances, it could be that the induced macrophage 
Chapter 5 
 
149 
 
depletion with doxycycline has led to this alternative activation of macrophages, 
as it has been shown that the presence of cell debris leads to potent polarization 
of alternatively activated macrophages in the case of pulmonary infection (Mares 
et al., 2011).  
Leukotriene B4 (LTB4) is well recognised for its significant role in clinical PAH, 
investigating the biosynthesis of LTB4 in MacLow-derived macrophages revealed 
that doxycycline-treated AMs express higher levels compared to control AMs, 
while the doxycycline treated BMDM express less level than that of control cells 
following doxycycline treatment. These findings give promising information 
regarding the importance of LTB4 pathway in the development of the sex-specific 
MacLow- induced PAH, especially since recent data has further demonstrated 
sex differences in levels of leukotriene (Pace et al., 2017).           
Collectively, based on these findings, the MacLow system can be proposed as a 
novel powerful tool that can be utilized for lineage tracing and fate mapping to 
individually target distinct lung macrophage population, the system can be used 
to sort out the relative contribution of AMs and IMs in PAH associated 
remodelling, by deleting only one of the subtypes (figure 5.12).    
The development of effective therapeutic targets for PAH needs to consider and 
fully understand the different aspect of macrophage activation as they could have 
opposing roles during the development of the disease. A better understanding of 
relative contribution from IMs and AMs in the initiation and maintenance of 
vascular remodelling may facilitate the reprogramming or the skewing toward the 
reparative phenotype of macrophage to attenuate the vascular remodelling. 
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Figure 5.12- proposed model of MacLow-induced depletion of lung macrophages: 
MacLow model of induced macrophage depletion targets tissue and the recruited 
macrophages while leaving the alveolar macrophages less- or un-affected. This could 
potentially lead to compartment-specific activation of the alveolar macrophages.      
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6  Sex bias in MacLow induced pulmonary 
arterial hypertension model 
 
6.1  Introduction 
As shown in the previous chapters, loss of CD68+ macrophages in MacLow mice 
induced PAH development in male and not female mice (chapter 3), and that the 
lung resident macrophages, as well as bone marrow- derived cells, need to be 
depleted to induce the development of PAH (chapter 4), and among the lung 
resident macrophages each subtype showed unique phenotype when inducing 
the depletion in vitro with doxycycline, this suggested a compartment-specific 
activation of the alveolar subtype following the loss of the interstitial subtype 
(chapter 5). This current chapter investigated in depth the implication of sex 
difference on the development of MacLow- induced PAH and how this impacts 
on disease development.  
In patients, PAH develops more predominantly in women than men with a 4.3:1 
female to male ratio among the total PAH group (Walker et al., 2006), and 4.1:1 
in idiopathic PAH subcategory (Badesch et al., 2010).  However, men showed 
poorer survival and women fare better (Badesch et al., 2010, Shapiro et al., 
2012). This is suggested to be in part due to the protective action of sex hormones 
mainly oestrogen (E2) since ovariectomy exacerbates PH and E2 pre-treatment 
attenuate its progression in the animal models (Farhat et al., 1993, Tofovic et al., 
2006). 
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The aim of this chapter was to characterize the possible phenotypic differences 
of macrophages taken from male and female in MacLow model in vivo, using the 
bone marrow transplant and generation of mixed-sex chimeras. The main 
question that will be addressed is whether or not male-derived bone marrow cells 
can induce disease in female MacLow mice.   
In addition, an attempt to look at the potential protective effect of oestrogen will 
be presented at the end of the chapter, however, some problems with the mouse 
colony occurred that hindered completion of the study. 
6.2 Material and method 
6.2.1  Generation of mixed-sex MacLow chimeric mice and 
induction of PAH 
Mixed-sex chimeric mice were generated by the process of BMT, the procedure 
was performed using the optimized protocol is detailed in section 2.1.3. In brief, 
age-matched male and female MacLow mice (8-10 weeks) were used as 
recipients to generate the chimeras described in the table (6.1), recipients were 
irradiated with 10 Gy in one shot and engrafted with around 5 X106 bone marrow 
cells. All the donor cells were taken from MacLow male/ female donor. Male donor 
BM cells were transplanted into the pre-irradiated female recipient and vice versa 
(female into male). In addition, two groups received a graft from identical sex of 
male-derived BM into male mice and female BM into female mice as positive and 
negative control groups respectively (figure 6.1-a).  Mice were left to recover for 
at least 30 days after the transplant then PAH was induced by doxycycline 
treatment (doxycycline containing diet) to induce macrophage depletion for 
another six weeks with no other insult.   
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Table 6.1. Mixed-sex MacLow chimeras generated from bone marrow transplantation for 
the PAH study 
Chimera Donor Recipient (n) 
1 (positive control) Male Male (8) 
2 Male Female (5) 
3 Female Male (5) 
4 (negative control) Female Female (5) 
 
6.2.2 Echocardiography and cardiac catheterization  
Following six weeks of doxycycline treatment, non-invasive assessment of the 
disease was performed using echocardiography under anaesthesia as described 
in section 2.1.4. Then the closed chest cardiac catheterization was used to take 
the pressure-volume measurements from both sides of the heart as described in 
section 2.1.5. 
6.2.3  Histological analysis  
Tissues were harvested, fixed, processed and stained according to the standard 
laboratory procedure described in sections 2.1.6 and 2.2. 
6.2.4  Statistical analysis 
All statistics were performed using GraphPad Prism version 7.2 (GraphPad 
software, SanDiego, California USA). Statistical comparison between the 
different groups was established by the use of one- way analysis of variance 
(ANOVA) followed by Bonferroni post- hoc analysis. Values are presented as 
mean ± SEM, and differences of P< 0.05 values were taken as significant. 
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6.3 Results 
6.3.1 Macrophage depletion in the chimeric mice 
It has been confirmed in chapter 4 that MacLow chimeric mice were susceptible 
to macrophage depletion following doxycycline treatment (although higher 
depletion was detected within the liver than that within the lungs). In the current 
study, all the recipient mice were MacLow mice so they were all expected to get 
the same level of reduction. To confirm this, 5 µm sections of paraffin-embedded 
liver were stained with anti-F4/80 antibody as previously shown (see section 2.2.3 
and 2.2.3), then the positively stained cells were counted in 6 fields of view and 
presented as the number of F4/80 positive cells per field. The results showed no 
statistical difference between male and female groups in term of F4/80+ 
macrophages remained within the liver following doxycycline treatment (figure 
6.1) 
In addition, all mice experienced some weight loss during the first week after the 
BMT procedure, then they regained this weight back gradually. No significant 
differences were detected at any point, however, the male recipient transplanted 
with male graft (positive controls) showed slower recovery to retrieve their start 
weight (figure 6.1-b).  
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6.3.2 Assessment of PAH in mixed-sex MacLow chimeras 
6.3.2.1  Haemodynamic evaluation 
Following the six weeks doxycycline treatment, disease progression was 
assessed by closed chest cardiac catheterization, echocardiography and 
measuring the hypertrophy of the right ventricle. The readings showed that the 
RVESP had increased significantly from 21.4 ± 0.339 in the negative control 
group (female BM to female) to 29.9 ± 2.289 in the positive control group (male 
BM to male). 
The transplantation also showed that injecting BM from male MacLow mice into 
female MacLow was not sufficient to cause a significant increase in their RVESP 
(figure 6.2). In addition, no conclusion can be made regarding whether female 
BM can protect males from the induced PAH as the RVESP changes was not 
significant. However, the average pressure suggests that female BM cells may 
attenuate but not protect males from the induced PAH.  
Figure 6.1- macrophages depletion in the liver after doxycycline treatment: a) schematic 
of study design displaying the bone marrow transplant procedure followed by 4 weeks    
recovery period before starting doxycycline treatment, the disease assessed at the end-point 
by echocardiography and cardiac catheterization. BM= bone marrow. b) Graph shows the 
difference in weight loss of the different groups after the bone marrow transplant procedure 
(BMT). c) Representative histological images of liver sections stained with anti- F4/80 
antibody with the correspondent quantification of the number of F4/80+ macrophages 
remaining within the liver after treatment with doxycycline. Positively stained cells were 
counted in 6 fields of view at X20 magnification. BM= bone marrow. Data analysed using a 
one- way ANOVA with Bonferroni post hoc test. Error bars represent mean ±SEM, n= 5-8/ 
group. (♂)  males, (♀) females. 
 
 
 
Chapter 6 
 
157 
 
These finding was consistent with other haemodynamic parameters measured 
from the right-side of the heart with no effect on the measurements from the left-
side heart (see appendix I). No changes in the cardiac index were detected 
between the different groups (figure 6.2-b). 
To further investigate whether the increase in pressure has led to right ventricular 
hypertrophy (RVH), the RVH index was calculated. The results showed no 
significant difference in the RVH value between the groups (figure 6.2-c), which 
again indicate that the disease phenotype was not pronounced and it was not 
enough to cause any effect on the heart.   
Taken together, these findings suggest that the recruited cells from the blood 
are not crucial in the development of MacLow- induced PAH as the female mice 
were still protected following transplantation with male hematopoietic cells.     
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Figure 6.2- Haemodynamic of the PAH phenotype in mixed- sex chimeric mice:  a) Right 
ventricle end-systolic pressure (RVESP) taken using closed chest cardiac pressure volume 
catheterization b) Cardiac index (cardiac output/ body weight) taken using Vevo 770 
echocardiography equipment, c) Right ventricle hypertrophy index (RVH). BM= bone marrow 
Data analysed by one- way ANOVA with Bonferroni post hoc test. Error bars represent mean 
±SEM, n= 5-8/ group.  *P <0.05, **P <0.005. (♂) males, (♀) females.   
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6.3.2.2 Analysis of vessel wall remodelling 
PAH is usually associated with vascular remodelling, therefore remodelling was 
assessed. Histological staining with anti-SMA (figure 6.3) and ABEVG was used 
to investigate the thickness of pulmonary vessels. In the small sized vessel 
category (10-50 µm), both the media layer thickness and the number of 
remodelled vessels were significantly increased in male chimeric group 
transplanted with male BM cells (the positive control group) following 
macrophage depletion. No significant increase was observed in both female 
groups following macrophage loss (figure 6.4) 
This further suggest that male MacLow haematopoietic cells are not sufficient to 
induce the PAH in females MacLow mice. 
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Figure 6.3- Remodelling of pulmonary arteries in mixed-sex MacLow chimeras: 
representative immunofluorescence histological of paraffin fixed lung sections shows the 
pulmonary vascular lesion in male MacLow chimeric mice compared to other groups. Sections 
stained with α- smooth muscle actin (SMA) (red) and cell nuclei labelled with DAPI (blue). 
Sections visualized using Zeiss multi-slide scanning microscope at X20 magnification, scale 
bar= 50 µm.  
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Figure 6.4- Analysis of the degree of remodelling in lung sections: a,c,e) Bar graphs 
represent Media to cross sectional area (CSA) of three different sized groups (10-50 µm, 51-
100µm and >100µm respectively), data analysed using a one- way ANOVA with Bonferroni 
post hoc test.  b,d,f) Graphs represent pulmonary vascular remodelling by percentage 
muscularised vessels of three different sized groups of vessels (10-50 µm, 51-100µm and 
>100µm respectively). BM= bone marrow. Data analysed using two- way ANOVA. In all data 
n= 4-8 / group.  *P <0.05, **P <0.005.  (♂) males, (♀) females.  
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6.3.3 Analysis of lung macrophages 
Immunohistochemical staining was utilized to assess the level of reduction of total 
macrophage, M1 and M2, using anti- F4/80, anti- iNOS and anti- CD206 
antibodies respectively as previously described. Since all the recipient groups the 
same level of macrophage reduction following doxycycline treatment was 
expected. This was confirmed by counting the number of F4/80+ stained cells 
remaining within the lungs (figure 6.5), the results presented in figure 6.6 showed 
no significant difference in total macrophage count between any of the groups.    
Furthermore, no significant differences detected in either the M1 (iNOS + stained 
cells) nor the M2 population (CD206 + stained cells) within the lungs following 
doxycycline treatment (figure 6.6-b,c).  
Although the disease phenotype shown previously in chapter 3 was associated 
with a prevalence of M2 population, but in this BMT study this was not the case. 
Again, this could be due to that the disease phenotype developed was less 
pronounced in the chimeric mice that underwent total body irradiation. 
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Figure 6.5- Total lung macrophages in mixed-sex MacLow chimeric mice: 
Representative photomicrographs of   lung sections stained with anti-F4/80 antibody (total 
macrophages). The images show the different in macrophage (stained brown- arrow head) 
remained within the lung of each group after six weeks doxycycline treatment. Image taken 
using Zeiss multi-slide scanning microscope at X20 magnification, scale bar= 50 µm.  
 
 
Chapter 6 
 
164 
 
         
0
5 0
1 0 0
1 5 0
F
4
/8
0
+
 m
a
c
r
o
p
h
a
g
e
s
/ 
fi
e
ld
(L
u
n
g
)
M ale  B M
to  M a le
F e m a le  B M
to  M a le
M a le  B M
 to  F e m a le
F e m a le  B M
to  F e m a le
a)
b )
c )
0
1 0
2 0
3 0
4 0
5 0
iN
O
S
+
 m
a
c
r
o
p
h
a
g
e
 /
fi
e
ld
(L
u
n
g
)
M ale  B M
to  M a le
F e m a le  B M
to  M a le
M a le  B M
 to  F e m a le
F e m a le  B M
to  F e m a le
0
1 0
2 0
3 0
4 0
C
D
2
0
6
+
 m
a
c
r
o
p
h
a
g
e
 /
fi
e
ld
(L
u
n
g
)
M ale  B M
to  M a le
F e m a le  B M
to  M a le
M a le  B M
 to  F e m a le
F e m a le  B M
to  F e m a le
 
Figure 6.6- Analysis of macrophage subsets in lung sections: Quantification of the 
number of macrophage remaining within the lung of the chimeric mice following doxycycline 
treatment. Positively stained cells were counted in 6 field of views / tissue at X20 magnification. 
a) Quantification of total macrophage using F4/80 antibody. b) Quantification of M1 
macrophage subset using iNOS antibody. c) Quantification of M2 macrophage subset using 
CD206 antibody. BM= bone marrow. Data analysed using a one- way ANOVA with Bonferroni 
post hoc test. Error bars represent mean ±SEM.  n= 5-6/ group. (♂) males, (♀) females. 
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6.3.4 Oestrogen prophylactic study (preliminary)  
To investigate the potential protective effect from oestrogen against the MacLow- 
induced PAH, the disease was induced in male MacLow mice using doxycycline 
treatment and the prophylactic effect of oestrogen was tested. Male MacLow mice 
(12-14 weeks of age) were randomized into 3 groups, the first group was received 
oestrogen alone as a negative control, the second group was received 
doxycycline alone as a positive control and the third group received both 
doxycycline and oestrogen for the same treatment period which was six weeks 
(figure 6.7-a).   
Unexpectedly, none of the groups developed PAH as shown by their normal 
RVESP, even the positive control group showed normal haemodynamic readings 
from the right and left ventricles. The study was then repeated and another batch 
of mice underwent the same procedure for the same period of time using another 
batch of doxycycline diet, again the same negative results claimed.  
To trace this problem, the efficiency of macrophage depletion within different 
tissues was investigated. The remaining F4/80 + macrophages were counted in 
the liver and lung sections. There was not any difference in macrophage count 
between the groups that received doxycycline and the group that did not (figure 
6.7), this means that for some unknown reason the macrophage depletion model 
did not work this time, and subsequently no disease was developed. 
It was very unlikely to be because of the doxycycline as the diet was fresh diet 
from the supplier and the drug should still be effective.  Another possibility is that 
there were some issues with the mouse colony caused by the loss of some of the 
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genetic features that led to reducing the depletion capability. To address this 
issue backcrossing of the MacLow double transgenic and the tetDTA single 
transgenic with the FVB mice will be recommended to tackle this issue.    
 
 
The negative results from the oestrogen study further suggested a positive 
correlation between the loss of macrophages and the increase in pressure in 
male mice. To test whether the reduction in lung F4/80 + macrophages correlates 
with RVESP increase, measuring of Pearson correlation coefficient was 
performed using pooled pressure readings from only male MacLow mice in the 
Figure 6.7- Oestrogen prophylactic study: a) Schematic of study design: male MacLow 
mice starting doxycycline treatment with or without oestrogen at day 0 and continued for six 
weeks, the disease assessed at the end-point by echocardiography and cardiac 
catheterization. b) Quantification of the number of F4/80+ macrophages remaining within the 
liver after treatment with doxycycline. Positively stained cells were counted in 6 fields of view 
at X20 magnification. c) Right ventricle end-systolic pressure taken using closed chest cardiac 
pressure-volume catheterization. Data analysed using a one- way ANOVA with Bonferroni 
post hoc test. Error bars represent mean ±SEM, n= 5-8/ group, Doxy= doxycycline. 
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different set of experiments presented in this thesis. The graph 6.8 did show a 
positive correlation between the RVESP and the percent reduction of lung 
macrophages with a significant P value of 0.0431. Thus as the percentage of lung 
macrophage loss increases, the pulmonary pressure also expected to increase.  
 
 
 
 
6.4 Discussion  
Data presented in this chapter demonstrate that  lung resident macrophages are 
the major contributors in the development of MacLow- induced PAH in male mice 
and that male- derived hematopoietic cells alone were not sufficient to induce the 
disease in females. Although the disease phenotype developed in male MacLow 
chimeras was not severe, it was pronounced enough to conclude that the female 
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Figure 6.8- Correlation between macrophage depletion and pulmonary pressure: the 
graph shows the positive correlation between percentage reductions of F4/80 positive 
macrophage in the lung with the right ventricle end-systolic pressure in male MacLow mice 
following doxycycline treatment. n=24.   
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chimera was still protected following transplantation with male inoculum. Again 
this traced back the origin of the effector cells responsible for the development of 
PAH in MacLow mice to be within the lung itself.    
As shown in our previous BMT study in chapter 4, the spontaneous increase in 
pressure following macrophage ablation was less pronounced in the chimeric 
mice that underwent total body irradiation compared to non-chimeric mice (figure 
4.3). This was probably due to irradiation, as irradiation thought to affects the lung 
macrophages (Matute-Bello et al., 2004). Taken into account that the alveolar 
macrophages are long- lived they shown to be resistant to  irradiation, and by the 
time of circulating leukocytes are completely replaced by donor cell, only 47% of 
the alveolar macrophages repopulate in 30 days following bone marrow 
transplant (Matute-Bello et al., 2004). This further emphasis the role of AMs in 
particular in the development and severity of MacLow- induced PH phenotype.     
Gender/ sex bias does exist in both clinical and experimental forms of PH, as the 
incident is higher in the female patients. In contrast, in various animal models, 
females showed less evidence of the disease compared with males. The female 
rat develops less severe PH, RVH and vascular remodelling following chronic 
hypoxia compared to males (Rabinovitch et al., 1981, Resta et al., 2001, Umar et 
al., 2009). These sex differences were mainly attributed to the effect of oestrogen 
and its metabolites (Umar et al., 2011). 
The ‘oestrogen paradox' phenomenon arose from the contradictory findings 
regarding the role of oestrogen in PH.  It has been shown that oestrogen and its 
metabolites can prevent PH in an experimental models of the disease (Farhat et 
al., 1993, Tofovic et al., 2005), also oestrogen can rescue pre-existing severe PH 
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in the male rat as it can restore lung and RV function, reduce pulmonary 
inflammation and limit the monocyte/ macrophage infiltration even after cessation 
of oestrogen treatment (Umar et al., 2011). On the other hand, unbalanced 
oestradiol metabolism has been shown to increase the risk of PAH in patients 
and animal models (Austin et al., 2009). Furthermore, oestrogen level has been 
shown to be high in male patients with PAH and the level associated with a 
shorter 6-minute-walk distance (Ventetuolo et al., 2016). Also in experimental PH, 
treatment with the aromatase inhibitor anastrazole (the aromatase converts 
androgens to oestrogen and responsible for most of the oestrogen production in 
men and postmenopausal women) reduced the pulmonary arterial pressure and 
RV hypertrophy (Mair et al., 2014b, Wright et al., 2015). And importantly, 
anastrazole significantly reduced oestrogen level in patients with PAH and 
improved the 6-minute-walk distance (Kawut et al., 2017). Longer and larger 
phase II clinical trial of anastrazole in this context is now underway (NCT 
1545336).    
Because of this apparent paradox, the full puzzle of the role of oestrogen in PH 
is still not completely solved. The MacLow model for inducing PAH provides a 
novel model to study the role of oestrogen in relation to macrophages.   
Gender differences have also been reported in a different types of diseases, 
however, very recently gender differences at the cellular level have been 
introduced (gender cytology). Cells from males and females can behave 
differently and display different features, including the mechanisms controlling 
cell death (Straface et al., 2012). Furthermore, it has been shown that cells have 
a ‘memory' and they can maintain their ‘sex' through a number of in vitro 
passages (Straface et al., 2012). There is a growing body of literature that claims 
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immune cells respond directly to the changes in the concentration of sex 
hormones via their sex hormone receptor. In term of macrophages, male- derived 
peritoneal macrophages following LPS stimulation in vivo express higher levels 
of inflammatory cytokine IL-6 and Toll-like receptor 4 (TLR4) protein than female-
derived cells in the murine models (Marriott et al., 2006, Rettew et al., 2008).  
Despite this evidence that suggested sex-based differences in the biology of 
immune cells, male- derived bone marrow cells were not enough to induce the 
disease in female MacLow mice, and more likely the female derived cell would 
not be able to protect males from developing the disease. My results further 
highlight the sex imbalance in PAH and add the immune cells to this paradigm.  
Finally, the work in MacLow mouse model further encourages the accurate 
reporting of the sex of animals in experimental research, which is something 
considered by many journals recently to improve rigour and reproducibility of 
biomedical research (Klein and Flanagan, 2016, Florez-Vargas et al., 2016).   
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7  General discussion and future work 
 
7.1 General discussion 
In the work presented in this thesis, I have utilized the MacLow mouse model for 
inducible macrophage depletion to investigate the role of macrophages and 
macrophage subsets in PAH pathogenicity. The data I collected further support 
the proposed modulatory role of macrophages in PAH, and emphasise the 
importance of the switch in macrophage polarity in disease development. The 
finding did not support my primary hypothesis, as the specific depletion of 
macrophages in MacLow mice did not protect against the induced vascular 
remodelling. In fact, I showed that macrophage loss actually lead to the 
development of PAH spontaneously. Additionally, the results showed a unique 
and interesting sex- specific PAH phenotype induced by loss of macrophages in 
male mice only. This suggests a correlation between sex and macrophages 
activation in PAH.   
In chapter 3, I showed that loss of CD68+ macrophages in MacLow mice induced 
PAH development in male and not female mice, the disease phenotype was 
associated with increased RVH and vascular remodelling. By tracing the origin of 
the effector macrophages responsible for the development of MacLow- induced 
PAH using chimeric mice (presented in chapters 4 and 6), it seems that the major 
contributor cells originate within the lung tissue. Furthermore, the in vitro 
characterization of lung macrophage subsets presented in chapter 5 suggested 
that the alveolar macrophage possess weak response to the doxycycline- 
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induced macrophage depletion in vitro, this may led to a compartment- specific 
activation of the alveolar subtype following the loss of the interstitial subtype.  
An additional important observation in the MacLow- induced PAH model was the 
skewing toward the CD206+ population (resembling the alternatively activated 
M2 subtype), this was seen in vivo within the lungs of the diseased male mice 
following six weeks doxycycline treatment, as well as in vitro using MacLow- 
derived BMDMs following doxycycline stimulation. Consistent with this finding, it 
has been shown previously that in hypoxia- induced PH, the hypoxia causes 
polarization of alveolar macrophages toward M2 phenotype and that was 
associated with the development of hypoxia- induced PH in vivo (Vergadi et al., 
2011, Hashimoto-Kataoka et al., 2015). It is possible that in MacLow mice 
following macrophage depletion, the surviving macrophages switch their 
phenotype to the alternative activation state to clear up the dead cells and cell 
debris (Weisser et al., 2012). It is also possible, however, that the skewing toward 
the M2 macrophage in MacLow- induced PAH is associated with the disease 
pathogenicity, this is shown by the female MacLow mice displaying less 
pronounced M2 population within the lungs. Again this further highlights the sex 
imbalance in PAH development and may add the immune cell to this paradigm.   
It became well evidenced that the inflammation associated with PH is 
characterized by influx of leukocytes particularly macrophages into the 
perivascular/ adventitial compartment of the pulmonary vessels (Stenmark et al., 
2011, Savai et al., 2012, Stenmark et al., 2012, Stenmark et al., 2013). However, 
less is known about the mechanism nor the stimuli that induce recruitment and 
activation of macrophages. The adventitial fibroblast has been shown to possess 
hyper-proliferative and pro-inflammatory phenotype that is involved in the 
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recruitment and activation of macrophages in patients and animal model of PH 
(Li et al., 2011, Wang et al., 2014). This though to be, or at least in part, due to 
the activation of STAT3 and HIF1 signalling alongside with expression of pro-
remodelling genes such as Arg-1 (El Kasmi et al., 2014). Moreover, T cells were 
also shown to have a role in regulating the recruitment and activation of 
inflammatory cells (such as monocyte, macrophages and dendritic cells) 
(Tamosiuniene et al., 2011). Maladaptation of the immune response has been 
also an area of interest in PH research as this may explain the accumulation of 
vascular inflammatory cells and the increased cytokine levels in patients. The T 
cells (particularly T reg cells) has a well-known role in controlling self- tolerance 
and a disturbed T reg function has been detected in PAH patients (Tamosiuniene 
et al., 2011). In athymic rat model (congenital absence of T cells) a vascular injury 
by VEGF inhibitor lead to development of PH in association with activation and 
recruitment of macrophages which is reversed by T cell reconstitution 
(Tamosiuniene et al., 2011). A convincing explanation of this is that the normal T 
regs functions lead to activation of macrophages to promote injury repair while in 
absence of T regs the activated macrophages participates in injury evolution 
(Rabinovitch et al., 2014). In MacLow-induced PH, the signalling pathways that 
might be involved in macrophages polarized activation and whether the MacLow 
mice have impaired T cells function will require further investigation to define.    
In addition, by studying the role of the circulating progenitor cells versus the lung 
resident macrophages using the BMT procedure, I found that the lung resident 
macrophages are the major contributors to the development of MacLow- induced 
PAH in male mice, and that male- derived hematopoietic cells alone were not 
sufficient to induce the disease in females. Interestingly, in this study, the 
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depletion of lung macrophages was less pronounced in the chimeric mice that 
underwent total body irradiation compared to the non- irradiated mice, this 
suggested to be most likely due to irradiation effect. 
Irradiation impact on the lung is not completely known, but it has been shown that 
irradiation can affects not only the circulating leukocytes but also can influence 
the lung macrophages especially the alveolar subtype (Tarling et al., 1987, 
Matute-Bello et al., 2004). Whilst circulating leukocytes are completely replaced 
by donor cells in 30 days following bone marrow transplant, only 47% of the 
alveolar macrophages repopulate in the same period (Matute-Bello et al., 2004). 
This suggests that the baseline count of the alveolar macrophages in the BMT 
studies was already below the normal before inducing the depletion even in the 
controls, this could affect the severity of disease phenotype developed, especially 
as I showed a positive correlation between the percent reduction in lung 
macrophages and the increase in RVESP in male MacLow mice (figure 6.8).   
Additionally, the circulating monocytes also seem to be affected by the MacLow 
depletion strategy. This can be seen as the blood monocyte count was notably 
reduced following doxycycline treatment in all of the studies conducted. This data 
suggests that all the monocyte/ macrophages lineage is affected in MacLow 
mouse model.    
I also showed using an in vitro culture system that different lung macrophages 
have unique characteristics in terms of their cell viability, polarization, expression 
of DTA and expression of LTB4 following the addition of doxycycline. MacLow- 
BMDM showed a change in their phenotype toward the alternative activation state 
following doxycycline stimulation in vitro, while the MacLow- derived AMs showed 
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less expression of CD68 and DTA and therefore may be more resistant to killing 
following the addition of doxycycline.  In consistent with this phenotypic 
differences between the AMs and the IMs, a recent study by (Pugliese et al., 
2017) showed a significant difference in overall gene expression of the AMs and 
IMs following hypoxia exposure, as the IMs switch phenotype to anti-
inflammatory phenotype later in course of the disease while the AMs conserve 
their pro-inflammatory phenotype.  
Taken together, I proposed that the MacLow induced depletion targets the tissue 
and the recruited macrophages while leaving the alveolar macrophages affected 
to a lesser degree (or unaffected). This could potentially lead to compartment-
specific activation (alternative activation) of the alveolar macrophages and 
dominancy of the pro-inflammatory phenotype. However, male sex susceptibility 
is still questionable. 
Gender/ sex bias does exist in both clinical and experimental forms of PH. In 
patients, PAH develops more predominantly in women than men with a 4.1:1 
female to male ratio in idiopathic PAH subcategory (Badesch et al., 2010).  
However, men showed more severe disease phenotype, worse RV function and 
poorer survival, while women showed better pulmonary hemodynamic and 
improvement of the RV function after treatment (Badesch et al., 2010, Shapiro et 
al., 2012, Jacobs et al., 2014). In contrast, in various animal models, female sex 
shown to be protective and females showed less evidence of the disease 
compared with males. Female rat develops less severe PH, RVH and vascular 
remodelling following chronic hypoxia compared to males (Rabinovitch et al., 
1981, Resta et al., 2001, Umar et al., 2009). 
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There are different contradictory literature about the cause of sex- difference in 
PAH prevalence and survival. Also the complex role played by the sex hormones 
(such as oestrogen) in the pulmonary circulation and the RV was not fully 
explained. In some reports, oestrogen shown to have protective effect against the 
induced PH in animal model (monocrotaline and hypoxia models) since 
ovariectomy exacerbates PH and E2 pre-treatment attenuate its progression in 
the animal models (Farhat et al., 1993, Tofovic et al., 2006, Umar et al., 2011). 
On the other hand, other reports correlates female sex, oestrogen and oestrogen 
metabolites to the development of PAH (Austin et al., 2009, White et al., 2012, 
Mair et al., 2014a). Also other transgenic mouse models demonstrated the 
increased susceptibility of female sex in the development of PAH, such as the 
transgenic mouse overexpressing human serotonin transporter SERT+ mice 
(White et al., 2011) and mice overexpressing calcium- binding protein S100A4/ 
Mits1 (Dempsie et al., 2011). Moreover, others argued that sex hormones alone 
may not be sufficient to clarify the gender imbalance in PAH, recent work by 
(Umar et al., 2017) showed that the Y chromosome have protective role against 
hypoxia- induced PH. In this work they studied the role of sex hormones 
independently of gonadal hormones using the Four Core Genotypes mouse 
(FCG mouse model), in this model male mice can have XX and XY and the female 
mice can carry XX and XY. They showed that hypoxic XY male developed less 
severe PH regardless of gonadal sex compared to XX mice (Umar et al., 2017). 
Collectively, the data collected from the MacLow- induced PAH model provides 
additional argument into the influence of sex in the development of PH. Increased 
susceptibility of male sex to the development of PAH following macrophage 
depletion can be correlated to the protective role of oestrogen in females, but also 
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can be correlated to the severe phenotype and worse RV function seen in male 
patients. Furthermore, this could also provide a new insight into the protective 
role of pulmonary macrophages in male mice as their depletion increase the 
susceptibility to pulmonary vascular diseases.           
The development of effective therapeutic targets for PAH needs to consider and 
fully understand the different aspects of macrophage activation as they could 
have opposing roles during the development of the disease. A better 
understanding of relative contribution from IMs and AMs in the initiation and 
maintenance of vascular remodelling may facilitate the reprogramming or the 
skewing toward the reparative phenotype of macrophage to attenuate the 
vascular remodelling.  The MacLow system can be proposed as a novel and 
powerful tool that can also be utilised for lineage tracing to target distinct lung 
macrophage populations. The system can be used to sort out the relative 
contribution of AMs and IMs in PAH associated remodelling, by depleting only 
one of the subtypes. 
7.2 Future work 
I believe that, in the future, there is huge amount of work that can be done to 
follow up from my research. For example, it would be very tempting to investigate 
the potential protective effect of oestrogen in the MacLow- induced PAH model, 
this can be done either by treating male MacLow mice with an oestrogen 
analogue alongside with doxycycline treatment to see whether oestrogen 
treatment can protect male MacLow from developing PAH, or by conducting an 
ovariectomy procedure to the female MacLow mice before being treated with 
doxycycline and investigate whether ovariectomy can induce PAH in females. 
The potential therapeutic effect of oestrogen can also be investigated by treating 
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the male mice with oestrogen analogue after establishing the PAH and determine 
whether the oestrogen treatment can reverse the established PAH. Alternatively, 
treatment of established PH in MacLow mice with the aromatase inhibitor 
anastrazole to evaluate its therapeutic efficacy is also very interesting future 
recommendation.     
My data also hint for a role of LTB4 released from macrophages in the 
development of MacLow- induced PAH. To investigate this further LTB4/ 5LO 
inhibitor (such as Bestatin) can be utilized to determine whether blocking LTB4 
formation will have an effect on the development of PAH in MacLow mice.       
In addition, the chimeric MacLow mice developed less severe phenotype 
compared to the non- irradiated mice, this has been speculated to be due to the 
irradiation effect and the short recovery period. To address this limitation I 
propose to assess the severity of PAH phenotype in MacLow chimeric mice 
following a longer recovery time after the irradiation (60 days instead of 30 days). 
As it has been shown that the alveolar macrophages need about 60 days to 
repopulate following TBI (Matute-Bello et al., 2004). Moreover, to further address 
the key role of AMs in MacLow- induced PAH, I propose the use of chlodronate 
liposome depletion model in association with the induced depletion of 
macrophages with doxycycline in MacLow male mice. Repeated intratracheal 
chlodronate liposome injections can be used to locally deplete alveolar 
macrophages (Zaloudikova et al., 2016), in combination with doxycycline 
treatment for six weeks. This experiment will give supportive evidence regarding 
the relative contribution of lung macrophage subsets by depleting both the tissue 
resident and the alveolar macrophages and then assessing the spontaneous 
development of PAH.    
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The role of AMs versus IMs in MacLow mice following macrophage depletion can 
be further addressed using fluorescence- activated cell sorting technique of lung 
digest preparations. Behavioural and genetic features of each population can be 
then studied separately following treatment with different stimulus including 
doxycycline and oestrogen.       
I also propose to investigate the sex- dependent role of macrophages in MacLow 
mice using other models of PH (other than the hypoxia model), the hypoxia model 
is inflammatory- based model and may not be comprehensive as hypoxia alone 
not able to recapitulate the full vascular pathological features seen in patients. 
Instead, the VEGF inhibitor SUGEN in combination with chronic hypoxia can be 
used as more pronounced model of PAH. this model provides human- like 
spectrum of PAH with endothelial proliferation, precapillary occlusion and 
formation of plexiform lesion (Taraseviciene-Stewart et al., 2001). Similarly, other 
models of PH such as the bleomycin model (Harrison and Lazo, 1987), high fat 
diet- fed ApoE knock out mouse model (Weng et al., 2011) and vasoactive 
intestinal peptide VIP knock out model (Said et al., 2007) can also be used in 
conjugation with MacLow induced macrophage depletion to further confirm the 
role of macrophage in relation to sex in the development of different forms of PH.         
Importantly, although animal models have significantly enriched our 
understanding of the pathological processes involved in the development of the 
disease, the conclusions drawn may not be fully translatable into human 
diseases. Thus my research should be further expanded to determine whether 
the sex- dependent macrophage phenotype observed in MacLow mice is also 
observed in human PAH. One way this could be established is by culturing human 
blood- derived macrophages from PAH patients of both genders and studying 
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their differentiation and polarization characteristics, also the changes in 
transcriptomic and metabolic profiles can be studied in isolated RNA samples to 
determine any conserved features between the MacLow model and human PAH.    
Finally, the work in MacLow mouse model further encourage the accurate 
reporting of the sex of animals in experimental research, which is something 
considered by many journals recently to improve rigour and reproducibility of the 
biomedical research (Klein and Flanagan, 2016, Florez-Vargas et al., 2016).   
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9  Appendices 
 
9.1 Appendix I - Haemodynamic measurements 
Haemodynamic parameters collected in the MacLow- induced 
PAH study: 
Table of the haemodynamic parameter collected by echocardiography  
 
control male MacLow male 
 
control female 
 
MacLow female 
Parameter Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
weight (g) 29.48 1.08 8 29.58 0.95 8 24.61 0.74 8 23.96 0.78 7 
LVIDd(mm) 3.98 0.17 8 3.48 0.10 8 3.47 0.17 8 3.51 0.12 8 
LVIDs(mm) 2.81 0.18 8 2.11 0.15 8 1.85 0.18 8 2.11 0.18 8 
LVEF% 56.33 4.78 8 69.76 3.91 8 77.87 4.01 8 70.73 5.08 8 
LVFS% 29.69 3.19 8 39.47 3.65 8 47.15 4.16 8 40.39 3.74 8 
LV mass (corr) 
mg 
123.7
3 
8.57 8 143.28 3.77 8 118.1
9 
6.45 8 114.26 14.1
4 
8 
LVSV(MM) 39.25 4.72 8 35.00 2.58 8 39.46 4.27 8 36.07 3.48 8 
LVCO(MM) 20.11 2.32 8 15.58 2.44 8 18.67 1.87 8 17.05 2.02 8 
Ao VTI (cm) 3.23 0.33 8 3.03 0.24 8 3.40 0.13 8 3.37 0.18 8 
AoV-Mean Vel 
(mm/s) 
529.3
0 
60.79 8 494.43 36.34 8 537.4
5 
28.45 8 503.82 20.4
9 
8 
Ao SV(ul) 44.81 4.77 8 35.73 3.71 8 44.97 2.12 8 39.98 2.41 8 
Ao CO (ml/min) 23.30 2.73 8 17.24 1.63 8 21.89 1.74 8 18.46 1.19 8 
Ao SVi (m/g) 1.52 0.15 8 1.22 0.13 8 1.84 0.11 8 1.66 0.09 7 
Ao CI (m/min/g) 792.4
3 
88.03 8 586.78 57.09 8 899.7
8 
85.26 8 758.96 52.7
1 
7 
PAAT (ms) 17.10 1.02 8 16.77 0.48 8 19.15 0.63 8 18.15 0.65 8 
PAET (mc) 58.48 1.61 8 61.25 0.92 8 63.85 2.08 8 60.81 2.49 8 
PA AT/ET ratio 0.29 0.02 8 0.27 0.01 8 0.30 0.01 8 0.30 0.00 8 
RVIDd 1.32 0.04 8 1.43 0.03 8 1.30 0.07 8 1.10 0.09 6 
RVIDs 0.68 0.04 8 0.69 0.07 8 0.57 0.06 8 0.49 0.04 6 
RVWTs 0.60 0.04 8 0.65 0.05 8 0.64 0.04 8 0.58 0.03 6 
RVFS% (M-
Mode) 
48.44 3.64 8 51.97 4.49 8 56.45 3.22 8 54.63 4.04 6 
PA VTI 2.78 0.14 8 2.72 0.21 8 3.07 0.18 8 2.64 0.10 8 
CI (from LV) 0.68 0.07 8 0.51 0.08 8 0.76 0.07 8 0.71 0.10 7 
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Table of the haemodynamic parameter collected by cardiac catheterization of the 
right ventricle 
 
control male 
 
MacLow male 
 
control female 
 
MacLow female 
 
Parameter Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
Heart rate 
(bpm) 
460.57 16.94 7 515 15.99 6 390.43 46.97 7 439.8 39.53 5 
Maximum 
Volume (RVU) 
21.98 1.5 7 20.44 2.22 6 20.87 1.96 7 18.61 1.5 5 
Minimum 
Volume (RVU) 
19.62 1.09 7 18.66 2 6 18.62 1.73 7 17.47 1.5 5 
End-systolic 
Volume (RVU) 
20.17 1.19 7 19.22 2.05 6 19.01 1.71 7 17.81 1.49 5 
End-diastolic 
Volume (RVU) 
21.47 1.33 7 19.76 2.25 6 20.53 2 7 18.11 1.37 5 
Maximum 
Pressure 
(mmHg) 
24.88 1.2 7 59.04 9.85 6 23.22 1.95 7 25.09 1.64 5 
Minimum 
Pressure 
(mmHg) 
0.27 0.04 7 0.47 0.13 6 0.28 0.06 7 0.76 0.47 5 
End-systolic 
Pressure 
(mmHg) 
24.51 1.23 7 58.74 9.72 6 23.11 1.95 7 25.07 1.63 5 
End-diastolic 
Pressure 
(mmHg) 
2.37 0.26 7 2.85 0.81 6 1.94 0.38 7 2.38 0.83 5 
Stroke 
Volume (RVU) 
2.36 0.62 7 1.78 0.34 6 2.25 0.66 7 1.13 0.21 5 
Ejection 
Fraction (%) 
10.25 2.14 7 8.59 1.26 6 10.6 2.42 7 6.21 1.28 5 
Cardiac 
Output 
(RVU/min) 
1100.7
7 
309.56 7 921.1 181.07 6 809.2 225.5 7 500.9
4 
99.9 5 
Stroke Work 
(mmHg*RVU) 
34.71 12.08 7 48.67 36.49 6 33.86 15.68 7 -0.6 9.09 5 
Arterial 
Elastance (Ea) 
(mmHg/RVU) 
15.81 3.77 7 44.16 16.95 6 18.68 6.2 7 25.03 3.96 5 
dPdt max 
(mmHg/sec) 
2213.2
9 
194.12 7 5421.6
7 
1237.3
9 
6 2183.4
3 
745.9
5 
7 2013 333.2
9 
5 
dPdt min 
(mmHg/sec) 
-
1676.5
7 
180.48 7 -
4712.6
7 
1473.4
9 
6 -
1545.5
7 
360.3
4 
7 -
1492.
2 
171.2 5 
dVdt max 
(RVU/sec) 
110.43 32.75 7 94.5 13.67 6 83.14 19.64 7 57.8 18.65 5 
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dVdt min 
(RVU/sec) 
-68.29 13.38 7 -88 17.58 6 -59.57 12.99 7 -35.6 6.49 5 
P@dVdt max 
(mmHg) 
1.12 0.53 7 8.64 2.5 6 3.56 1.54 7 11.91 4.15 5 
P@dPdt max 
(mmHg) 
12.14 1.69 7 26.95 7.24 6 9.94 2 7 10.49 1.55 5 
V@dPdt max 
(RVU) 
21.31 1.36 7 19.69 2.3 6 20.45 1.94 7 18 1.36 5 
V@dPdt min 
(RVU) 
19.72 1.11 7 19.26 1.92 6 18.85 1.77 7 17.87 1.55 5 
Tau_w (msec) 8.18 0.74 7 6.72 1.68 6 10.06 1.87 7 10.12 1.58 5 
Tau_g (msec) 16.15 2.87 7 12.63 3.54 6 32.98 15.48 7 13.13 1.1 5 
Tau_l (msec) 0 0 7 0 0 6 0 0 7 0 0 5 
Maximal 
Power 
(mWatts) 
0.18 0.04 7 0.57 0.27 6 0.13 0.04 7 0.06 0.02 5 
Preload 
adjusted 
maximal 
power 
(mWatts/µL^2) 
3.87 0.75 7 11.57 2.92 6 3.03 0.62 7 1.83 0.53 5 
 
 
Table of the haemodynamic parameter collected by cardiac catheterization of the 
left ventricle 
 
control male 
 
MacLow male control female MacLow female 
Parameter Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
Heart rate 
(bpm) 
465.67 39.56 3 501.25 20.62 4 477.25 51.10 4 367.00 51.79 3 
Maximum 
Volume (RVU) 
24.68 0.50 3 24.06 1.94 4 24.52 1.47 4 17.86 0.70 3 
Minimum 
Volume (RVU) 
20.99 0.76 3 19.46 1.09 4 20.28 0.72 4 15.64 0.70 3 
End-systolic 
Volume (RVU) 
21.62 0.92 3 20.20 1.01 4 21.70 0.86 4 16.42 0.82 3 
End-diastolic 
Volume (RVU) 
23.67 0.39 3 23.60 1.91 4 24.09 1.53 4 17.34 0.91 3 
Maximum 
Pressure 
(mmHg) 
98.85 9.81 3 79.34 2.16 4 82.67 8.99 4 72.56 16.03 3 
Minimum 
Pressure 
(mmHg) 
0.40 0.08 3 1.60 1.21 4 0.42 0.08 4 0.27 0.02 3 
End-systolic 
Pressure 
(mmHg) 
97.14 10.59 3 77.64 2.68 4 81.50 9.51 4 72.26 15.99 3 
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End-diastolic 
Pressure 
(mmHg) 
3.56 0.42 3 3.99 1.15 4 3.18 0.56 4 2.53 0.30 3 
Stroke 
Volume (RVU) 
3.68 0.90 3 4.61 1.31 4 4.25 0.92 4 2.22 0.75 3 
Ejection 
Fraction (%) 
14.86 3.55 3 18.35 4.54 4 16.82 2.85 4 12.30 3.81 3 
Cardiac 
Output 
(RVU/min) 
1772.0
0 
511.96 3 2287.1
7 
609.54 4 2163.4
3 
657.0
7 
4 811.32 254.93 3 
Stroke Work 
(mmHg*RVU) 
252.33 51.41 3 265.00 89.57 4 210.00 44.58 4 52.00 86.40 3 
Arterial 
Elastance (Ea) 
(mmHg/RVU) 
33.28 14.13 3 28.59 14.66 4 24.09 7.55 4 36.97 8.13 3 
dPdt max 
(mmHg/sec) 
9639.3
3 
1525.1
8 
3 6153.0
0 
381.82 4 6168.5
0 
558.6
1 
4 4297.3
3 
1372.7
7 
3 
dPdt min 
(mmHg/sec) 
-
9986.6
7 
2141.4
5 
3 -
6328.2
5 
1276.5
2 
4 -
5406.7
5 
515.5
0 
4 -
4095.3
3 
1797.9
0 
3 
dVdt max 
(RVU/sec) 
127.33 37.67 3 156.25 44.47 4 163.50 44.44 4 98.00 25.12 3 
dVdt min 
(RVU/sec) 
-
139.67 
44.35 3 -
152.50 
40.34 4 -
186.25 
57.66 4 -70.00 18.50 3 
P@dVdt max 
(mmHg) 
34.32 4.10 3 8.89 4.19 4 10.58 0.71 4 6.35 4.66 3 
P@dPdt max 
(mmHg) 
65.71 8.32 3 41.36 2.59 4 41.81 9.56 4 34.07 6.91 3 
V@dPdt max 
(RVU) 
24.43 0.32 3 23.40 2.06 4 23.96 1.53 4 17.03 1.19 3 
V@dPdt min 
(RVU) 
21.38 0.74 3 19.70 1.18 4 21.00 0.81 4 16.14 0.78 3 
Tau_w (msec) 5.67 0.13 3 7.06 1.09 4 6.74 1.41 4 11.44 2.32 3 
Tau_g (msec) 9.37 0.74 3 11.28 2.50 4 12.76 3.63 4 19.60 4.11 3 
Tau_l (msec) 0.00 0.00 3 0.00 0.00 4 0.00 0.00 4 0.00 0.00 3 
Maximal 
Power 
(mWatts) 
1.70 0.49 3 1.48 0.42 4 1.65 0.52 4 0.36 0.17 3 
Preload 
adjusted 
maximal 
power 
(mWatts/µL^2) 
30.03 8.23 3 24.40 4.41 4 25.87 5.86 4 11.50 4.50 3 
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Haemodynamic parameters collected in the bone marrow transplant study 
presented in chapter 3 
Table of the main haemodynamic parameter collected by echocardiography  
 
MacLow BM to 
MacLow 
control BM to 
MacLow 
MacLow BM to 
control 
 
control BM to 
control 
Parameter Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
Weight (g) 32.51 1.15 8 31.82 0.72 5 31.22 0.53 5 31.20 0.92 5 
AoET (ms) 58.50 1.82 7 57.10 0.89 5 55.00 1.52 5 56.25 1.64 4 
RVWTd (mm) 0.49 0.04 7 0.47 0.01 4 0.51 0.01 5 0.51 0.02 4 
RVIDd 1.37 0.05 7 1.36 0.22 4 1.57 0.09 5 1.47 0.07 4 
RVWTs 0.68 0.09 7 0.75 0.14 4 0.65 0.02 5 0.78 0.07 4 
RVIDs 0.71 0.09 7 0.65 0.17 4 0.69 0.06 5 0.81 0.05 4 
PAAT (ms) 16.60 1.14 7 18.37 0.21 5 17.93 0.87 5 16.00 0.78 4 
PAET (ms) 62.07 2.33 7 63.23 2.00 5 59.97 1.46 5 58.92 3.73 4 
PAAT/ET 0.27 0.01 7 0.29 0.01 5 0.30 0.02 5 0.27 0.00 4 
CI (m/min/g) 0.59 0.04 7 0.63 0.12 4 0.60 0.06 5 0.82 0.12 3 
 
Table of the haemodynamic parameter collected by cardiac catheterization of the 
right ventricle 
 
MacLow BM to 
MacLow 
control BM to 
MacLow 
MacLow BM to 
control 
control BM to 
Control 
 
 Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
Heart rate 
(bpm) 
530.38 17.52 8 501.20 13.02 5 449.40 15.34 5 501.75 32.6
1 
4 
Maximum 
Volume (RVU) 
26.81 0.89 8 28.01 1.80 5 26.81 1.95 5 26.21 1.03 4 
Minimum 
Volume (RVU) 
24.74 0.96 8 25.89 1.27 5 24.72 1.71 5 23.82 0.45 4 
End-systolic 
Volume (RVU) 
25.30 0.88 8 26.66 1.41 5 25.12 1.63 5 24.59 0.48 4 
End-diastolic 
Volume (RVU) 
26.09 0.89 8 27.41 1.75 5 26.01 1.91 5 25.61 1.14 4 
Maximum 
Pressure 
(mmHg) 
29.01 2.17 8 23.30 0.60 5 20.60 1.56 5 24.19 0.62 4 
Minimum 
Pressure 
(mmHg) 
0.28 0.04 8 0.26 0.03 5 0.29 0.11 5 0.20 0.02 4 
End-systolic 
Pressure 
(mmHg) 
28.94 2.19 8 23.26 0.61 5 20.58 1.57 5 24.11 0.57 4 
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End-diastolic 
Pressure 
(mmHg) 
1.35 0.20 8 1.60 0.18 5 2.20 0.53 5 1.95 0.23 4 
Stroke Volume 
(RVU) 
2.07 0.34 8 2.12 0.56 5 2.09 0.85 5 2.40 0.71 4 
Ejection 
Fraction (%) 
7.76 1.31 8 7.16 1.65 5 7.47 2.84 5 8.88 2.37 4 
Cardiac Output 
(RVU/min) 
1078.7
9 
172.34 8 1074.54 292.50 5 921.40 365.37 5 1153.92 293.
03 
4 
Stroke Work 
(mmHg*RVU) 
23.63 11.03 8 22.20 12.25 5 12.40 10.27 5 15.25 22.0
5 
4 
Arterial 
Elastance (Ea) 
(mmHg/RVU) 
17.60 3.27 8 17.64 6.22 5 16.66 4.92 5 13.61 4.17 4 
dPdt max 
(mmHg/sec) 
2486.1
3 
289.42 8 2344.00 133.89 5 1826.2
0 
314.07 5 2302.50 281.
36 
4 
dPdt min 
(mmHg/sec) 
-
2339.8
8 
310.67 8 -1619.60 42.33 5 -
1680.0
0 
400.74 5 -1835.50 200.
10 
4 
dVdt max 
(RVU/sec) 
114.75 14.59 8 122.80 35.42 5 90.80 36.89 5 112.00 26.5
6 
4 
dVdt min 
(RVU/sec) 
-87.38 11.45 8 -78.60 22.69 5 -72.00 11.97 5 -94.25 23.9
4 
4 
P@dVdt max 
(mmHg) 
4.24 1.97 8 5.26 4.76 5 4.45 2.89 5 11.93 6.68 4 
P@dPdt max 
(mmHg) 
10.98 0.92 8 9.39 0.98 5 8.54 1.40 5 11.23 0.87 4 
V@dPdt max 
(RVU) 
26.17 0.89 8 27.31 1.72 5 25.84 1.92 5 25.16 1.06 4 
V@dPdt min 
(RVU) 
25.02 1.00 8 26.18 1.30 5 24.98 1.62 5 24.42 0.55 4 
Tau_w (msec) 7.94 0.50 8 8.24 1.00 5 6.58 2.33 5 7.12 0.68 4 
Tau_g (msec) 61.43 43.17 8 128.86 111.66 5 102.43 70.15 5 10.08 1.18 4 
Tau_l (msec) 0.00 0.00 8 0.00 0.00 5 0.00 0.00 5 0.00 0.00 4 
Maximal Power 
(mWatts) 
0.22 0.04 8 0.13 0.03 5 0.12 0.02 5 0.16 0.08 4 
Preload 
adjusted 
maximal power 
(mWatts/µL^2) 
3.09 0.51 8 1.61 0.31 5 1.78 0.33 5 2.17 1.03 4 
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Haemodynamic parameters from the bone marrow transplant study 
presented in chapter 6 
Table of the main haemodynamic parameter collected by echocardiography  
 
Male BM to Male 
 
Female BM to Male 
 
Male BM to Female 
 
Female BM to 
Female 
 Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
Weight (g) 32.51 1.15 8 31.23 0.65 6 28.87 0.31 6 28.98 1.21 6 
LVCO (MM) 18.88 1.41 7 18.31 1.21 5 18.36 1.61 6 18.11 1.03 6 
AoET (ms) 58.50 1.82 7 56.30 1.91 5 53.83 0.71 6 54.00 1.37 6 
RVWTd ((mm) 0.49 0.04 7 0.54 0.02 6 0.46 0.03 6 0.45 0.01 6 
RVIDd (mm) 1.37 0.05 7 1.49 0.06 6 1.30 0.08 6 1.41 0.09 6 
RVWTs  0.68 0.09 7 0.79 0.06 6 0.69 0.03 6 0.89 0.05 6 
RVIDs 0.71 0.09 7 0.67 0.03 6 0.52 0.06 6 0.53 0.07 6 
PAAT (ms) 16.60 1.14 7 16.58 0.45 6 16.25 0.50 6 15.67 0.66 6 
PAET (ms) 62.07 2.33 7 58.89 0.67 6 55.89 0.72 6 55.72 1.54 6 
PAAT/ET 0.27 0.01 7 0.28 0.01 6 0.29 0.01 6 0.28 0.01 6 
CI (m/min/g) 0.59 0.04 7 0.58 0.04 5 0.64 0.06 6 0.63 0.06 6 
 
 
Table of the haemodynamic parameter collected by cardiac catheterization of the 
right ventricle 
 
Male BM to Male 
 
Female BM to Male 
 
Male BM to Female 
 
Female BM to 
Female 
Parameter Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
Heart rate 
(bpm) 
530.38 17.52 8 483.00 34.69 6 454.33 33.93 6 423.67 42.56 6 
Minimum 
Volume (RVU) 
24.74 0.96 8 26.42 2.02 6 26.12 2.34 6 21.86 1.65 6 
End-systolic 
Volume (RVU) 
25.30 0.88 8 27.22 2.05 6 26.57 2.34 6 22.04 1.66 6 
End-diastolic 
Volume (RVU) 
26.09 0.89 8 27.72 2.09 6 28.04 2.76 6 22.99 1.71 6 
Maximum 
Pressure 
(mmHg) 
29.01 2.17 8 27.29 1.52 6 21.97 0.56 6 23.61 0.79 6 
Minimum 
Pressure 
(mmHg) 
0.28 0.04 8 0.40 0.12 6 0.21 0.02 6 0.23 0.02 6 
End-systolic 
Pressure 
(mmHg) 
28.94 2.19 8 27.41 1.47 6 21.40 0.34 6 23.60 0.79 6 
End-diastolic 
Pressure 
(mmHg) 
1.35 0.20 8 1.96 0.22 6 2.17 0.47 6 2.24 0.26 6 
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Stroke Volume 
(RVU) 
2.07 0.34 8 1.80 0.36 6 2.51 0.54 6 1.44 0.26 6 
Ejection 
Fraction (%) 
7.76 1.31 8 6.32 1.10 6 8.14 1.30 6 6.14 0.93 6 
Cardiac 
Output 
(RVU/min) 
1078.7
9 
172.3
4 
8 1225.2
1 
158.36 6 1220.1
6 
315.3
3 
6 595.62 133.1
4 
6 
Stroke Work 
(mmHg*RVU) 
23.63 11.03 8 32.33 6.26 6 31.67 8.88 6 17.83 4.02 6 
Arterial 
Elastance (Ea) 
(mmHg/RVU) 
17.60 3.27 8 10.74 1.53 6 13.82 5.36 6 21.70 6.69 6 
dPdt max 
(mmHg/sec) 
2486.1
3 
289.4
2 
8 2369.3
3 
293.59 6 1627.1
7 
161.2
6 
6 1503.1
7 
167.8
7 
6 
dPdt min 
(mmHg/sec) 
-
2339.8
8 
310.6
7 
8 -
1589.1
7 
216.81 6 -
1324.6
7 
123.7
2 
6 -
1281.5
0 
177.1
7 
6 
dVdt max 
(RVU/sec) 
114.75 14.59 8 82.67 14.97 6 103.67 21.85 6 72.00 10.48 6 
dVdt min 
(RVU/sec) 
-87.38 11.45 8 -71.67 15.18 6 -85.33 22.41 6 -44.00 8.09 6 
P@dVdt max 
(mmHg) 
4.24 1.97 8 10.90 5.10 6 1.38 0.68 6 2.29 0.85 6 
P@dPdt max 
(mmHg) 
10.98 0.92 8 12.32 1.63 6 7.82 0.92 6 10.01 0.76 6 
V@dPdt max 
(RVU) 
26.17 0.89 8 27.62 2.07 6 27.93 2.75 6 22.90 1.66 6 
V@dPdt min 
(RVU) 
25.02 1.00 8 26.83 2.13 6 26.24 2.34 6 21.95 1.67 6 
Tau_w (msec) 7.94 0.50 8 9.76 2.51 6 10.10 1.54 6 12.50 2.46 6 
Tau_g (msec) 61.43 43.17 8 26.94 2.55 6 50.28 32.75 6 41.93 15.72 6 
Tau_l (msec) 0.00 0.00 8 0.00 0.00 6 0.00 0.00 6 0.00 0.00 6 
Maximal 
Power 
(mWatts) 
0.22 0.04 8 0.17 0.04 6 0.21 0.06 6 0.11 0.02 6 
Preload 
adjusted 
maximal 
power 
(mWatts/µL^2) 
3.09 0.51 8 2.05 0.41 6 2.27 0.46 6 2.12 0.37 6 
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9.2 Appendix II – Animal work reagent 
Genotyping reagents and buffers 
Tail Lysis Buffer (TLB) 
 10ml of 1M Tris-Hcl pH 8.5 
 0.4ml of 0.5M EDTA PH8 
 10ml of 10% v/v Tween 20 
 Make up to 200ml with dH2o 
Filtered, aliquoted and stored at -20⁰C 
0.5 M EDTA (pH8) 
 186.1g of disodium ethylene-diamine tetra-acetic acid.dihydrate (EDTA) 
 800ml dH20 
 Stir thoroughly in magnetic stirrer 
 Adjust pH to 8 with ~20g NaOH pellets   
Sterilized with autoclave and stored at room temperature away from direct sun 
light. 
10 mg/ml Proteinase K stock solution 
 100mg Proteinase K )Proteinase K from Tritirachium album supplied by 
SIGMA- P2308) 
 10 ml storage buffer  
Aliquoted and stored at -20⁰C 
Storage buffer:  
 50ml Glycerol 
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 1ml of 1M Tris-Hcl pH7.5 
 Make up to 100 ml with Deionized dH2O 
Autoclaved and stored at room temperature 
10X TBE buffer 
 108g Tris base 
 55g Boric acid 
 800ml dH2O 
 Stir in magnetic stirrer 
 40ml of 0.5M EDTA (pH8) 
 Make up to 1000ml with dH2O 
Stored at room temperature away from light. For X1 working solution dilute with 
deionized dH2O. 
Other reagents: 
X100 Acidified water used in BMT studies 
 10ml sterile filter conc HCl .12M (37%)  
 840ml dH2O 
Autoclaved and stored at room temperature away from direct sunlight. For X1 
working solution dilute 10.1ml of the X100 stock in 1000m dH2O.  
Sodium citrate 
 4g Sodium citrate dihydrate 
 Make up to 100ml with H2O 
Sterile filtered and stored at 2-8⁰C. 
10% formalin 
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 4g sodium phosphate (NaH2PO4) 
 7.1g Di-sodium hydrogen orthophosphate (Na2HPO4) 
 100ml formaldehyde  
 900ml dH2O 
Stored at room temperature away from direct sunlight. 
9.3 Appendix III - Immunohistochemistry buffers and reagents 
Primary antibodies used in immune-histological staining of tissue sections: 
antibody clone Catalogue 
number and 
supplier 
reactivity Dilution 
used 
storage 
Anti-F4/80 
antibody 
Cl: A3-1 Ab6640 abcam 
Cambridge, UK 
mouse 1:100 -20⁰C 
Anti-iNOS 
antibody 
polyclonal Ab15323 abcam 
Cambridge, UK 
Mouse, 
rat 
1:100 -20⁰C 
MMR/CD206 
antibody 
polyclonal AF2535 
R&D systems 
Minnesota, US 
mouse 1:100  -20⁰C 
Anti-SMA 
antibody 
Cl:1A4 M0851  
Dako, Agilent 
Santa Clara, US 
Human, 
mouse 
1:150 2-8 ⁰C 
Anti-vWF 
antibody 
polyclonal A0082 
Dako, Agilent 
Santa Clara, US 
Human, 
cow, 
horse, 
1:300 2-8 ⁰C 
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mouse, 
swine 
Anti-PCNA 
antibody 
PC10 M0876 
Dako, Agilent 
Santa Clara, US 
Mouse, 
rat, 
zebrafish 
1:125 2-8 ⁰C 
Anti-IL-4 
antibody 
polyclonal Orb360766 
Biorbyt 
California, US 
Human, 
mouse, 
rat 
1:150 -20⁰C 
 
Secondary antibodies used in immune-histological staining of tissue 
sections: 
All secondary antibodies used at 1:200 dilution and stored at 2-8 ⁰C 
 
Antibody Catalogue number and supplier 
Biotinylated goat anti-rat IgG BA9400 
Vector Laboratories, Peterborough, UK 
Biotinylated goat anti-mouse 
IgG 
BA9200  
Vector Laboratories, Peterborough, UK 
Biotinylated goat anti-rabbit IgG BA1000  
Vector Laboratories, Peterborough, UK 
Alexa Fluor® 488 goat anti-rat 
IgG (H+L)  
A11006 
Invitrogen by ThermoFisher 
MA, US 
Alexa FuorTM 555 goat anti-
mouse IgG (H+L) 
A21422 
Invitrogen by ThermoFisher 
MA, US 
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Acid alcohol 
 5 ml of 1% v/v Hcl  
 495 ml of 70% v/v IMS  
Stored at room temperature away from direct sunlight. 
10mM Citrate Buffer 
 2.1g citric acid monohydrate 
 900 ml dH2O 
 Adjusted to PH6 with ~ 13ml of 2M NaOH 
 Fill with dH2O to 1000ml 
 
Stored at room temperature away from direct sunlight. 
Curtis’ Modified Van Gieson 
 10 ml of 1% w/v Ponceau S [aq]  
 90 ml of saturated aq. Picric acid 
 1 ml of glacial acetic 
Stored at room temperature away from direct sunlight. 
Alcian blue 
 5g Alcian blue 
 485 ml H2O 
 15ml acetic acid 
Stored at room temperature away from direct sunlight. 
3% Hydrogen peroxide solution 
 1 ml of 30% stock solution  
 9 ml of PBS 
Stock solution was stored at 4°C. 
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1% Milk blocking buffer 
 4g of Marvel dried milk (from local supermarket)  
 400 ml of PBS 
 Marvel dried milk powder was stored at room temperature.   
Tris buffered saline (TBS) 
 1 foil pouches of TBS powder (T-6664-10PAK, SIGMA) 
 1000ml dH2O 
The buffered saline (0.05M TBS, pH8) stored at room temperature away from 
direct sunlight.  
SIGMAFAST™ 3,3’-Diaminobenzidine tablets (D4418,Sigma Aldrich, 
Dorset, UK) 
 1 Urea Hydrogen Peroxide tablet 
 1 3,3’-Diaminobenzidine (DAB) tablet 
 added to 15 ml of water 
The DAB kit was stored at -20°C. 
VECTASTAIN Elite ABC Kit (Standard*) (PK-6100, Vector Laboratories, 
Peterborough, UK) 
 1 drop of Reagent A  
 1 drop of Reagent B  
 2.5 ml of PBS 
The kit was stored at 4°C. 
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9.4 Appendix IV – Flow cytometry reagents 
Antibodies used in flow cytometry analysis of mouse derived monocyte/ 
macrophage cells: all antibodies stored in dark at 2-8 ⁰C  
Antibody Clone Catalogue number 
and the supplier 
reactivity Dilution 
used  
Alexa Fluor® 
488 anti-
mouse CD115 
(CSF-1R) 
AFS98 135511 
BioLegend  
California, US 
mouse 1µg/ 100µl 
(2 µl/ million 
cell) 
FITC anti-
mouse CD68 
FA-11 137005 
BioLegend 
California, US 
mouse 0.2µg/ 100µl 
(1 µl/ million 
cell) 
PE anti-
mouse CD206 
(MMR) 
C068C2 141705 
BioLegend  
California, US 
 
mouse 0.2µg/ 100µl 
(1 µl/ million 
cell) 
Pacific blueTM 
anti-mouse 
CD86 
GL-1 105021 
BioLegend  
California, US 
mouse 0.5µg/ 100µl 
(1 µl/ million 
cell) 
APC anti-
mouse F4/80 
BM8 123115 
BioLegend  
California, US 
mouse 0.2µg/ 100µl 
(1 µl/ million 
cell) 
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9.5 Appendix V- In vitro work reagents 
Freezing media for BMDM 
 90ml FBS 
 10ml di-methyl sulfoxide DMSO(D-5879, Sigma)  
Stored at 2-8 ⁰C.  
RIPA buffer (radio- immunoprecipitation assay buffer) 
 150 mM NaCl 
 20 mM Tris  
 1% Triton X-100 
 0.1% sodium dodecyl sulfate (SDS) 
Stored at 2-8⁰C. 
20 mM Tris- HCl (pH8) for M-CSF reconstitution 
 31.52g Tris- HCl 
 10ml sterile H2O 
 Adjust pH with NaOH 
Stored at 2-8 ⁰C. 
Antibodies used in immunocytochemistry  
Primary antibody: rabbit polyclonal Anti-5 Lipoxygenase antibody, from abcam 
(ab39347). Used at 1:100 dilution. 
Secondary antibody: Alexa Fluor® 555 goat anti-rabbit IgG H&L, from abcam 
(ab150078). Used at 1:200 diluion. 
Antibodies used in dot blot assay   
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Primary antibody: mouse anti-Diphtheria toxin A subunit [8A4], from abcam 
(ab8308). Used at 1:2000 dilution 
Secondary antibody: goat anti-mouse IgG (H&L) from Dyssey. Used at 1:10000 
dilution. 
 
 
